{"meta":{"query_hash":"e549f4ad412f","filters":{"venue":"CNS Drugs"},"cohort_total":173,"direct_labels_cover":0,"predictions_cover":173,"exported":173,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/e549f4ad412f","api":"https://metacan.xera.ac/api/v1/cohort?venue=CNS+Drugs"},"results":[{"id":"W1166074170","doi":"10.1007/s40263-015-0270-y","title":"Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Aggression; Psychopharmacology; Dementia; Psychiatry; Psychology; Clinical trial; Alzheimer's disease; Disease; Medicine; Internal medicine","score_opus":0.09630533766773305,"score_gpt":0.42002174040197104,"score_spread":0.32371640273423796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1166074170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010697089,0.9934324,0.0000022142615,0.0029693528,0.00012327381,0.003119938,0.0001543428,0.00000891894,0.00008260334],"genre_scores_gemma":[0.000031208805,0.99490285,0.000014872613,0.000042520005,0.00017974564,0.0013270195,0.00022561882,0.00003994585,0.00323619],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872047,0.00007586481,0.00038072577,0.0002910074,0.00029761577,0.00023433918],"domain_scores_gemma":[0.9987982,0.000058093767,0.00016657001,0.0003886636,0.00033877653,0.00024971124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030433212,0.00024223498,0.0009364396,0.00020363083,0.000048663198,0.000017309441,0.00009028815,0.00012448263,0.000015911184],"category_scores_gemma":[0.00015128775,0.00012772874,0.00029827713,0.00023013237,0.00014271495,0.000026566408,0.00002882832,0.00011615731,0.0000035401101],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009863632,0.00018676625,0.000013027058,0.0036096324,0.000104538114,0.000009842821,0.00044335984,3.9463004e-7,2.184522e-7,0.000022335786,0.030946052,0.9645652],"study_design_scores_gemma":[0.0010769387,0.0003994764,0.000078907484,0.0077219126,0.0016899976,0.0000060814587,0.00015641944,0.00004783999,0.0000024535898,0.000049257793,0.9886553,0.0001154149],"about_ca_topic_score_codex":0.00015048767,"about_ca_topic_score_gemma":0.000020628062,"teacher_disagreement_score":0.96444976,"about_ca_system_score_codex":0.00023615206,"about_ca_system_score_gemma":0.0011875011,"threshold_uncertainty_score":0.52086264},"labels":[],"label_agreement":null},{"id":"W120655898","doi":"10.2165/11534420-000000000-00000","title":"Agomelatine in the Treatment of Major Depressive Disorder","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"University Health Network","keywords":"Agomelatine; Venlafaxine; Sertraline; Antidepressant; Fluoxetine; Major depressive disorder; Medicine; Discontinuation; Escitalopram; Placebo; Adverse effect; Psychology; Psychiatry; Internal medicine; Mood; Serotonin; Anxiety; Receptor","score_opus":0.029761622584474318,"score_gpt":0.34473524870846084,"score_spread":0.3149736261239865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W120655898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001628291,0.9911735,0.0000020057478,0.00017311118,0.00017306716,0.0022896142,0.000057253215,0.00002843571,0.004474717],"genre_scores_gemma":[0.00044617607,0.995738,0.00016747361,0.000020274048,0.00019268572,0.0005691172,0.00032379027,0.00006277284,0.002479666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982785,0.00014925854,0.0005689842,0.00040095122,0.00034663285,0.00025569773],"domain_scores_gemma":[0.99806726,0.00041864358,0.0003659079,0.0010406587,0.000033346427,0.000074197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011073197,0.0004510504,0.001694343,0.00023597787,0.00004420529,0.000010931994,0.00023244729,0.0003848847,0.00019202539],"category_scores_gemma":[0.000050461913,0.00021528821,0.0005681253,0.00026757206,0.000098487915,0.000032960983,0.00003454101,0.0003707536,0.000101709215],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001840386,0.00138124,0.00049180625,0.0022737738,0.00015983137,0.00007845947,0.0007697057,9.5255025e-8,0.0000015957145,0.00003484213,0.00018932756,0.9946009],"study_design_scores_gemma":[0.0023960539,0.000394468,0.0005221091,0.0057247626,0.0023586927,0.00006580887,0.00006352545,0.0000011381009,0.000014365866,0.000028723232,0.9882655,0.00016481936],"about_ca_topic_score_codex":0.00008927054,"about_ca_topic_score_gemma":0.000038587055,"teacher_disagreement_score":0.9944361,"about_ca_system_score_codex":0.00012124328,"about_ca_system_score_gemma":0.00016846253,"threshold_uncertainty_score":0.8779198},"labels":[],"label_agreement":null},{"id":"W14166098","doi":"10.2165/00023210-200721060-00001","title":"Long-Acting Formulations of Atypical Antipsychotics","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Risperidone; Tolerability; Discontinuation; Paliperidone Palmitate; Paliperidone; Antipsychotic; Medicine; Atypical antipsychotic; Psychiatry; Schizophrenia (object-oriented programming); Amisulpride; Clozapine; Psychopharmacology; Psychosis; Psychology; Pediatrics; Pharmacology; Adverse effect","score_opus":0.1295796801124919,"score_gpt":0.4456436120748377,"score_spread":0.31606393196234583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W14166098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036313458,0.9952662,0.00032787462,0.000038965292,0.00013308147,0.000805766,0.000027255737,0.000035911744,0.0030018],"genre_scores_gemma":[0.0017358408,0.9930143,0.0041187615,0.000011261105,0.00025330513,0.000019946569,0.00022877868,0.000042850465,0.0005749942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855316,0.00003591016,0.00049893686,0.00023972611,0.00035658097,0.0003156684],"domain_scores_gemma":[0.99871975,0.00032697362,0.00017416159,0.00044642913,0.00010331059,0.00022936358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020221986,0.00022688562,0.0010741155,0.00028102042,0.000054112,0.0000104036835,0.0001049398,0.00022436546,0.00017055019],"category_scores_gemma":[0.00013347654,0.00016152977,0.0005093032,0.00039599376,0.00007012319,0.00002849096,0.000042364227,0.00041275815,0.00017031356],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005313672,0.00018922867,0.00014947316,0.005961668,0.00029157242,0.00006393691,0.00003239628,3.883143e-8,6.2257975e-8,0.0010038047,0.00020241097,0.99157405],"study_design_scores_gemma":[0.0015276972,0.00021486985,0.00202488,0.013128092,0.0014485705,0.00014922603,0.000022655062,0.000008290214,0.0000070286987,0.00016771426,0.98109525,0.00020569879],"about_ca_topic_score_codex":0.000004183645,"about_ca_topic_score_gemma":0.000007891518,"teacher_disagreement_score":0.99136835,"about_ca_system_score_codex":0.00013502309,"about_ca_system_score_gemma":0.00047646766,"threshold_uncertainty_score":0.6586993},"labels":[],"label_agreement":null},{"id":"W143349262","doi":"10.2165/11588160-000000000-00000","title":"Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimerʼs Disease","year":2011,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; North York General Hospital; Sunnybrook Health Science Centre; University of Toronto","funders":"H. Lundbeck A/S","keywords":"Memantine; Psychopharmacology; Aggression; Medicine; Disease; Neurology; Psychiatry; Alzheimer's disease; Dementia; Psychology; Intensive care medicine; Internal medicine","score_opus":0.024210451479408535,"score_gpt":0.3406652819355511,"score_spread":0.3164548304561426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W143349262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572855,0.0014047544,0.00014284442,0.0010353649,0.000034704757,0.0012308129,0.000006760816,0.00001550853,0.0004007001],"genre_scores_gemma":[0.998918,0.00009387243,0.0003205906,0.00017035264,0.00004018536,0.00015376629,0.000076705015,0.00002085836,0.00020564842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906975,0.000037274138,0.000119720185,0.0002706167,0.00023243188,0.0002702262],"domain_scores_gemma":[0.9995186,0.000025222134,0.00003168705,0.00010788936,0.00014841792,0.00016819937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014009279,0.00011320467,0.00016668007,0.00026248422,0.000057081943,0.000025112067,0.000044314642,0.000030853764,0.000017276976],"category_scores_gemma":[0.00006559339,0.000093011826,0.000024955665,0.00016346131,0.000025206951,0.000123518,0.00003071788,0.00007435161,0.0000030471715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003438854,0.0001448315,0.8788659,0.00038073654,0.0000431993,0.00028418514,0.02119859,0.0000038861613,0.0008904674,0.0000054283237,0.00004445288,0.094699465],"study_design_scores_gemma":[0.0041473545,0.0003400087,0.97692186,0.010179803,0.00012551819,0.0000035243193,0.003709978,0.00018494303,0.004154073,0.00009629541,0.000002526026,0.00013410348],"about_ca_topic_score_codex":0.00008283938,"about_ca_topic_score_gemma":0.0003329105,"teacher_disagreement_score":0.098055966,"about_ca_system_score_codex":0.000046207868,"about_ca_system_score_gemma":0.000055678895,"threshold_uncertainty_score":0.37929124},"labels":[],"label_agreement":null},{"id":"W149262272","doi":"10.2165/00023210-200115060-00002","title":"Homocysteine Levels in Patients with Stroke","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Stroke (engine); Homocysteine; Neurology; Medicine; Psychopharmacology; Internal medicine; Cardiology; Pharmacology; Psychiatry","score_opus":0.051505983492836485,"score_gpt":0.3499109390735307,"score_spread":0.29840495558069424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W149262272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029597743,0.98381233,0.0000018037322,0.000027100117,0.00007106914,0.0013578635,0.00010387854,0.00003221212,0.01163396],"genre_scores_gemma":[0.0006743883,0.9716362,0.00005770734,0.0000334626,0.00014762871,0.00007045104,0.00034233596,0.00007706403,0.026960775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803686,0.00007595784,0.00042339004,0.00040149104,0.0005945049,0.0004678098],"domain_scores_gemma":[0.9989755,0.00006647747,0.00010563744,0.00055698626,0.000117520285,0.00017785346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019069435,0.00033890115,0.0014975667,0.00050370424,0.00003201591,0.000022153947,0.00019530338,0.00027628118,0.0003571098],"category_scores_gemma":[0.000043083986,0.00021321763,0.00020204685,0.0007372426,0.00006894923,0.00005814577,0.00008155652,0.00073260843,0.00046706028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003040729,0.00027497218,0.0014216844,0.007196137,0.00014085909,0.00014944868,0.00004684625,4.119813e-8,6.015431e-8,0.0000056707277,0.000704692,0.99002916],"study_design_scores_gemma":[0.0020175031,0.00045491077,0.0027621672,0.013603478,0.00030321864,0.000020745969,0.000014733291,8.474502e-7,5.1319114e-7,8.992836e-7,0.9805909,0.00023009305],"about_ca_topic_score_codex":0.000045019107,"about_ca_topic_score_gemma":0.0000136263725,"teacher_disagreement_score":0.9897991,"about_ca_system_score_codex":0.0002568672,"about_ca_system_score_gemma":0.00042011388,"threshold_uncertainty_score":0.86947626},"labels":[],"label_agreement":null},{"id":"W1819417743","doi":"10.1007/s40263-015-0263-x","title":"The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Major depressive disorder; Cognition; Clinical psychology; Psychology; MEDLINE; Psychiatry; Psychotherapist","score_opus":0.054123109356715667,"score_gpt":0.33149881329799513,"score_spread":0.2773757039412795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1819417743","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036507759,0.990313,0.0000011082683,0.00015351846,0.0001721099,0.0040386636,0.00008885227,0.000019790972,0.0015622018],"genre_scores_gemma":[0.002828766,0.9940121,0.000023077686,0.0000131150155,0.00006341954,0.00065805955,0.000026069116,0.000055083638,0.0023202896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973888,0.0005034688,0.0005549568,0.00048984407,0.00076098175,0.00030196714],"domain_scores_gemma":[0.99807125,0.00043111359,0.00047604335,0.0006948204,0.00020127934,0.00012549618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042658672,0.00047752948,0.0012866518,0.00011225596,0.00015601903,0.000019000252,0.00018606891,0.00021254556,0.000016305103],"category_scores_gemma":[0.00022190054,0.00019770446,0.00032786213,0.00026995866,0.00031964373,0.000042527194,0.0001657701,0.00021854193,0.00001593211],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011532408,0.0006018994,0.0028687522,0.0039012094,0.0005272111,0.000022448967,0.0008068833,6.732385e-8,0.0000019988952,0.000025725702,0.00036411817,0.9907644],"study_design_scores_gemma":[0.0073642945,0.0004982777,0.004654806,0.04298717,0.0065679164,0.00007089425,0.00044597394,0.0000016699305,0.00003880652,0.00017601537,0.93687797,0.00031622176],"about_ca_topic_score_codex":0.00004918649,"about_ca_topic_score_gemma":0.000069376394,"teacher_disagreement_score":0.9904481,"about_ca_system_score_codex":0.0004215142,"about_ca_system_score_gemma":0.0004853545,"threshold_uncertainty_score":0.8062154},"labels":[],"label_agreement":null},{"id":"W183088063","doi":"10.2165/00023210-200216080-00004","title":"Newer Antiepileptic Drugs in Bipolar Disorder","year":2002,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University","funders":"","keywords":"Lamotrigine; Topiramate; Gabapentin; Bipolar disorder; Adjunctive treatment; Carbamazepine; Medicine; Valproic Acid; Mood stabilizer; Mania; Tiagabine; Mood; Mood disorders; Psychiatry; Epilepsy; Internal medicine; Anxiety","score_opus":0.026611214741317578,"score_gpt":0.306428633989374,"score_spread":0.2798174192480564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W183088063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043608667,0.98810524,0.0000053680556,0.00013923283,0.00034015055,0.0014767696,0.00005178629,0.00010991012,0.009727914],"genre_scores_gemma":[0.00016368982,0.98992854,0.0001000845,0.000075026095,0.00020812561,0.00020276655,0.00035157648,0.00016178789,0.008808375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733967,0.00014199922,0.0007688666,0.0007222126,0.0003935071,0.00063373393],"domain_scores_gemma":[0.99850106,0.00011069326,0.00019256043,0.00091020204,0.00004338525,0.00024212297],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000171063,0.0007234898,0.0023547532,0.00057044055,0.000074417694,0.00003440867,0.00023739618,0.00052899163,0.0011393797],"category_scores_gemma":[0.000035035988,0.0005489822,0.0008242692,0.00082555076,0.00010450728,0.000074650285,0.000104290775,0.0008286863,0.0022399877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000044639473,0.0006834997,0.0016559238,0.0074618785,0.00026802756,0.000028014969,0.00050560967,6.0826856e-8,3.2877217e-8,0.00007691266,0.0011268413,0.98818874],"study_design_scores_gemma":[0.0012452945,0.00010300039,0.00045345645,0.0073779337,0.0017433404,0.000068993366,0.000078122284,0.000007212966,1.7520324e-7,0.000023723105,0.98843324,0.0004654943],"about_ca_topic_score_codex":0.000202876,"about_ca_topic_score_gemma":0.000048176582,"teacher_disagreement_score":0.98772323,"about_ca_system_score_codex":0.0002794872,"about_ca_system_score_gemma":0.00024566386,"threshold_uncertainty_score":0.99977374},"labels":[],"label_agreement":null},{"id":"W1965399275","doi":"10.2165/00023210-200822100-00007","title":"Oral Zolmitriptan in the Short-Term Prevention of Menstrual Migraine","year":2008,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Allergan; AstraZeneca","keywords":"Zolmitriptan; Placebo; Medicine; Migraine; Tolerability; Population; Anesthesia; Sumatriptan; Internal medicine; Adverse effect","score_opus":0.05251262070736227,"score_gpt":0.32524584845227344,"score_spread":0.27273322774491116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965399275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364,0.00057495007,0.00001197365,0.0012019997,0.000017581271,0.0002646242,0.000003568063,0.000014684912,0.01427058],"genre_scores_gemma":[0.9937031,0.00019203468,0.00020845012,0.00019852135,0.00010391569,0.000016897837,0.000017145372,0.0000074158843,0.0055525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999218,0.00004396892,0.00023839688,0.00012249642,0.00021723998,0.0001598984],"domain_scores_gemma":[0.9996466,0.00003818771,0.000035432993,0.00020372626,0.00004561143,0.000030442332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002400694,0.00009093586,0.00024693998,0.00007937069,0.00005482329,0.0000019232907,0.000073120835,0.000042903444,0.00006795922],"category_scores_gemma":[0.000051035637,0.00005913905,0.00012099567,0.00020522201,0.00012286735,0.000032425814,0.000024290117,0.00013774991,0.000008659556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039341356,0.0015231237,0.6284667,0.00039279496,0.0003042273,0.00027430843,0.09974342,0.0000012619116,0.010047673,0.0020126794,0.23801856,0.018821836],"study_design_scores_gemma":[0.0019575437,0.000542926,0.96586496,0.00015794564,0.00012867809,0.0001777806,0.007317942,0.000039414965,0.0018491814,0.0002636356,0.02155196,0.00014802327],"about_ca_topic_score_codex":0.00008112675,"about_ca_topic_score_gemma":0.00020821714,"teacher_disagreement_score":0.33739826,"about_ca_system_score_codex":0.00001975688,"about_ca_system_score_gemma":0.000052083727,"threshold_uncertainty_score":0.24116203},"labels":[],"label_agreement":null},{"id":"W1966938384","doi":"10.2165/11533710-000000000-00000","title":"Medication Errors in Psychiatry","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Psychiatry; Pharmacy; MEDLINE; Health care; Patient safety; Family medicine","score_opus":0.14679243568557324,"score_gpt":0.4773872628042648,"score_spread":0.3305948271186916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966938384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005316162,0.97809565,0.000002508681,0.0015790042,0.0023825306,0.00074156595,0.000008078389,0.000038700095,0.017098777],"genre_scores_gemma":[0.000034960587,0.997179,0.0003448452,0.0008039438,0.00042185522,0.000059434748,0.000159416,0.00003645124,0.00096014293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864435,0.000087007975,0.00050969847,0.0002765548,0.000266062,0.00021633648],"domain_scores_gemma":[0.99893326,0.00021388904,0.00026097064,0.00037952504,0.000019564786,0.00019280218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003584426,0.00022526308,0.00093469594,0.00021047264,0.000026139553,0.000009157049,0.00015279849,0.0003922231,0.0004921461],"category_scores_gemma":[0.00019975862,0.00016082935,0.00026956788,0.00027270868,0.000056113662,0.00006786858,0.000039258968,0.0014564383,0.00059601996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007461844,0.00013087774,0.00047039625,0.008742405,0.000035035977,0.000006019456,0.00006305972,8.871599e-9,7.626081e-8,0.00027657655,0.0018372302,0.98843086],"study_design_scores_gemma":[0.00039578008,0.00002682061,0.00009055921,0.005563498,0.00074807944,0.00003095616,0.00002044219,0.000012327207,1.257062e-7,0.00006407689,0.9928986,0.00014873376],"about_ca_topic_score_codex":0.000011637178,"about_ca_topic_score_gemma":0.000009086452,"teacher_disagreement_score":0.9910614,"about_ca_system_score_codex":0.00006345803,"about_ca_system_score_gemma":0.0004604315,"threshold_uncertainty_score":0.766083},"labels":[],"label_agreement":null},{"id":"W1968958193","doi":"10.2165/00023210-200216050-00005","title":"Brain Metastases","year":2002,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiosurgery; Prophylactic cranial irradiation; Radiation therapy; Chemotherapy; Neurosurgery; Brain tumor; Neurology; Oncology; Surgery; Internal medicine; Pathology","score_opus":0.07425616006804142,"score_gpt":0.36175676949319985,"score_spread":0.2875006094251584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968958193","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.2998823e-7,0.98735946,0.000014658033,0.00047252263,0.00021729998,0.0010258706,0.0003111892,0.00010297328,0.010495083],"genre_scores_gemma":[0.0000017246426,0.9777407,0.0010078432,0.00057871244,0.00036343065,0.00016497773,0.00081438135,0.00009709793,0.019231126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980876,0.00019701634,0.0005149454,0.00050789944,0.00031660995,0.0003759333],"domain_scores_gemma":[0.9983501,0.00034601672,0.00020791136,0.0007942392,0.00003777082,0.00026398725],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027513868,0.00052583596,0.002313424,0.00022327034,0.00006921716,0.000031229756,0.00014209897,0.00019922204,0.0027349216],"category_scores_gemma":[0.00011396168,0.0003474583,0.0011964913,0.00034231175,0.00007447461,0.000033203785,0.000069323374,0.00035716698,0.0023364506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000022362108,0.00020297986,3.8365596e-7,0.0076740114,0.0007502427,0.00030579366,0.000031116513,2.3348454e-8,1.3811793e-8,0.00031571393,0.075486116,0.91523135],"study_design_scores_gemma":[0.00057765143,0.0001360021,6.826256e-7,0.0067122695,0.0057537192,0.0004230442,0.000019081699,9.456254e-7,6.238948e-7,0.000019043442,0.98609316,0.00026375378],"about_ca_topic_score_codex":0.000015725784,"about_ca_topic_score_gemma":9.112093e-7,"teacher_disagreement_score":0.9149676,"about_ca_system_score_codex":0.0001564591,"about_ca_system_score_gemma":0.00017494184,"threshold_uncertainty_score":0.9998977},"labels":[],"label_agreement":null},{"id":"W1970445748","doi":"10.1007/s40263-013-0074-x","title":"Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"H. Lundbeck A/S","keywords":"Memantine; Meta-analysis; Context (archaeology); Clinical trial; Psychology; Placebo; Concomitant; Disease; Medicine; Pharmacology; Internal medicine; Clinical psychology; Dementia; Alternative medicine; Pathology","score_opus":0.40846183247815765,"score_gpt":0.4981860252367227,"score_spread":0.08972419275856502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970445748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22316533,0.77495486,0.0000013049919,0.00019551764,0.000024263587,0.0014143006,0.00021141337,0.0000041525086,0.000028852312],"genre_scores_gemma":[0.49930963,0.4999535,0.000080666985,0.000100385536,0.000059549253,0.00026090007,0.000032792974,0.000047924903,0.000154637],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970822,0.0008006959,0.0011349368,0.00035289233,0.00047436383,0.00015493997],"domain_scores_gemma":[0.9964666,0.0015613411,0.00080970174,0.00080536405,0.00023799976,0.00011904538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044034328,0.0003571128,0.0030849369,0.00017164342,0.00004824117,0.000013196216,0.00024022348,0.000058605805,0.00010056965],"category_scores_gemma":[0.0013952802,0.00015766344,0.00096092996,0.00041890552,0.00015175297,0.00004012765,0.00017815552,0.00018341385,0.0000022268741],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097019784,0.0031462328,0.0042024725,0.061429087,0.031103333,0.000015214335,0.0043324837,0.0026974932,0.002347174,0.00010488312,0.0021345664,0.88751686],"study_design_scores_gemma":[0.0034964366,0.0005931448,0.019420087,0.052474853,0.8399062,0.000018594159,0.0012358685,0.003595076,0.060303975,0.000043995507,0.017269922,0.0016418487],"about_ca_topic_score_codex":0.00006698995,"about_ca_topic_score_gemma":0.000006236926,"teacher_disagreement_score":0.885875,"about_ca_system_score_codex":0.000011120129,"about_ca_system_score_gemma":0.00027401175,"threshold_uncertainty_score":0.64293283},"labels":[],"label_agreement":null},{"id":"W1970668720","doi":"10.2165/00023210-200317130-00006","title":"Gabapentin","year":2003,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Gabapentin; Medicine; Psychopharmacology; Pharmacology","score_opus":0.05921623046700229,"score_gpt":0.3718747708260612,"score_spread":0.3126585403590589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970668720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001347245,0.9576006,0.000018950952,0.0000123121945,0.0002903646,0.0006274915,0.000012401384,0.000048068432,0.04138847],"genre_scores_gemma":[0.0000011103526,0.95891476,0.00067371357,0.00014642975,0.00010887902,0.00008785589,0.00016960448,0.00005723269,0.039840396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894446,0.00006695432,0.0002686612,0.00030255472,0.00017568002,0.00024170343],"domain_scores_gemma":[0.9992571,0.000038922037,0.00011869205,0.00042240683,0.00002261829,0.00014029918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014054317,0.00029144486,0.0012114695,0.00010634577,0.000042170763,0.000013095959,0.000077024204,0.00020571519,0.0008421465],"category_scores_gemma":[0.000022423757,0.00020327512,0.0004997393,0.00016359889,0.000017466737,0.000015359747,0.000024989933,0.00021854563,0.002712342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.7185794e-7,0.00009862713,0.0000013954173,0.005459638,0.00021972878,0.000121700105,0.000015375761,1.1401552e-9,8.595164e-8,0.00051977014,0.0031231062,0.9904397],"study_design_scores_gemma":[0.0003332117,0.00003786451,8.159324e-7,0.0070033087,0.0017589352,0.00012273528,0.000007549886,2.4533855e-7,0.0000010905038,0.00006850465,0.99051607,0.00014969138],"about_ca_topic_score_codex":0.0000033201497,"about_ca_topic_score_gemma":1.7952911e-7,"teacher_disagreement_score":0.99029,"about_ca_system_score_codex":0.000108685905,"about_ca_system_score_gemma":0.00020935909,"threshold_uncertainty_score":0.99806416},"labels":[],"label_agreement":null},{"id":"W1973032604","doi":"10.2165/00023210-200923040-00004","title":"Insomnia in Patients with Depression","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Sleep and related disorders","field":"Psychology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Mirtazapine; Venlafaxine; Trazodone; Antidepressant; Depression (economics); Insomnia; Psychiatry; Medicine; Agomelatine; Psychology; Bupropion; Anxiety","score_opus":0.013013225737509685,"score_gpt":0.3057613353038931,"score_spread":0.2927481095663834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973032604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040507573,0.93930244,0.0000016734944,0.0000056182193,0.00044925997,0.0006289117,0.0000077534305,0.00004896361,0.05915029],"genre_scores_gemma":[0.00019295592,0.9980136,0.000016957778,0.00007900697,0.000046034467,0.0000625691,0.00018051427,0.00005508302,0.0013532621],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861443,0.0001465783,0.00034388492,0.00043310982,0.00015512075,0.00030685318],"domain_scores_gemma":[0.99921995,0.000049971244,0.00018296474,0.00045881566,0.000020035532,0.000068232046],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006834324,0.00031054943,0.0007581155,0.00028270655,0.00003512932,0.000012192976,0.0002525086,0.00060476706,0.00039975066],"category_scores_gemma":[0.000008002144,0.00019974927,0.00014039633,0.00041028226,0.000039530914,0.000034150868,0.000029186616,0.0005920247,0.001010961],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018156436,0.00038744256,0.00090524845,0.00027105532,0.00013578458,0.0000102279155,0.00036976166,4.2860177e-7,2.4681962e-10,0.000035554916,0.0028436335,0.9950227],"study_design_scores_gemma":[0.0016420954,0.00006588652,0.0020032958,0.005050747,0.00036945133,0.000001799692,0.000038489965,1.0685714e-7,4.655803e-9,0.00001972664,0.99051553,0.0002928698],"about_ca_topic_score_codex":0.000030862535,"about_ca_topic_score_gemma":0.0000046899895,"teacher_disagreement_score":0.9947298,"about_ca_system_score_codex":0.000054132124,"about_ca_system_score_gemma":0.000048972484,"threshold_uncertainty_score":0.9997669},"labels":[],"label_agreement":null},{"id":"W1974781892","doi":"10.2165/00023210-200620080-00004","title":"Management of Psychiatric Comorbidity in Anorexia Nervosa and??Bulimia Nervosa","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Eating Disorders and Behaviors","field":"Psychology","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Comorbidity; Anorexia nervosa; Bulimia nervosa; Psychiatry; Eating disorders; Panic disorder; Anxiety; Psychology; Phobias; Clinical psychology; Substance abuse; Medicine","score_opus":0.03855472855716737,"score_gpt":0.35430935541663194,"score_spread":0.3157546268594646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974781892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035227113,0.95974284,0.000006328945,0.000021131482,0.00077405095,0.00080958294,0.000047090543,0.00004982204,0.035026424],"genre_scores_gemma":[0.00066001737,0.99508196,0.00045947562,0.00002208304,0.00010772816,0.00016210838,0.00022662965,0.00007081011,0.0032091597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756134,0.00023266123,0.0009127904,0.00065199303,0.00021017705,0.00043101722],"domain_scores_gemma":[0.99862045,0.00006932501,0.0004925568,0.0007214213,0.00002395125,0.0000722825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003018277,0.00047086488,0.001400477,0.0004220031,0.000056000532,0.000022330098,0.0004104946,0.00041286758,0.00029019467],"category_scores_gemma":[0.0000021491887,0.00041734692,0.0003548033,0.00079094496,0.00012461282,0.0000329672,0.00014989151,0.00047482896,0.00011090232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000568713,0.0005421515,0.0051381197,0.0074012456,0.00008189264,0.00006585331,0.000183344,5.036283e-7,2.1870664e-8,0.0014997172,0.012937362,0.9721441],"study_design_scores_gemma":[0.00068077183,0.00009431833,0.00886116,0.0026181645,0.00096983864,0.00001645251,0.0002527174,9.625705e-7,1.4788698e-8,0.00021109162,0.98577017,0.00052433275],"about_ca_topic_score_codex":0.0008321329,"about_ca_topic_score_gemma":0.00006714883,"teacher_disagreement_score":0.9728328,"about_ca_system_score_codex":0.00005668889,"about_ca_system_score_gemma":0.000042636708,"threshold_uncertainty_score":0.99982786},"labels":[],"label_agreement":null},{"id":"W1975713412","doi":"10.1007/s40263-014-0154-6","title":"Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs","year":2014,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; British Columbia Centre of Excellence for Women's Health; University of British Columbia; BC Centre for Disease Control; B.C. Women's Hospital & Health Centre; University of British Columbia Hospital; Vancouver Coastal Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Birth weight; Glatiramer acetate; Pediatrics; Gestational age; Population; Pregnancy; Cohort; Multiple sclerosis; Obstetrics; Internal medicine; Immunology; Biology; Environmental health","score_opus":0.04489987703917808,"score_gpt":0.2901461299783005,"score_spread":0.24524625293912244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975713412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778206,0.00017126881,0.00047329025,0.0056459205,0.000054076245,0.0016241337,0.000112318194,0.00020895936,0.0039279666],"genre_scores_gemma":[0.9938693,0.00012091601,0.0015599072,0.0009422618,0.0001009171,0.00043852875,0.00004075764,0.00009491596,0.0028324716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681044,0.00016371146,0.00043811652,0.0007411156,0.00094095845,0.0009056412],"domain_scores_gemma":[0.9975241,0.0005630827,0.000092426155,0.000830162,0.00015732826,0.00083290844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005040938,0.0004116997,0.00077965,0.0003399872,0.00020061672,0.00007360104,0.00032283136,0.00007973935,0.00009035736],"category_scores_gemma":[0.0010907513,0.00030491574,0.00014329731,0.0005728349,0.00016999667,0.00015783735,0.00024229015,0.00031961763,0.00015866738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014103594,0.0007957866,0.8865858,0.00026974024,0.00024926887,0.000011903508,0.010723647,0.000110901776,0.049233604,0.000031158703,0.01249228,0.038085587],"study_design_scores_gemma":[0.0122413635,0.0003840694,0.9565274,0.0006546816,0.00006384835,6.163774e-7,0.004213605,0.0041957884,0.006372401,0.000017882076,0.014742156,0.0005861502],"about_ca_topic_score_codex":0.0005463054,"about_ca_topic_score_gemma":0.00018586696,"teacher_disagreement_score":0.06994168,"about_ca_system_score_codex":0.0002752233,"about_ca_system_score_gemma":0.00010630679,"threshold_uncertainty_score":0.9999403},"labels":[],"label_agreement":null},{"id":"W1975732958","doi":"10.2165/00023210-200721110-00003","title":"Long-Term and Preventative Treatment for Seasonal Affective Disorder","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Light therapy; Psychiatry; Antidepressant; Medicine; Population; Major depressive disorder; Psychosocial; Bupropion; Pharmacotherapy; Depression (economics); Placebo; Pediatrics; Mood; Psychology; Anxiety; Smoking cessation; Alternative medicine","score_opus":0.06740838111612428,"score_gpt":0.38238176173023886,"score_spread":0.31497338061411456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975732958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017129343,0.9933149,0.0002340329,0.000012402726,0.0003011995,0.0027631356,0.00041034693,0.000043447635,0.0012075569],"genre_scores_gemma":[0.00032514782,0.9924365,0.0000429819,0.000046491743,0.00022619612,0.0006444639,0.00005294501,0.000062439125,0.0061627883],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839544,0.00013261406,0.00023466245,0.0007032343,0.00014357419,0.00039049503],"domain_scores_gemma":[0.998346,0.0010628562,0.00017835647,0.00022074088,0.000018078259,0.00017397148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011020907,0.00041570966,0.0008584308,0.00012417563,0.00015484905,0.000049432212,0.000117532596,0.00018533347,0.00004114568],"category_scores_gemma":[0.00007964203,0.0003180214,0.00039540592,0.00018660331,0.00016118557,0.00008397576,0.000047173955,0.00015374814,0.00006411227],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009745404,0.00010076956,0.00004750669,0.0019719314,0.000041006813,0.000025263607,0.00059105706,4.6255956e-8,0.0000015799909,0.0014222951,0.000044557404,0.9957442],"study_design_scores_gemma":[0.00079150905,0.00023358513,0.00027645455,0.002248201,0.00050194154,0.00012186381,0.000027064138,0.0000020580567,0.00027763433,0.000041351355,0.9950611,0.00041724177],"about_ca_topic_score_codex":0.0000033066224,"about_ca_topic_score_gemma":0.0000077167615,"teacher_disagreement_score":0.995327,"about_ca_system_score_codex":0.00023561121,"about_ca_system_score_gemma":0.00020258577,"threshold_uncertainty_score":0.99992716},"labels":[],"label_agreement":null},{"id":"W1975745615","doi":"10.1007/s40263-014-0181-3","title":"Effect of Extended-Release Dexmethylphenidate and Mixed Amphetamine Salts on Sleep: A Double-Blind, Randomized, Crossover Study in Youth with Attention-Deficit Hyperactivity Disorder","year":2014,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"National Center for Research Resources; University of Illinois at Chicago; Shire; Pfizer","keywords":"Placebo; Attention deficit hyperactivity disorder; Actigraphy; Crossover study; Randomized controlled trial; Medicine; Methylphenidate; Child and adolescent psychiatry; Psychology; Pediatrics; Psychiatry; Physical therapy; Internal medicine; Insomnia","score_opus":0.016511864475409747,"score_gpt":0.302332137416213,"score_spread":0.28582027294080325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975745615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940598,0.00012852186,0.0005189279,0.00019611183,0.00013254835,0.004100885,0.000020933956,0.000079326564,0.00076291926],"genre_scores_gemma":[0.99899274,0.000019486755,0.000062028426,0.000052040097,0.000052542764,0.0002722341,0.00007637026,0.00008767796,0.00038486294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99630964,0.0010016066,0.00066619494,0.0008230972,0.00073963817,0.000459798],"domain_scores_gemma":[0.9969368,0.0015284488,0.00040080157,0.0007532973,0.00017997123,0.00020070751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019766877,0.0005303729,0.0017116427,0.0004283675,0.00013187986,0.000057166162,0.00012744084,0.00015691988,0.00007013644],"category_scores_gemma":[0.0006518221,0.00038086934,0.000255144,0.00055487396,0.00032783937,0.00030464624,0.00009930932,0.00054048176,0.000046393958],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51353884,0.0049243676,0.4633657,0.00030223178,0.00049116125,0.000028582792,0.0011389821,0.0003274039,0.00083926244,0.00009377167,0.0000029959945,0.0149467215],"study_design_scores_gemma":[0.75512695,0.003104125,0.2346981,0.00028078517,0.0014095263,0.000027222146,0.0031050583,0.0013806318,0.00033808892,0.000012423584,0.000014438371,0.0005026669],"about_ca_topic_score_codex":0.00070957013,"about_ca_topic_score_gemma":0.00032134546,"teacher_disagreement_score":0.2415881,"about_ca_system_score_codex":0.00006986456,"about_ca_system_score_gemma":0.000052304305,"threshold_uncertainty_score":0.99986434},"labels":[],"label_agreement":null},{"id":"W1977367905","doi":"10.2165/11318660-000000000-00000","title":"Agomelatine","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"St. Jude Medical","keywords":"Agomelatine; Clinical Global Impression; Tolerability; Venlafaxine; Antidepressant; Placebo; Medicine; Major depressive disorder; Internal medicine; Pharmacotherapy; Psychology; Psychiatry; Mood; Anxiety; Adverse effect","score_opus":0.05068819814957893,"score_gpt":0.3752197086533771,"score_spread":0.3245315105037982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977367905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000035343328,0.9437573,0.0000024905094,0.00012399907,0.00016325554,0.0007334181,0.000011847123,0.00016168067,0.055042505],"genre_scores_gemma":[0.0000042563443,0.96894354,0.00048368156,0.00009091001,0.00042361853,0.000042039203,0.0003431039,0.000059253653,0.029609626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987106,0.000047473794,0.00036405772,0.00037024022,0.0002786149,0.00022905385],"domain_scores_gemma":[0.99890375,0.00007774082,0.0001776726,0.00065671856,0.000024187115,0.00015991516],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000084538246,0.0003557139,0.0015486713,0.00018507031,0.000036512152,0.00001270094,0.00011791464,0.00031061543,0.0004333192],"category_scores_gemma":[0.000045497294,0.00023321496,0.00051190535,0.00018019394,0.000026951098,0.000030474912,0.000044661007,0.00036366688,0.0017787428],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035473672,0.000110272755,0.0000029140922,0.004164996,0.0000921345,0.000090500005,0.000021862777,1.0777274e-8,1.3615487e-7,0.00003266367,0.010307433,0.9851735],"study_design_scores_gemma":[0.00048642687,0.00010298819,0.000026790252,0.023059003,0.0019043019,0.00013737036,0.000002756688,3.8364294e-7,0.0000013318979,0.000028057599,0.97407544,0.00017515264],"about_ca_topic_score_codex":0.000002663262,"about_ca_topic_score_gemma":1.6565178e-7,"teacher_disagreement_score":0.9849984,"about_ca_system_score_codex":0.0001556272,"about_ca_system_score_gemma":0.00017551855,"threshold_uncertainty_score":0.99899846},"labels":[],"label_agreement":null},{"id":"W1979036437","doi":"10.2165/00023210-200822070-00003","title":"Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Parkinson's UK; Valeant Pharmaceuticals International","keywords":"Ropinirole; Pramipexole; Rasagiline; Medicine; Levodopa; Parkinson's disease; Quality of life (healthcare); Clinical trial; Selegiline; Disease; Psychology; Physical medicine and rehabilitation; Internal medicine","score_opus":0.05992035562253328,"score_gpt":0.38266966703549743,"score_spread":0.32274931141296415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979036437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47209242,0.52450556,7.5555437e-7,0.0000039029783,0.00006585275,0.0018488005,0.0010838584,0.000022116494,0.00037670525],"genre_scores_gemma":[0.26442412,0.73441637,0.000040178686,0.000033396653,0.000039186387,0.00016641298,0.00071955053,0.000053603384,0.00010716401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971065,0.0002954922,0.0009201008,0.0006140874,0.0006755709,0.00038824853],"domain_scores_gemma":[0.997739,0.00014014896,0.0007620134,0.0005451845,0.00011967893,0.0006939383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008711143,0.00065237784,0.0028642388,0.00032738282,0.00003578328,0.000004510902,0.0001605591,0.00020419569,0.0002471725],"category_scores_gemma":[0.00008938098,0.00037445387,0.0010589625,0.0004089973,0.0001168927,0.000049715567,0.000050832212,0.00024077564,0.000037057383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067043914,0.024497185,0.5948254,0.005117708,0.0059327064,0.0002675656,0.000105882544,0.0000048271554,2.838212e-7,0.000021513797,0.0005438407,0.3619787],"study_design_scores_gemma":[0.013920213,0.0023322112,0.9226718,0.0059910174,0.0041199354,0.0000016385899,0.0000049481923,0.0000020013047,0.0000014000349,0.00000991027,0.050530806,0.0004141501],"about_ca_topic_score_codex":0.0001260664,"about_ca_topic_score_gemma":0.0000010444095,"teacher_disagreement_score":0.36156455,"about_ca_system_score_codex":0.0005514595,"about_ca_system_score_gemma":0.0011330548,"threshold_uncertainty_score":0.9998707},"labels":[],"label_agreement":null},{"id":"W1980903742","doi":"10.2165/00023210-200721060-00006","title":"Impact of Psychotropic Medications on Simulated Driving","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Older Adults Driving Studies","field":"Health Professions","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"PsycINFO; Psychotropic drug; Medicine; Poison control; Driving simulator; Injury prevention; MEDLINE; Human factors and ergonomics; Population; Psychiatry; Physical medicine and rehabilitation; Emergency medicine; Simulation; Drug; Computer science","score_opus":0.1407989081027825,"score_gpt":0.5623821765905959,"score_spread":0.42158326848781336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980903742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00092323485,0.97900665,0.000056081233,0.00008306569,0.0012662848,0.0019521927,0.00010079147,0.00022404955,0.016387679],"genre_scores_gemma":[0.002600254,0.9933893,0.000060820894,0.000065869244,0.0005510497,0.00009627659,0.000103596154,0.000119205055,0.0030136365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996105,0.00058758626,0.0015567247,0.0005221157,0.00046182342,0.0007667218],"domain_scores_gemma":[0.9937316,0.003491138,0.0011858334,0.0011126776,0.00027199974,0.00020672263],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006458242,0.00054040924,0.0021062572,0.00061906944,0.00053514657,0.0000053502968,0.00055488566,0.0006594297,0.00068386184],"category_scores_gemma":[0.00064254797,0.00037858888,0.0007820714,0.0008508128,0.00015367426,0.000047947175,0.00017083004,0.0016754603,0.0012040465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004197597,0.00032706544,0.009475168,0.023575576,0.0017677333,0.000005561411,0.005001506,0.000010024607,2.9323098e-7,0.00022530004,0.033738695,0.92586887],"study_design_scores_gemma":[0.00040498463,0.00010808205,0.011068226,0.06286955,0.00069887587,0.0000010069763,0.00015354152,0.0000078437015,4.3247127e-8,0.000056389774,0.92426884,0.00036260978],"about_ca_topic_score_codex":0.00014658314,"about_ca_topic_score_gemma":0.000078886515,"teacher_disagreement_score":0.9255063,"about_ca_system_score_codex":0.0006828337,"about_ca_system_score_gemma":0.00096776994,"threshold_uncertainty_score":0.9998666},"labels":[],"label_agreement":null},{"id":"W1981711813","doi":"10.2165/00023210-200620010-00003","title":"Polytherapy in Bipolar Disorder","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"H. Lundbeck A/S; Eli Lilly and Company","keywords":"Bipolar disorder; Lamotrigine; Lithium (medication); Olanzapine; Treatment of bipolar disorder; Mania; Mood stabilizer; Quetiapine; Psychiatry; Psychology; Polypharmacy; Antipsychotic; Medicine; Atypical antipsychotic; Bipolar I disorder; Antidepressant; Mood; Fluoxetine; Internal medicine; Schizophrenia (object-oriented programming); Epilepsy; Anxiety","score_opus":0.02294556742025127,"score_gpt":0.32654263498281927,"score_spread":0.303597067562568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981711813","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000140403135,0.99394006,0.000007316736,0.00013159249,0.00013847611,0.0010177869,0.000047580663,0.00006978705,0.004633391],"genre_scores_gemma":[0.000028229138,0.9942536,0.00007382422,0.000054618227,0.00015165318,0.00016413066,0.00054983166,0.000101023805,0.004623129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984541,0.00007574713,0.00047175624,0.00042213508,0.00021132301,0.00036495185],"domain_scores_gemma":[0.99918985,0.000051258943,0.00011160561,0.00052927,0.000018942677,0.000099064615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009849653,0.0004479034,0.0015387412,0.00035526013,0.00004013351,0.000016947073,0.00012570074,0.0002779957,0.00020137035],"category_scores_gemma":[0.000006786043,0.00032445564,0.0005485357,0.00047785608,0.000052887965,0.00003126645,0.000033192136,0.00044442798,0.00039646483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000041892586,0.00046395132,0.0018706211,0.0037557278,0.00014539943,0.000023895373,0.000055002496,3.0119608e-8,3.3915377e-8,0.00011046566,0.00045000174,0.9931207],"study_design_scores_gemma":[0.0009417621,0.00007144454,0.0005540928,0.0034833371,0.00068047893,0.0000611143,0.0000120769555,8.1394137e-7,2.1478196e-7,0.000035699515,0.99389106,0.00026787783],"about_ca_topic_score_codex":0.0004176537,"about_ca_topic_score_gemma":0.000274338,"teacher_disagreement_score":0.9934411,"about_ca_system_score_codex":0.00018496923,"about_ca_system_score_gemma":0.000274498,"threshold_uncertainty_score":0.9999207},"labels":[],"label_agreement":null},{"id":"W1981954205","doi":"10.2165/11204820-000000000-00000","title":"Spotlight on Cerebrolysin in Dementia†","year":2010,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Neurological Disorders and Treatments","field":"Neuroscience","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cerebrolysin; Dementia; Medicine; Clinical trial; Placebo; Randomized controlled trial; Vascular dementia; Internal medicine; Disease; Pathology; Alternative medicine","score_opus":0.016491946130179354,"score_gpt":0.2528667359144064,"score_spread":0.23637478978422705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981954205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531861,0.0000060686907,0.0000016247569,0.0012774786,0.0002693321,0.00012039482,0.000004060289,0.00004904682,0.045085922],"genre_scores_gemma":[0.99568444,0.000009545827,0.000022407708,0.0036955015,0.000021487273,0.00001700137,8.816024e-7,0.000009822554,0.00053889584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991746,0.00003794151,0.00010350274,0.00032119767,0.00014111417,0.00022165025],"domain_scores_gemma":[0.99960965,0.00008826385,0.000027109716,0.00021444114,0.000004015562,0.000056499754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041523428,0.00009864633,0.0000910993,0.000063648156,0.00006362316,0.000026757767,0.00016799633,0.000048874645,0.0004005957],"category_scores_gemma":[0.00009000267,0.00007437657,0.000040899824,0.00017488272,0.000057273024,0.000054218985,0.000040082567,0.00021162421,0.00076521764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020299098,0.003210438,0.061453138,0.0000116907695,0.000013519549,0.0004707621,0.0005550702,0.000031296648,0.8100773,0.079599604,0.0030089624,0.041365247],"study_design_scores_gemma":[0.003950405,0.000521224,0.20954269,0.000013728622,0.000027610165,0.000010007623,0.000032556232,0.00032565437,0.6813562,0.04542866,0.05824499,0.00054629665],"about_ca_topic_score_codex":0.000013086842,"about_ca_topic_score_gemma":0.000024348643,"teacher_disagreement_score":0.14808956,"about_ca_system_score_codex":0.0000054424827,"about_ca_system_score_gemma":0.000007719943,"threshold_uncertainty_score":0.98355794},"labels":[],"label_agreement":null},{"id":"W1986575050","doi":"10.1007/s40263-014-0170-6","title":"Changes in Gait Variability with Anti-dementia Drugs: A Systematic Review and Meta-analysis","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Balance, Gait, and Falls Prevention","field":"Health Professions","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Dementia; Memantine; Meta-analysis; Galantamine; Medicine; Donepezil; Gait; Delirium; Strictly standardized mean difference; Confidence interval; Physical medicine and rehabilitation; Psychology; Psychiatry; Physical therapy; Disease; Internal medicine","score_opus":0.06437633476044347,"score_gpt":0.3955352433222,"score_spread":0.33115890856175656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986575050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000031226446,0.989131,0.00009953024,0.00031052233,0.00008718964,0.008325881,0.00014937612,0.00007309963,0.0018202886],"genre_scores_gemma":[0.00017549872,0.9911395,0.00015054051,0.000939727,0.000069549154,0.004916605,0.0003025733,0.00006502514,0.002241016],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9884049,0.0073673762,0.0021887545,0.0009796554,0.0004276644,0.0006315932],"domain_scores_gemma":[0.99467164,0.0012248823,0.0022085642,0.0015346698,0.00018273594,0.00017752255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009126137,0.00071688625,0.013131428,0.0004480731,0.00026829683,0.000028353703,0.0004618185,0.0005040188,0.0002858267],"category_scores_gemma":[0.000287915,0.00042868458,0.0013853073,0.0014663765,0.00008708309,0.000099745426,0.00016304426,0.0009846126,0.00020639361],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[9.1107745e-7,0.00010188549,0.000029307872,0.9521533,0.045993384,0.0000014316555,0.00033842635,1.3708532e-8,2.6979114e-8,0.00018279161,0.00036580054,0.0008327055],"study_design_scores_gemma":[0.0002000068,0.000019220099,0.0000677421,0.13627358,0.78719467,0.0000019245167,0.00011968955,0.000004459392,2.4375564e-9,0.0000630149,0.075648695,0.00040700307],"about_ca_topic_score_codex":0.00011681226,"about_ca_topic_score_gemma":0.0004363149,"teacher_disagreement_score":0.81587976,"about_ca_system_score_codex":0.00016464555,"about_ca_system_score_gemma":0.0002463923,"threshold_uncertainty_score":0.9998165},"labels":[],"label_agreement":null},{"id":"W1989649280","doi":"10.2165/00023210-200721010-00004","title":"Pharmacological Management of Attention-Deficit Hyperactivity Disorder in Adolescents","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"Pfizer","keywords":"Evening; Discontinuation; Methylphenidate; Attention deficit hyperactivity disorder; Comorbidity; Psychiatry; Stimulant; Psychology; Atomoxetine; Medicine; Clinical psychology; Pediatrics","score_opus":0.07513405611314446,"score_gpt":0.40225640376968713,"score_spread":0.3271223476565427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989649280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.071945615,0.92085207,0.00014085449,0.000048692185,0.00036748158,0.0024158123,0.000029615656,0.0000783583,0.004121495],"genre_scores_gemma":[0.053341962,0.94438905,0.00015410551,0.000039004954,0.00007908109,0.00015104804,0.00013534697,0.00009360329,0.0016167917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966754,0.00021907703,0.001117653,0.0007610419,0.0006764087,0.00055044476],"domain_scores_gemma":[0.99853235,0.00012074834,0.0005438323,0.00054054364,0.00010480399,0.00015770688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054538844,0.0005894928,0.0022898947,0.00062622136,0.000056670146,0.000015513011,0.00026070292,0.00047152987,0.00043027548],"category_scores_gemma":[0.000038238995,0.0005069321,0.000896093,0.0010074935,0.00013152536,0.00013160991,0.00022969242,0.0010740083,0.0004112509],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006422201,0.003285382,0.020562988,0.035789616,0.0005067027,0.00023077024,0.000014799404,0.0000020203402,0.000004491813,0.00007495106,0.000035001493,0.93942904],"study_design_scores_gemma":[0.0061748424,0.00017787874,0.066168465,0.076227434,0.007744948,0.00018823655,0.0014944213,0.00003447716,5.689166e-7,0.0000105432,0.8404584,0.0013197685],"about_ca_topic_score_codex":0.000029332403,"about_ca_topic_score_gemma":0.00000642733,"teacher_disagreement_score":0.9381093,"about_ca_system_score_codex":0.00031749363,"about_ca_system_score_gemma":0.00012161726,"threshold_uncertainty_score":0.9997382},"labels":[],"label_agreement":null},{"id":"W1989957365","doi":"10.2165/11530220-000000000-00000","title":"Medical Management of Lennox-Gastaut Syndrome","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Lennox–Gastaut syndrome; Lamotrigine; Topiramate; Felbamate; Epilepsy; Medicine; Vigabatrin; Dravet syndrome; Seizure types; Pediatrics; Epilepsy syndromes; Anticonvulsant; Adjunctive treatment; Ketogenic diet; Psychiatry; Anesthesia; Psychology; Internal medicine","score_opus":0.03815240175996676,"score_gpt":0.37968651696910316,"score_spread":0.3415341152091364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989957365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009073591,0.9676708,0.0000070430997,0.00018548404,0.00021573975,0.0012118754,0.00004248548,0.00004604468,0.030529777],"genre_scores_gemma":[0.00011963781,0.98923457,0.00040207166,0.000028784543,0.00010379083,0.00020686339,0.00024972262,0.000058403442,0.009596151],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973476,0.00007513932,0.0005907296,0.000406855,0.001142604,0.00043710726],"domain_scores_gemma":[0.9982741,0.00011481,0.00016633303,0.00082202937,0.000062077444,0.00056068285],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00044533476,0.00034219213,0.0017952182,0.00023922225,0.000037284735,0.000009520563,0.0003255335,0.000414919,0.001957621],"category_scores_gemma":[0.00004292644,0.00022639356,0.0006034697,0.0002767545,0.00018880384,0.000022598886,0.00022508208,0.00087998534,0.0007980525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008486761,0.00033969712,0.00001719716,0.036918208,0.00084044633,0.0028302467,0.000016999456,1.8578454e-9,3.314803e-8,0.000525186,0.0010223783,0.95748115],"study_design_scores_gemma":[0.00074865605,0.00024328889,0.000060840353,0.030008525,0.0014269539,0.0007844467,0.000021611757,7.639394e-7,8.987829e-7,0.000030235718,0.9665304,0.00014337199],"about_ca_topic_score_codex":0.000012954269,"about_ca_topic_score_gemma":0.0000021081196,"teacher_disagreement_score":0.96550804,"about_ca_system_score_codex":0.00011503592,"about_ca_system_score_gemma":0.0005478664,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W1992472429","doi":"10.2165/00023210-200317090-00005","title":"Speed of Onset and Efficacy of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine","year":2003,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Zolmitriptan; Migraine; Medicine; Aura; Tolerability; Sumatriptan; Nasal spray; Anesthesia; Placebo; Migraine treatment; Headaches; Neurology; Adverse effect; Internal medicine; Surgery; Nasal administration; Agonist; Pharmacology","score_opus":0.023659572465400125,"score_gpt":0.3068186002694172,"score_spread":0.2831590278040171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992472429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072534,0.0019140756,0.0000010176313,0.00087490433,0.000008983595,0.00031667153,0.000023307108,0.0000037699124,0.006131961],"genre_scores_gemma":[0.99767387,0.0005333944,0.00020378771,0.00006953922,0.000019479006,0.0000037321843,0.0000075050148,0.000006522319,0.001482148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992949,0.000053732776,0.00027601366,0.00010977576,0.00014362196,0.00012195741],"domain_scores_gemma":[0.99943066,0.00018043764,0.000088004126,0.00022243477,0.000047508976,0.000030973028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018523385,0.000102050835,0.00041828596,0.000087974295,0.000016952405,0.0000011304328,0.00003964939,0.00003635497,0.00003001535],"category_scores_gemma":[0.000108512904,0.000060233153,0.00010234992,0.0001944488,0.00015592072,0.000011638795,0.000009005372,0.000049359667,0.0000011369416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002458338,0.008391627,0.5942848,0.0009646531,0.0024585451,0.00016853497,0.2351057,0.0000028533718,0.09649049,0.0047896868,0.047032174,0.007852651],"study_design_scores_gemma":[0.019404298,0.0046904087,0.7827214,0.00033728033,0.0012159724,0.00009962388,0.019059723,0.000015551348,0.13545904,0.00025123998,0.036504388,0.00024110968],"about_ca_topic_score_codex":0.00016887713,"about_ca_topic_score_gemma":0.00009492467,"teacher_disagreement_score":0.21604598,"about_ca_system_score_codex":0.00001595213,"about_ca_system_score_gemma":0.000055564877,"threshold_uncertainty_score":0.24562368},"labels":[],"label_agreement":null},{"id":"W1993556404","doi":"10.1007/s40263-014-0171-5","title":"Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; H. Lundbeck A/S; Canadian Network for Mood and Anxiety Treatments; GlaxoSmithKline; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Antidepressant; Major depressive disorder; Medicine; Randomized controlled trial; Depression (economics); Psychiatry; Clinical trial; Psychology; Internal medicine; Mood; Anxiety","score_opus":0.13009671777666748,"score_gpt":0.46305596167243873,"score_spread":0.33295924389577125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993556404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003146121,0.99301344,0.00001486093,0.00030996944,0.0005995941,0.0016459932,0.000008448814,0.00008871349,0.0011728328],"genre_scores_gemma":[0.0039078672,0.99399674,0.00011508051,0.0000066503494,0.001250983,0.00027040017,0.000026659543,0.00008038874,0.00034521354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640673,0.0006818501,0.00063299725,0.0008976878,0.00080326246,0.0005774391],"domain_scores_gemma":[0.99739957,0.0011490597,0.00021097044,0.00085864187,0.00013343613,0.00024834726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013758792,0.0004963846,0.0016398897,0.0010647253,0.00022063853,0.00021766247,0.00027897613,0.00038427758,0.000033880086],"category_scores_gemma":[0.00025972453,0.00035373052,0.00026522425,0.0007364071,0.00013410154,0.0003826679,0.0002617568,0.0019378628,0.00009240403],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003893579,0.00016592817,0.0003946138,0.014995976,0.00006958246,0.00006758461,0.0009403901,1.10383404e-7,0.0000064220726,0.00010436289,0.0006520279,0.9825641],"study_design_scores_gemma":[0.0005640273,0.00016135565,0.005438161,0.103708826,0.00044234822,0.000062725434,0.00047851473,0.0000071136974,0.0000023489513,0.00008736817,0.88875824,0.0002889774],"about_ca_topic_score_codex":0.00024057472,"about_ca_topic_score_gemma":0.000032419794,"teacher_disagreement_score":0.98227507,"about_ca_system_score_codex":0.00028295178,"about_ca_system_score_gemma":0.0006761238,"threshold_uncertainty_score":0.99989146},"labels":[],"label_agreement":null},{"id":"W1997515685","doi":"10.2165/00023210-200418001-00003","title":"Sociodemographic Profile of Insomniac Patients across National Surveys","year":2004,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Sleep and related disorders","field":"Psychology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Psychopharmacology; Medicine; MEDLINE; Psychology; Psychiatry; Clinical psychology; Political science","score_opus":0.013071866697118809,"score_gpt":0.30012676987453624,"score_spread":0.28705490317741744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997515685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96053815,0.00018450615,0.00008867847,0.00015191121,0.0006937165,0.00018570569,0.00010877339,0.000048979226,0.037999585],"genre_scores_gemma":[0.9989543,0.000013386331,0.00005580083,0.00014940489,0.000033507757,0.000026400308,0.000111985566,0.000017387856,0.000637803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989628,0.00010706639,0.00022149149,0.00020426155,0.0002552843,0.00024907608],"domain_scores_gemma":[0.99947417,0.000049943872,0.000098872886,0.0001526775,0.00017531705,0.00004900319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031595852,0.00010234787,0.00012725103,0.00008213446,0.000094562245,0.0000071010863,0.00014844068,0.00019050288,0.0004563705],"category_scores_gemma":[0.00003602195,0.00009363898,0.00010168228,0.0003317741,0.00018943826,0.0000549453,0.000029561119,0.00016382399,0.0004423795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012687674,0.006607984,0.8116514,0.00006154285,0.0016001601,0.000006015324,0.07061421,0.00026042695,0.00014135802,0.02592519,0.014795192,0.06820961],"study_design_scores_gemma":[0.008190674,0.00014608359,0.97790116,0.000028485658,0.00003642868,0.0000012408304,0.0028694244,0.0000057749685,0.00021018952,0.006809559,0.003506379,0.00029457788],"about_ca_topic_score_codex":0.00015023393,"about_ca_topic_score_gemma":0.000013338989,"teacher_disagreement_score":0.16624975,"about_ca_system_score_codex":0.000031013224,"about_ca_system_score_gemma":0.00004751597,"threshold_uncertainty_score":0.5686041},"labels":[],"label_agreement":null},{"id":"W2010260169","doi":"10.2165/0023210-200923010-00001","title":"Psychopharmacological Treatment of Oppositional Defiant Disorder","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psychopharmacology; Conduct disorder; Psychology; Psychotherapist; Neurology; Medicine; Psychiatry","score_opus":0.11637437986233445,"score_gpt":0.42922391749292177,"score_spread":0.3128495376305873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010260169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00093545154,0.9885994,0.000030966017,0.00017257276,0.00017812413,0.0012423388,0.00013344569,0.000060948343,0.00864674],"genre_scores_gemma":[0.00037375762,0.9951733,0.00020500997,0.000058276346,0.00019490147,0.00027977515,0.00056119874,0.000060871087,0.0030929134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981878,0.00012214777,0.0006091649,0.00045612155,0.0003615047,0.00026327433],"domain_scores_gemma":[0.9988749,0.00019578567,0.00030496367,0.00037236343,0.00009303829,0.00015896843],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000037917216,0.00044359048,0.0019501215,0.00021141183,0.00007713401,0.0000065509807,0.00010201691,0.00032617603,0.0015857681],"category_scores_gemma":[0.000022463873,0.00030836122,0.0011995868,0.0002926962,0.00016202842,0.000043362274,0.00003070597,0.00023897192,0.0004978307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048683036,0.0032826718,0.000103127655,0.0026308387,0.00062870956,0.00010868699,0.00009209158,0.0000010855439,0.0000028004067,0.00008129309,0.0031341724,0.98988587],"study_design_scores_gemma":[0.0016096398,0.00037961203,0.00013071208,0.001526546,0.0015542008,0.00072174886,0.000074402196,0.000007025335,5.853854e-7,0.0000062332133,0.9937396,0.0002497108],"about_ca_topic_score_codex":0.000011987519,"about_ca_topic_score_gemma":5.1408927e-7,"teacher_disagreement_score":0.9906054,"about_ca_system_score_codex":0.00022985454,"about_ca_system_score_gemma":0.00039634935,"threshold_uncertainty_score":0.9999368},"labels":[],"label_agreement":null},{"id":"W2011191894","doi":"10.2165/11530250-000000000-00000","title":"Progress in Defining Optimal Treatment Outcome in Schizophrenia","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"National Institutes of Health; National Institute of Mental Health; Medicure; Eli Lilly and Company","keywords":"Conceptualization; Tolerability; Clozapine; Schizophrenia (object-oriented programming); Psychology; Quality of life (healthcare); Psychiatry; Cognition; Psychotherapist; Psychopharmacology; Medicine; Clinical psychology; Adverse effect","score_opus":0.0640252557170683,"score_gpt":0.39485922979359467,"score_spread":0.33083397407652637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011191894","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004279154,0.99202085,3.7869444e-7,0.00022018544,0.000088742796,0.0023186642,0.000041156618,0.000080888065,0.0009500096],"genre_scores_gemma":[0.0015976304,0.99182016,0.00430774,0.000023627583,0.00014581675,0.0009985793,0.00044902615,0.000087459324,0.0005699483],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659324,0.00019496238,0.0010367945,0.0008083905,0.00047912452,0.00088751497],"domain_scores_gemma":[0.9984946,0.00018165704,0.00019415583,0.0007175196,0.000034514545,0.0003775308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003161268,0.00074884633,0.0029511945,0.001136145,0.000049418886,0.00005744573,0.00023271082,0.00039121142,0.000087838744],"category_scores_gemma":[0.000064780084,0.00051707507,0.0006541495,0.0008893073,0.00009701653,0.000068903,0.00008045685,0.0007614395,0.0005652086],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079877203,0.0008697113,0.0026971395,0.0020042358,0.00016251323,0.0021514304,0.000113311966,6.010827e-7,8.326231e-9,0.00031169306,0.000031234373,0.9908593],"study_design_scores_gemma":[0.036118384,0.0035493732,0.014083242,0.053823978,0.0022570395,0.0007877194,0.00014645174,0.00006307026,0.0000041092094,0.00015301288,0.88734394,0.0016696529],"about_ca_topic_score_codex":0.00007373654,"about_ca_topic_score_gemma":0.00011603593,"teacher_disagreement_score":0.9891897,"about_ca_system_score_codex":0.0018704253,"about_ca_system_score_gemma":0.0014588718,"threshold_uncertainty_score":0.9997281},"labels":[],"label_agreement":null},{"id":"W2012825205","doi":"10.2165/00023210-200317070-00001","title":"Vaccines for Alzheimer??s Disease","year":2003,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Genetically modified mouse; Disease; Amyloid precursor protein; Alzheimer's disease; Pathogenesis; Presenilin; Dementia; Amyloid (mycology); BACE1-AS; Transgene; Medicine; Neuroscience; Neurology; Pathology; Biology; Gene; Genetics","score_opus":0.09274854522922653,"score_gpt":0.4092834529539729,"score_spread":0.31653490772474635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012825205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023107077,0.9923469,0.000007965974,0.00010061565,0.00022810468,0.0040613334,0.00061314553,0.00009697225,0.0025426925],"genre_scores_gemma":[0.00002279235,0.9940536,0.00021407918,0.00012983338,0.00045912183,0.0017482254,0.001948639,0.00016304014,0.0012606853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765444,0.000102191814,0.0004806114,0.0006774465,0.00040738354,0.0006779442],"domain_scores_gemma":[0.9972754,0.00022157088,0.00017293444,0.00085302006,0.00016909244,0.0013079519],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014613042,0.0006002706,0.0017258836,0.00024975213,0.00015081505,0.00004306449,0.00019974896,0.00020378496,0.0003863573],"category_scores_gemma":[0.00010568516,0.0004246099,0.0013826253,0.0003025273,0.00006577732,0.00006782651,0.000059795435,0.00025019387,0.00084876525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012829524,0.0006207008,0.00005154049,0.014262551,0.020340608,0.00023435823,0.000012483893,2.7071355e-8,4.4880237e-9,0.00025452685,0.02292481,0.9411701],"study_design_scores_gemma":[0.0012610566,0.000116765674,0.00001927286,0.004887565,0.03143114,0.000026110023,0.000008526329,0.000002443355,4.183247e-7,0.00015552036,0.96175456,0.0003366294],"about_ca_topic_score_codex":0.0000047396143,"about_ca_topic_score_gemma":3.553627e-7,"teacher_disagreement_score":0.94083345,"about_ca_system_score_codex":0.00012632261,"about_ca_system_score_gemma":0.0017522193,"threshold_uncertainty_score":0.9999292},"labels":[],"label_agreement":null},{"id":"W2017931746","doi":"10.2165/00023210-200822040-00001","title":"Use of Smoking Cessation Therapies in Individuals with Psychiatric Illness","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Psychiatry; Medicine; Bupropion; Smoking cessation; Population; Psychological intervention; Mental illness; Nicotine replacement therapy; Mental health; Depression (economics); Medical prescription; Varenicline; Nicotine","score_opus":0.06734823777550802,"score_gpt":0.33724200484006217,"score_spread":0.26989376706455415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017931746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08217373,0.91636705,0.000012769038,0.00002432375,0.00019540994,0.0008683386,0.000029003873,0.000046689678,0.0002826828],"genre_scores_gemma":[0.03365272,0.9655267,0.00012084142,0.000023735296,0.00010420328,0.000107896194,0.0002972123,0.000058340625,0.00010835527],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983175,0.0001164833,0.00056511967,0.0003032981,0.00051252247,0.00018511864],"domain_scores_gemma":[0.99884486,0.0001300949,0.0005081507,0.0003834744,0.000089125395,0.000044308235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016025055,0.0002913571,0.0011603774,0.00072642614,0.000059668273,0.00002198309,0.00011304324,0.00031493237,0.00005590398],"category_scores_gemma":[0.000029748655,0.00020653584,0.00018059931,0.0009871472,0.000084583044,0.00014264563,0.00002003101,0.00039270963,0.000001572294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008164162,0.0002001393,0.10803277,0.004652333,0.00015363764,0.000008719837,0.0022821606,0.0000012227595,1.9836013e-7,0.00004199424,0.00015151934,0.8844671],"study_design_scores_gemma":[0.0017310865,0.00020745334,0.11979431,0.030851308,0.0031568622,0.00018350451,0.00054559717,0.000001401532,0.000015208128,0.000024290064,0.84275675,0.00073224533],"about_ca_topic_score_codex":0.00007872494,"about_ca_topic_score_gemma":0.0000037689563,"teacher_disagreement_score":0.8837349,"about_ca_system_score_codex":0.00013083781,"about_ca_system_score_gemma":0.00031231658,"threshold_uncertainty_score":0.8422287},"labels":[],"label_agreement":null},{"id":"W2021985890","doi":"10.2165/00023210-200721090-00001","title":"Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Riverview Hospital; Simon Fraser University; University of British Columbia","funders":"","keywords":"Schizophrenia (object-oriented programming); Clinical trial; Psychiatry; Antipsychotic; Psychological intervention; Quality of life (healthcare); Medicine; Psychosis; Management of schizophrenia; Psychopharmacology; Psychology; Clinical psychology; Psychotherapist; Internal medicine","score_opus":0.7156904257415474,"score_gpt":0.6128598546362802,"score_spread":0.10283057110526717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021985890","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006732749,0.99094176,0.0017693657,0.00028363676,0.00020346769,0.0058924393,0.00018672837,0.000008023127,0.000041322462],"genre_scores_gemma":[0.0006103785,0.96661055,0.03190525,0.000014913957,0.00043785485,0.00023089578,0.000060369865,0.000029711935,0.00010006572],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910571,0.004978785,0.002713121,0.00043739987,0.0004691211,0.00034448013],"domain_scores_gemma":[0.9295174,0.06840699,0.001073604,0.00073036307,0.00014298118,0.00012865655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014960599,0.00039938485,0.0052391216,0.0002048914,0.000050499206,0.000010164331,0.00033525343,0.000465431,0.000043787026],"category_scores_gemma":[0.0059946165,0.00015543717,0.001532293,0.00039092952,0.0011078513,0.000017708877,0.0000299793,0.00037502163,0.0000030315805],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013616951,0.0011348329,0.00004343565,0.0013759906,0.0012342684,0.000027052576,0.00041417914,3.90151e-7,0.0000011067411,0.0029218649,0.00031283923,0.97891706],"study_design_scores_gemma":[0.02713269,0.013524791,0.00068961555,0.0051085735,0.0110782515,0.00013203862,0.001105136,0.00006470702,0.00012016518,0.0014261281,0.9392856,0.0003323315],"about_ca_topic_score_codex":0.000020802354,"about_ca_topic_score_gemma":0.000004789624,"teacher_disagreement_score":0.97858477,"about_ca_system_score_codex":0.00003849024,"about_ca_system_score_gemma":0.0006500114,"threshold_uncertainty_score":0.7176549},"labels":[],"label_agreement":null},{"id":"W2024978322","doi":"10.1007/s40263-013-0070-1","title":"The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in Schizophrenia","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oakville-Trafalgar Memorial Hospital; Humber River Regional Hospital","funders":"","keywords":"Asenapine; Ziprasidone; Psychiatry; Medicine; Aripiprazole; Management of schizophrenia; Schizophrenia (object-oriented programming); Quality of life (healthcare); Paliperidone; Bipolar disorder; Antipsychotic; Pharmacoeconomics; Health care; Intensive care medicine; Mood; Nursing","score_opus":0.054409241382750044,"score_gpt":0.394740900139156,"score_spread":0.340331658756406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024978322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08868173,0.90768087,5.335525e-7,0.00015330529,0.00024828926,0.0026213937,0.00004813734,0.000034114946,0.00053165684],"genre_scores_gemma":[0.015690356,0.9830967,0.00020721232,0.000014057319,0.00009133539,0.00019352681,0.00010927817,0.00007055401,0.0005269633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720925,0.00019581601,0.0010003047,0.00042639574,0.00062249147,0.0005457474],"domain_scores_gemma":[0.9972676,0.00071140536,0.00041489548,0.0011408171,0.00013790041,0.000327405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002164475,0.0005142293,0.0019658613,0.00034587574,0.0000709126,0.000040234816,0.0002550201,0.00029009974,0.0001594027],"category_scores_gemma":[0.00046308496,0.00023125006,0.0011637538,0.00047587437,0.00016619962,0.000035608602,0.00008056533,0.00080346817,0.0003346263],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045085694,0.0007514421,0.0014716594,0.00068965007,0.0012442515,0.000118695,0.000042623054,4.0578254e-7,2.7777781e-7,0.00018353737,0.002107633,0.98888123],"study_design_scores_gemma":[0.03642109,0.00994246,0.279119,0.04651757,0.0045275236,0.00057478534,0.00018727819,0.00008361241,0.000028442217,0.0019721123,0.6184453,0.0021808697],"about_ca_topic_score_codex":0.00009067569,"about_ca_topic_score_gemma":0.0000138523355,"teacher_disagreement_score":0.9867004,"about_ca_system_score_codex":0.00036333493,"about_ca_system_score_gemma":0.0011083672,"threshold_uncertainty_score":0.9430104},"labels":[],"label_agreement":null},{"id":"W2025609969","doi":"10.2165/00023210-200317110-00005","title":"Tolerability and Consistency of Effect of Zolmitriptan Nasal Spray in a Long-Term Migraine Treatment Trial","year":2003,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Zolmitriptan; Medicine; Tolerability; Nasal spray; Migraine; Anesthesia; Adverse effect; Crossover study; Sumatriptan; Placebo; Neurology; Migraine treatment; Headaches; Aura; Clinical trial; Nasal administration; Internal medicine; Surgery; Pharmacology","score_opus":0.01741955514908747,"score_gpt":0.3084012574985081,"score_spread":0.2909817023494206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025609969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912724,0.0026742392,0.0000016510476,0.00019885537,0.000032689477,0.0009892025,0.000009648799,0.000009662212,0.0048116874],"genre_scores_gemma":[0.9987461,0.00016506587,0.00007159182,0.000023400169,0.000039876948,0.000039951094,0.0000061718847,0.000008416571,0.0008994523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988956,0.00014810749,0.00043508166,0.00021185692,0.00013830396,0.00017109099],"domain_scores_gemma":[0.99922365,0.00030554127,0.000097290525,0.00025115575,0.00005168394,0.000070662776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004503528,0.00015822318,0.00082297507,0.00009865266,0.000024391946,0.000002100369,0.000026242951,0.00006714193,0.000060527884],"category_scores_gemma":[0.00045023128,0.00010972241,0.00017061953,0.00015318862,0.00020189548,0.000020022968,0.000014171663,0.00007935288,0.0000013321863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012808583,0.0011899631,0.96930593,0.0009713075,0.0002704258,0.00003783961,0.0054291156,1.304047e-7,0.004717882,0.00024368247,0.0005127743,0.004512361],"study_design_scores_gemma":[0.18108982,0.018040268,0.72886705,0.00056077854,0.00080464315,0.000046304383,0.00091165054,0.0000066863404,0.0676564,0.00010450948,0.0015992039,0.0003126656],"about_ca_topic_score_codex":0.00018253046,"about_ca_topic_score_gemma":0.0003273946,"teacher_disagreement_score":0.24043885,"about_ca_system_score_codex":0.000057659123,"about_ca_system_score_gemma":0.00010248827,"threshold_uncertainty_score":0.447435},"labels":[],"label_agreement":null},{"id":"W2025802145","doi":"10.2165/0023210-200822120-00007","title":"Classifying Antipsychotic Agents","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Tolerability; Antipsychotic; Psychopharmacology; Antipsychotic Agent; Atypical antipsychotic; Medicine; Pharmacology; Schizophrenia (object-oriented programming); Adverse effect; Psychology; Psychiatry","score_opus":0.14317742840228587,"score_gpt":0.41812196690521936,"score_spread":0.2749445385029335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025802145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006410927,0.9912292,0.0000032218768,0.00009135603,0.0002869243,0.0010311705,0.000021595237,0.00009017926,0.0071822717],"genre_scores_gemma":[0.00004991503,0.99438167,0.0004981258,0.000050851144,0.00039094815,0.00013135855,0.00026588404,0.00008101622,0.004150215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808836,0.00008857974,0.00038569715,0.00047207082,0.00049100537,0.0004743155],"domain_scores_gemma":[0.998651,0.00011154686,0.00012339556,0.0006595289,0.000048143844,0.0004063376],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007247998,0.0003925413,0.0014597545,0.0003076755,0.00011450115,0.000025015464,0.0001780502,0.00024018028,0.00036602223],"category_scores_gemma":[0.000060761453,0.00026933858,0.0007451291,0.0003860328,0.00008765571,0.000033177515,0.0000617098,0.000557274,0.0030403861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008520495,0.00017190102,0.00001688742,0.0051728846,0.00044389255,0.0008529225,0.000034879085,7.750725e-9,3.1107998e-8,0.000048336875,0.0131745655,0.97999847],"study_design_scores_gemma":[0.0013195433,0.000074163945,0.0001072292,0.010720942,0.0006055638,0.00081149844,0.000008450138,0.000002486167,4.786667e-7,0.000023188872,0.9861318,0.00019468965],"about_ca_topic_score_codex":0.000007429701,"about_ca_topic_score_gemma":0.0000013699747,"teacher_disagreement_score":0.9798038,"about_ca_system_score_codex":0.00028693813,"about_ca_system_score_gemma":0.00085791474,"threshold_uncertainty_score":0.99997586},"labels":[],"label_agreement":null},{"id":"W2033466502","doi":"10.2165/00023210-200822050-00003","title":"Burden of Bipolar Depression","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bipolar disorder; Hypomania; Mania; Psychiatry; Psychology; Mood; Depression (economics); Quality of life (healthcare); Anxiety; Clinical psychology; Treatment of bipolar disorder; Prevalence of mental disorders; Schizophrenia (object-oriented programming); Psychotherapist","score_opus":0.031076717555406246,"score_gpt":0.32448693635578485,"score_spread":0.2934102188003786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033466502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000071838713,0.9921004,0.0000053869016,0.000015886428,0.00010796206,0.00058639655,0.000038925602,0.000041196698,0.007096667],"genre_scores_gemma":[0.00006714375,0.9975499,0.00014292721,0.000006671546,0.00016828654,0.00004328766,0.0002307468,0.000053590727,0.001737476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988809,0.000048952777,0.0003761155,0.00027618124,0.00023687373,0.00018095998],"domain_scores_gemma":[0.9990793,0.000051612755,0.00018024625,0.0005324498,0.000042065847,0.00011434125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039141603,0.0002841329,0.0013940063,0.000165103,0.000042483327,0.0000031681814,0.00011507844,0.00027590094,0.00014187102],"category_scores_gemma":[0.000018926417,0.00018942755,0.0005953708,0.00019612383,0.000062961,0.000019811527,0.0000626217,0.00025360243,0.00021767657],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003837242,0.000114496244,0.00009534867,0.007124495,0.00026380955,0.000013001271,0.00020720338,4.072117e-8,3.6567178e-7,0.0000102842705,0.0006509798,0.9915161],"study_design_scores_gemma":[0.00041959487,0.00005622838,0.00004879413,0.00880128,0.0013568175,0.0002240588,0.00001558012,9.0328143e-7,0.0000072083826,0.000005425274,0.9889278,0.00013633729],"about_ca_topic_score_codex":0.00010632495,"about_ca_topic_score_gemma":0.0000015167075,"teacher_disagreement_score":0.9913798,"about_ca_system_score_codex":0.00006363099,"about_ca_system_score_gemma":0.00026840894,"threshold_uncertainty_score":0.77246314},"labels":[],"label_agreement":null},{"id":"W2033814944","doi":"10.2165/00023210-200822060-00005","title":"Intermittent Subcutaneous Apomorphine Therapy for ???Off??? Episodes in Parkinson??s Disease","year":2008,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Tolerability; Apomorphine; Medicine; Parkinson's disease; Anesthesia; Adverse effect; Outpatient clinic; Internal medicine; Disease; Physical therapy; Dopamine; Dopaminergic","score_opus":0.025429063344204098,"score_gpt":0.2721094218536344,"score_spread":0.24668035850943032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033814944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991806,0.004928349,0.00012753058,0.00096453325,0.00021256377,0.0011689047,0.00011121949,0.000100969904,0.0005799353],"genre_scores_gemma":[0.99311894,0.002479977,0.000494833,0.0010921417,0.00015049255,0.00038086937,0.00016617936,0.00005485536,0.002061716],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985594,0.000032545657,0.0002819355,0.00045682583,0.0002488987,0.00042036414],"domain_scores_gemma":[0.9989843,0.0000708152,0.000073587136,0.00039820792,0.000067327856,0.00040580952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086487904,0.00027129363,0.00039323105,0.00016620487,0.000120252,0.0000131791085,0.000117593714,0.00006731938,0.00016755682],"category_scores_gemma":[0.000042990676,0.00022183354,0.00024006964,0.00015813916,0.000083188956,0.00006618199,0.000030223799,0.00010694747,0.000072396935],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023543872,0.011541361,0.4514925,0.00038754806,0.00090969505,0.021788426,0.003843255,0.000041186697,0.0035481688,0.0011896507,0.0123239085,0.46939045],"study_design_scores_gemma":[0.018530672,0.0014438786,0.5569726,0.00028148593,0.00022362093,0.00051491754,0.00021346906,0.001913829,0.0036820609,0.0019345531,0.4136117,0.0006771653],"about_ca_topic_score_codex":0.000035768047,"about_ca_topic_score_gemma":0.000007756866,"teacher_disagreement_score":0.46871328,"about_ca_system_score_codex":0.0001433926,"about_ca_system_score_gemma":0.00015479211,"threshold_uncertainty_score":0.90461093},"labels":[],"label_agreement":null},{"id":"W2035426363","doi":"10.2165/00023210-200721120-00004","title":"Role of the Melatonin System in the Control of Sleep","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Melatonin; Circadian rhythm; Dark therapy; Agomelatine; Suprachiasmatic nucleus; Internal medicine; Endocrinology; Insomnia; Delayed sleep phase; Hypnotic; Pineal gland; Melatonin receptor; Free-running sleep; Light effects on circadian rhythm; Sleep disorder; Psychology; Medicine; Pharmacology; Hippocampus; Antidepressant","score_opus":0.027649189449893023,"score_gpt":0.283628599143557,"score_spread":0.25597940969366395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035426363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007453601,0.9779206,0.000005325869,0.000017559498,0.00025813413,0.0012222765,0.00009882629,0.000016695889,0.019715222],"genre_scores_gemma":[0.2381959,0.76089394,0.0000035190787,0.00012685319,0.00014162625,0.000090559886,0.0000020575965,0.000051222665,0.0004942959],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753875,0.0006284818,0.00076048716,0.0003196342,0.00044401485,0.00030861748],"domain_scores_gemma":[0.99737126,0.0010969207,0.00061341503,0.0008490615,0.000025295387,0.000044059238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095823966,0.000256821,0.0011342597,0.00016241091,0.000060502538,0.0000144328815,0.0009879566,0.00023988602,0.000016568029],"category_scores_gemma":[0.00019318576,0.00013359766,0.000554709,0.00079611974,0.00022445265,0.000037254096,0.00006950229,0.0004815277,0.00008562928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011454812,0.00013584548,0.000049834794,0.0114337625,0.000044394223,0.000029575978,0.002914693,0.0000116882065,0.00051546027,0.15176915,0.00013160193,0.83295256],"study_design_scores_gemma":[0.00030379876,0.000014948285,0.000048195492,0.005939329,0.00023003084,0.00012116429,0.00025802772,0.00006175583,0.0022555252,0.00002105558,0.99057615,0.00017000851],"about_ca_topic_score_codex":0.000016886244,"about_ca_topic_score_gemma":0.000002022158,"teacher_disagreement_score":0.99044454,"about_ca_system_score_codex":0.000083493775,"about_ca_system_score_gemma":0.00018424213,"threshold_uncertainty_score":0.5447954},"labels":[],"label_agreement":null},{"id":"W2035993893","doi":"10.2165/11599560-000000000-00000","title":"Depression Following Traumatic Brain Injury","year":2012,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Traumatic Brain Injury Research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Traumatic brain injury; Depression (economics); Medicine; Psychosocial; Psychiatry; Concussion; Neurology; Poison control; Comorbidity; Psychopharmacology; Psychology; Injury prevention; Clinical psychology","score_opus":0.18579872070985756,"score_gpt":0.44816357693944464,"score_spread":0.26236485622958705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035993893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016874334,0.9806466,0.00004183443,0.00019009062,0.00070502865,0.0022287949,0.0000318563,0.00022464091,0.015762407],"genre_scores_gemma":[0.00055576157,0.9876652,0.00097421726,0.00024252896,0.00086654245,0.00049301557,0.00025842446,0.00027247806,0.008671831],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99594694,0.00044359505,0.0010580594,0.00060352066,0.0010166232,0.00093126256],"domain_scores_gemma":[0.9965865,0.001080876,0.0003000569,0.0013889022,0.0000507622,0.00059290486],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015636233,0.0006436872,0.002795187,0.00056649034,0.00015071804,0.000063482745,0.0004494792,0.0006758979,0.0009964075],"category_scores_gemma":[0.0005436766,0.00047178127,0.0014060689,0.00067491335,0.00010216643,0.00016661947,0.00022936687,0.0013697135,0.0024393823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001078482,0.00013236307,0.000022044582,0.033480756,0.00036186117,0.00003174271,0.0005404647,5.422163e-9,0.0000018547923,0.00003512135,0.01021201,0.955171],"study_design_scores_gemma":[0.0004750646,0.00007034315,0.00004712294,0.039264593,0.0020413904,0.0001332192,0.000114572766,0.0000036974113,0.0000036007089,0.000033247194,0.95740056,0.00041259595],"about_ca_topic_score_codex":0.000013480033,"about_ca_topic_score_gemma":8.809673e-7,"teacher_disagreement_score":0.9547584,"about_ca_system_score_codex":0.0003595329,"about_ca_system_score_gemma":0.0005878219,"threshold_uncertainty_score":0.9999168},"labels":[],"label_agreement":null},{"id":"W2036605937","doi":"10.1007/s40263-013-0080-z","title":"Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Teriflunomide; Fingolimod; Tolerability; Medicine; Relapsing remitting; Cladribine; Multiple sclerosis; Dimethyl fumarate; Clinical trial; Neurology; Adverse effect; Intensive care medicine; Internal medicine; Immunology; Psychiatry","score_opus":0.16802789843083926,"score_gpt":0.38202515296350203,"score_spread":0.21399725453266277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036605937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015305168,0.99191785,0.000055332923,0.00031005547,0.00018753891,0.005288496,0.00016503282,0.00008527846,0.00045987303],"genre_scores_gemma":[0.0020794973,0.9909794,0.0053135552,0.000030289062,0.00021858292,0.0005704942,0.000116449155,0.00012110276,0.0005706325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966074,0.00023759314,0.001263752,0.0007600791,0.0005115408,0.0006195865],"domain_scores_gemma":[0.9941578,0.003860926,0.00052443723,0.0007905576,0.0004272785,0.00023899318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011963006,0.00058804586,0.0034485266,0.00027826452,0.00025522945,0.000055664335,0.00029040704,0.0003546323,0.000087832224],"category_scores_gemma":[0.0037708848,0.00041942293,0.00080409145,0.00033559024,0.00059792824,0.000099555094,0.00045223703,0.00053779746,0.000022410348],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007117441,0.00020312269,0.00039778644,0.02541689,0.0006867048,3.3416538e-7,0.0008940694,2.2912008e-7,0.00005388015,0.00001860642,0.0015422819,0.9707149],"study_design_scores_gemma":[0.0042115934,0.0003391617,0.0033301539,0.03989277,0.0012077511,0.0000073369933,0.00039016904,0.00009394678,0.00003893603,0.000025101974,0.949953,0.00051007106],"about_ca_topic_score_codex":0.00014054669,"about_ca_topic_score_gemma":0.000010836048,"teacher_disagreement_score":0.97020483,"about_ca_system_score_codex":0.00020276119,"about_ca_system_score_gemma":0.0002459089,"threshold_uncertainty_score":0.9998258},"labels":[],"label_agreement":null},{"id":"W2039589814","doi":"10.2165/00023210-200519020-00001","title":"Do Atypical Antipsychotics Cause Stroke?","year":2005,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Olanzapine; Risperidone; Medicine; Dementia; Adverse effect; Stroke (engine); Delirium; Incidence (geometry); Psychiatry; Internal medicine; Pediatrics; Schizophrenia (object-oriented programming)","score_opus":0.07937219987630402,"score_gpt":0.4347318961158408,"score_spread":0.3553596962395368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039589814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020618727,0.979869,0.00003617019,0.00016160143,0.0002669185,0.00124447,0.000085104955,0.00007774223,0.018052826],"genre_scores_gemma":[0.0002519661,0.97181237,0.00019070014,0.00017616518,0.0009899379,0.00008413319,0.00023994004,0.00007965661,0.02617513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974836,0.00014023662,0.0005277425,0.0005428195,0.0006999692,0.00060560956],"domain_scores_gemma":[0.99859256,0.00013785437,0.00012760502,0.0006043584,0.00014965216,0.00038794757],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00033587604,0.0004169037,0.0013912785,0.00031980837,0.00007646633,0.0000731999,0.00024567568,0.00034514422,0.0022576482],"category_scores_gemma":[0.000086385335,0.0003113461,0.00066266424,0.00033222305,0.0001390579,0.000053335752,0.00012149919,0.00091682543,0.0031308199],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008938211,0.00032942308,0.00031051555,0.0048897536,0.00043310056,0.00015104917,0.00003527341,5.760367e-9,2.882176e-7,0.00011166374,0.01012838,0.98352116],"study_design_scores_gemma":[0.00077934255,0.00018084125,0.00076885114,0.006721969,0.0019717242,0.00015246568,0.000037957154,0.0000016845853,0.0000014991801,0.00000954776,0.9891066,0.00026752363],"about_ca_topic_score_codex":9.596081e-7,"about_ca_topic_score_gemma":0.0000011773519,"teacher_disagreement_score":0.98325366,"about_ca_system_score_codex":0.00012284177,"about_ca_system_score_gemma":0.00048930454,"threshold_uncertainty_score":0.99993384},"labels":[],"label_agreement":null},{"id":"W2041110161","doi":"10.2165/11539530-000000000-00000","title":"The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"H. Lundbeck A/S; Pfizer","keywords":"Galantamine; Rivastigmine; Donepezil; Memantine; Medicine; Disease; Dementia; Alzheimer's disease; Pharmacoeconomics; Population; Psychiatry; Intensive care medicine; Internal medicine","score_opus":0.313348912749973,"score_gpt":0.4904148973609592,"score_spread":0.17706598461098622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041110161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078597805,0.98567766,0.000115173156,0.002979012,0.0013868797,0.0028073215,0.0024984416,0.000026901891,0.0037226616],"genre_scores_gemma":[0.001007918,0.9931417,0.00014822498,0.0029183566,0.0004441616,0.00096088223,0.00016189208,0.00010976572,0.001107113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919761,0.0004719434,0.0059284,0.00091167394,0.00008831743,0.00062355766],"domain_scores_gemma":[0.9912673,0.0036889305,0.0037240612,0.0007840678,0.00008714265,0.00044850187],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009768206,0.0004996096,0.003156533,0.0005234836,0.00021065139,0.000118321805,0.0007872865,0.00031920543,0.00027746253],"category_scores_gemma":[0.0025901843,0.0005182434,0.0005160755,0.0003282023,0.0001562358,0.00028335804,0.00016665756,0.00071243965,0.00321189],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002006298,0.00036040627,0.00030058506,0.018342625,0.0012567178,0.0000068239915,0.0068015843,0.0003075549,7.901753e-8,0.039907813,0.029873814,0.90264136],"study_design_scores_gemma":[0.0004948637,0.000019058807,0.0000384044,0.0033716043,0.0001232157,0.000001755941,0.00033353787,0.00049654295,5.907879e-7,0.0019492783,0.9925796,0.0005915594],"about_ca_topic_score_codex":0.00026009703,"about_ca_topic_score_gemma":0.00015673436,"teacher_disagreement_score":0.9627058,"about_ca_system_score_codex":0.00063895504,"about_ca_system_score_gemma":0.0011169809,"threshold_uncertainty_score":0.9997269},"labels":[],"label_agreement":null},{"id":"W2042095037","doi":"10.1007/s40263-013-0131-5","title":"A Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for Multiple Sclerosis","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Centre of Excellence for Women's Health; University of British Columbia Hospital; B.C. Women's Hospital & Health Centre; University of British Columbia; Stornoway Diamond (Canada); Vancouver Coastal Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Fingolimod; Medicine; Teriflunomide; Pregnancy; Multiple sclerosis; Clinical trial; Drug; Disease; Intensive care medicine; Pediatrics; Pharmacology; Psychiatry; Internal medicine","score_opus":0.32731455655854896,"score_gpt":0.4251250417444166,"score_spread":0.09781048518586766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042095037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000037103998,0.98172224,0.00006908601,0.0008557118,0.00042562297,0.014004521,0.0023700125,0.00011424685,0.0004348453],"genre_scores_gemma":[0.00006312378,0.99095994,0.0007917246,0.00017203056,0.0002318477,0.0027235267,0.0036119062,0.00021164751,0.0012342782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937034,0.0007022553,0.002171249,0.0013172885,0.0010800324,0.0010257558],"domain_scores_gemma":[0.989833,0.0038488368,0.0011971777,0.004004048,0.00063663966,0.0004802853],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025999704,0.0009045219,0.0043357876,0.00028786177,0.00051120855,0.00007872704,0.0019881162,0.00027692365,0.00022638985],"category_scores_gemma":[0.008491703,0.0005412727,0.0013833345,0.0010455658,0.0005253363,0.00032988508,0.0018014538,0.00094901165,0.00013819493],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025445292,0.00011450536,0.000027560667,0.31980088,0.0008198444,0.0000015141799,0.00015356299,1.2215119e-7,0.0000016793473,0.000024901652,0.01786747,0.6611625],"study_design_scores_gemma":[0.000983646,0.000032855143,0.000050674244,0.44370088,0.0027886077,0.0000028269435,0.000076717355,0.00019868629,5.871402e-7,0.0000060298494,0.5518568,0.00030167645],"about_ca_topic_score_codex":0.00013805334,"about_ca_topic_score_gemma":0.000006614283,"teacher_disagreement_score":0.66086084,"about_ca_system_score_codex":0.00043230597,"about_ca_system_score_gemma":0.00095606357,"threshold_uncertainty_score":0.99986017},"labels":[],"label_agreement":null},{"id":"W2043381283","doi":"10.1007/s40263-013-0076-8","title":"Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":469,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"RWTH Aachen University; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Alzheimer Society; National Institute on Aging; Eli Lilly and Company; Deutsche Forschungsgemeinschaft; National Institutes of Health; John Simon Guggenheim Memorial Foundation","keywords":"Insulin; Insulin resistance; Insulin receptor; Medicine; Neuroprotection; Neuroscience; Internal medicine; Endocrinology; Psychology","score_opus":0.4543022185407687,"score_gpt":0.5255115660076726,"score_spread":0.07120934746690388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043381283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012832788,0.99414104,0.0000041521994,0.00076786784,0.00013727893,0.0043465206,0.000098757075,0.000024263023,0.0003518195],"genre_scores_gemma":[0.000028064002,0.9977043,0.00010151295,0.00020273348,0.00022254948,0.0005736676,0.000025027017,0.000037525453,0.0011045713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961995,0.00095354515,0.0010591926,0.00087829225,0.0005450952,0.00036438587],"domain_scores_gemma":[0.9933532,0.00484605,0.00041386654,0.00080010603,0.00021541375,0.00037139075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015872042,0.000325994,0.0015626107,0.00016411413,0.00015104131,0.000058252717,0.00049948465,0.00017290284,0.00018960047],"category_scores_gemma":[0.002790572,0.00022857577,0.0005934433,0.0004755729,0.00058773323,0.00016910635,0.0001660232,0.0002867477,0.00025145191],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027593105,0.00019561156,0.0000050568383,0.036464076,0.00003808258,0.0000057417637,0.000020669397,1.3695539e-8,7.561357e-7,0.0009818241,0.0030473329,0.95921326],"study_design_scores_gemma":[0.0002106986,0.0004444816,0.000021781987,0.10112726,0.0006533386,0.000005557814,0.000002591562,0.000008642165,0.000031901094,0.00032039586,0.896992,0.00018133949],"about_ca_topic_score_codex":0.000022560496,"about_ca_topic_score_gemma":0.0000014610634,"teacher_disagreement_score":0.9590319,"about_ca_system_score_codex":0.00007629277,"about_ca_system_score_gemma":0.00091003673,"threshold_uncertainty_score":0.93210495},"labels":[],"label_agreement":null},{"id":"W2045172500","doi":"10.2165/00023210-200923070-00002","title":"Lacosamide","year":2009,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"UCB Pharma; Canadian Institutes of Health Research; Fondazione Pierfranco e Luisa Mariani; Savoy Foundation; Valeant Pharmaceuticals International; Pfizer","keywords":"Lacosamide; Medicine; Psychopharmacology; Pharmacology; Psychology; Epilepsy; Psychiatry","score_opus":0.018692930926662993,"score_gpt":0.3253858074043506,"score_spread":0.3066928764776876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045172500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8490828,0.0003775402,0.000034377987,0.013288921,0.00008883717,0.00015769895,0.000001344923,0.00011611367,0.13685234],"genre_scores_gemma":[0.9854169,0.00005744868,0.00014026405,0.011705239,0.00017474887,0.000003345244,0.000001887087,0.0000028535455,0.0024973003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995883,0.000010737494,0.000067787834,0.00010208521,0.000088861925,0.00014220965],"domain_scores_gemma":[0.9997697,0.000040183735,0.000013384494,0.000075568176,0.000020274407,0.00008089004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000662318,0.00006295786,0.00014216578,0.000022200084,0.000048342557,0.00000488906,0.000031915974,0.000028473927,0.00013872776],"category_scores_gemma":[0.000057789075,0.000042075582,0.00005159667,0.00007610754,0.000030928048,0.000020603162,0.000013304898,0.00009616009,0.00014587687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054547936,0.0016789637,0.0054902327,0.00011142185,0.00025185762,0.0005414002,0.0019300893,0.000013026418,0.20724978,0.009408132,0.2845126,0.488267],"study_design_scores_gemma":[0.0051874523,0.0020379815,0.53885967,0.000110734865,0.00027321267,0.00005616237,0.00023764468,0.0005777875,0.062489994,0.0053298934,0.38442495,0.00041449736],"about_ca_topic_score_codex":0.000002242566,"about_ca_topic_score_gemma":1.941604e-7,"teacher_disagreement_score":0.5333695,"about_ca_system_score_codex":0.000020280411,"about_ca_system_score_gemma":0.000010142332,"threshold_uncertainty_score":0.18750007},"labels":[],"label_agreement":null},{"id":"W2046049297","doi":"10.2165/00023210-200822060-00001","title":"Insulin, Insulin-Like Growth Factors??and Incretins","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McMaster University; University of Toronto; University Health Network","funders":"","keywords":"Insulin; Neurocognitive; Mood; Neuroscience; Psychology; Insulin receptor; Mood disorders; Psychopharmacology; Insulin-like growth factor; Cognition; Cognitive decline; Endocrinology; Internal medicine; Medicine; Insulin resistance; Disease; Growth factor; Dementia; Psychiatry; Receptor; Anxiety","score_opus":0.034875239274973026,"score_gpt":0.28947402411520184,"score_spread":0.2545987848402288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046049297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066666496,0.98077446,0.000009934663,0.00010181908,0.0010122198,0.0018189908,0.00021050946,0.0004248341,0.008980554],"genre_scores_gemma":[0.0029035674,0.9923446,0.00021942589,0.00057824596,0.00092532183,0.000130147,0.0012021761,0.00036114003,0.0013353382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942699,0.00029028265,0.0018561868,0.0014925498,0.00094451016,0.0011465821],"domain_scores_gemma":[0.99593693,0.00061092706,0.00075807807,0.0012512046,0.00035020467,0.0010926344],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00029905673,0.0017471217,0.004942109,0.0010516096,0.00039251996,0.000089536865,0.0005927184,0.0015729698,0.00015505304],"category_scores_gemma":[0.0006505898,0.001299316,0.0013964584,0.0012816873,0.00054775795,0.00027311553,0.0004803525,0.0022637397,0.0006607288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015198218,0.00085980166,0.003249446,0.035284765,0.0020234247,0.0007142824,0.0040687085,3.1322433e-8,0.000006805107,0.00081863115,0.047387138,0.90543497],"study_design_scores_gemma":[0.0014156053,0.0003735948,0.0013334831,0.005633987,0.0016092889,0.0006576594,0.00013217183,0.0000020429081,0.000016632548,0.00005359869,0.98756444,0.0012074735],"about_ca_topic_score_codex":0.00022611303,"about_ca_topic_score_gemma":0.000003470296,"teacher_disagreement_score":0.9401773,"about_ca_system_score_codex":0.00038923073,"about_ca_system_score_gemma":0.0011434042,"threshold_uncertainty_score":0.9997232},"labels":[],"label_agreement":null},{"id":"W2046948383","doi":"10.2165/00023210-200519100-00004","title":"Augmentation Strategies in Clozapine-Resistant Schizophrenia","year":2005,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Clozapine; Schizophrenia (object-oriented programming); Intensive care medicine; Medicine; Psychiatry; Psychopharmacology; Adverse effect; Clinical trial; Electroconvulsive therapy; Psychology; Pharmacology; Internal medicine","score_opus":0.02067580920945473,"score_gpt":0.3038656170304971,"score_spread":0.28318980782104236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046948383","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11879256,0.0048579755,0.000016132419,0.86206764,0.00041670114,0.0018372774,0.00015671876,0.00023052246,0.011624452],"genre_scores_gemma":[0.33729678,0.004128717,0.016522296,0.5579161,0.02685582,0.001692924,0.012358821,0.00062029454,0.042608224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973078,0.00010793041,0.00047606463,0.000599921,0.00084073516,0.0006675746],"domain_scores_gemma":[0.99892014,0.00010936962,0.00012605789,0.00059268245,0.0000921908,0.00015955236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000161923,0.00043956892,0.0006066694,0.0005967712,0.00007167615,0.00012274939,0.00019295985,0.00053589797,0.0008294481],"category_scores_gemma":[0.000036740756,0.00036801386,0.00021322323,0.00033403595,0.000121974226,0.00016261016,0.00005757179,0.0017053848,0.0006462653],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071309665,0.00023763003,0.00012819629,0.00045271046,0.0003037112,0.0039531183,0.00035938693,0.000007025524,0.0003677914,0.0005815879,0.958088,0.028389888],"study_design_scores_gemma":[0.023756808,0.00082702487,0.014354637,0.0011860951,0.0003871695,0.0001220494,0.00067899853,0.000103729006,0.0009997373,0.0027560894,0.95394117,0.00088647526],"about_ca_topic_score_codex":0.00029553747,"about_ca_topic_score_gemma":0.0003616175,"teacher_disagreement_score":0.30415154,"about_ca_system_score_codex":0.00068607513,"about_ca_system_score_gemma":0.0011714202,"threshold_uncertainty_score":0.99987715},"labels":[],"label_agreement":null},{"id":"W2047152345","doi":"10.1007/s40263-013-0069-7","title":"Luteal Phase and Symptom-Onset Dosing of SSRIs/SNRIs in the Treatment of Premenstrual Dysphoria: Clinical Evidence and Rationale","year":2013,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Menstrual Health and Disorders","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; AstraZeneca","keywords":"Dosing; Psychopharmacology; Luteal phase; Medicine; Dysphoria; Premenstrual dysphoric disorder; Neurology; Internal medicine; Psychiatry; Menstrual cycle; Anxiety; Hormone","score_opus":0.0773305689568435,"score_gpt":0.41636075689494206,"score_spread":0.3390301879380986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047152345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953702,0.0021858388,0.000007054781,0.0012660474,0.00006715276,0.00079209503,0.000012260603,0.0000045587344,0.0002947585],"genre_scores_gemma":[0.9973568,0.0018771851,0.00040339332,0.00020772337,0.000053294265,0.000037946247,0.000010742337,0.0000045408215,0.00004837628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989807,0.00010491931,0.00043646464,0.00016310869,0.0001706926,0.00014408535],"domain_scores_gemma":[0.99901426,0.00054255786,0.000110393936,0.00016653253,0.00005780035,0.00010846239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037431813,0.0000869134,0.00027263083,0.00004924313,0.00003664014,0.000006925076,0.000035226294,0.000060051785,0.000054410528],"category_scores_gemma":[0.00014653525,0.000056006793,0.00003255164,0.00008863341,0.00021927005,0.00007431659,0.000010826725,0.00007052638,0.0000025437935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011644763,0.002770159,0.641743,0.000668552,0.00008327773,0.000009324399,0.022027444,0.0000014066399,0.0007658438,0.0003482374,0.002651648,0.32776663],"study_design_scores_gemma":[0.02476801,0.0096354,0.9423906,0.0008575338,0.00030229607,0.0000840857,0.01509653,0.0019244791,0.001362687,0.0012603487,0.0020704705,0.0002475378],"about_ca_topic_score_codex":0.0004751091,"about_ca_topic_score_gemma":0.000029821578,"teacher_disagreement_score":0.3275191,"about_ca_system_score_codex":0.000021387701,"about_ca_system_score_gemma":0.0001439944,"threshold_uncertainty_score":0.22838907},"labels":[],"label_agreement":null},{"id":"W2051981816","doi":"10.2165/00023210-200721100-00001","title":"The Role of Anti-Inflammatory Agents in Parkinson???s Disease","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Microglia; Neuroscience; Inflammation; Dopaminergic; Parkinson's disease; Basal ganglia; Disease; Medicine; Dementia; Neuroinflammation; Neurology; Pharmacology; Immunology; Dopamine; Pathology; Biology; Central nervous system","score_opus":0.03428443526629798,"score_gpt":0.3292433758723501,"score_spread":0.2949589406060521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051981816","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021770636,0.99327326,0.0000015248133,0.000013966943,0.0002378066,0.0012352193,0.00011123318,0.000036128204,0.0029138161],"genre_scores_gemma":[0.008103927,0.99056005,0.000026689811,0.000040527608,0.00014593881,0.00016029115,0.00015807079,0.000076799384,0.000727692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977649,0.000120827135,0.00070886733,0.00045376,0.00047797774,0.0004737046],"domain_scores_gemma":[0.99823636,0.00014071044,0.00036388397,0.0007955198,0.000053387943,0.00041014212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037612268,0.00044169626,0.0012930634,0.00027907518,0.000094148185,0.000019289353,0.00027339495,0.00019994704,0.000064712294],"category_scores_gemma":[0.000063648346,0.00028202566,0.00067185576,0.0003366294,0.000102663274,0.000039621125,0.00010214098,0.00029575187,0.00018230137],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005444218,0.00035108923,0.0027149483,0.0043247077,0.00030206266,0.00046677038,0.00005212267,1.3109904e-7,3.5147414e-7,0.0003493716,0.00019203659,0.991192],"study_design_scores_gemma":[0.0006740504,0.000024689412,0.005444048,0.0069589913,0.001275083,0.000008245657,0.00004706056,0.000008564159,0.000007785363,0.0001758445,0.98516744,0.00020816499],"about_ca_topic_score_codex":0.000016893217,"about_ca_topic_score_gemma":0.0000042692695,"teacher_disagreement_score":0.9909838,"about_ca_system_score_codex":0.00022915925,"about_ca_system_score_gemma":0.00064125814,"threshold_uncertainty_score":0.99996316},"labels":[],"label_agreement":null},{"id":"W2057023582","doi":"10.1007/s40263-014-0174-2","title":"Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence","year":2014,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Neuroinflammation and Neurodegeneration Mechanisms","field":"Neuroscience","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Saint-Luc","funders":"","keywords":"Medicine; Stroke (engine); Etanercept; Neuroinflammation; Neuropathic pain; Neurology; Neuroscience; Chronic pain; Penumbra; Microglia; Neuroprotection; Tumor necrosis factor alpha; Inflammation; Psychology; Internal medicine; Pharmacology; Physical therapy; Psychiatry; Ischemia","score_opus":0.05813358585527987,"score_gpt":0.294226795298877,"score_spread":0.23609320944359716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057023582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861379,0.00012180157,0.0101134805,0.0018326598,0.0009255158,0.0005972241,0.000063642976,0.00008793724,0.000119796816],"genre_scores_gemma":[0.99575365,0.000064108186,0.0001751572,0.0019840037,0.00017155946,0.00009231968,0.000009612461,0.000012859471,0.0017367374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984328,0.00020925052,0.00020410304,0.00067126297,0.0002803538,0.00020220553],"domain_scores_gemma":[0.9986169,0.0008712828,0.00008845101,0.00013871884,0.00014753305,0.00013714621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000330911,0.00014536601,0.00012618735,0.00010581672,0.0006531595,0.00032649713,0.000096167096,0.00003988694,0.00009472268],"category_scores_gemma":[0.0023962695,0.00013036132,0.000043414915,0.000117623975,0.00028465493,0.00035728593,0.00007128622,0.00014125311,0.000043908378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015255756,0.00004120376,0.00011599962,0.00003774125,0.00000106706,0.0000017663267,0.00037356743,0.000010442546,0.94773173,0.011905481,0.00029888665,0.03932957],"study_design_scores_gemma":[0.0023560221,0.0021551272,0.0074222577,0.00011641628,0.00009295337,0.00024851842,0.00020096374,0.07158245,0.844576,0.0021114675,0.06839348,0.0007443485],"about_ca_topic_score_codex":2.4867293e-7,"about_ca_topic_score_gemma":0.0000015749158,"teacher_disagreement_score":0.103155725,"about_ca_system_score_codex":0.00000512939,"about_ca_system_score_gemma":0.00003862391,"threshold_uncertainty_score":0.53159803},"labels":[],"label_agreement":null},{"id":"W2059127737","doi":"10.2165/00023210-200418130-00004","title":"Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia","year":2004,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Schizophrenia Society of Ontario; Humber River Regional Hospital","funders":"","keywords":"Risperidone; Quetiapine; Amisulpride; Olanzapine; Tolerability; Psychiatry; Antipsychotic; Sertindole; Ziprasidone; Clozapine; Atypical antipsychotic; Psychology; Neurocognitive; Population; Aripiprazole; Schizophrenia (object-oriented programming); Medicine; Adverse effect; Cognition; Internal medicine","score_opus":0.05394648863535521,"score_gpt":0.39554153089717864,"score_spread":0.3415950422618234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059127737","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51275086,0.48554832,0.0000014111138,0.000012945671,0.000040750983,0.0013165012,0.00021338138,0.000013045412,0.00010277354],"genre_scores_gemma":[0.34126326,0.6576382,0.0005912998,0.00000593625,0.000051430947,0.000029874673,0.0003429023,0.000056113717,0.000020966367],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974306,0.00018224868,0.0009067751,0.000383306,0.00075473724,0.00034230348],"domain_scores_gemma":[0.99808013,0.0002190792,0.00045012665,0.0007401968,0.00016788465,0.00034258227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022970614,0.0003971376,0.0025069444,0.00042292866,0.000016909382,0.000006250695,0.00017659669,0.00024647452,0.00008151778],"category_scores_gemma":[0.00026176003,0.00022883413,0.000640144,0.0005800845,0.00016401574,0.000028396846,0.000039685092,0.00054565736,0.000042155545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14522028,0.008957681,0.15821867,0.03147685,0.0023103652,0.000034699067,0.00011482673,0.0000055025735,1.4660746e-7,0.00084801216,0.00011886699,0.6526941],"study_design_scores_gemma":[0.022231009,0.0044616098,0.93715405,0.034430273,0.0004952846,0.0000025910238,0.0000061134774,4.768098e-7,0.000001301752,0.00009115546,0.0008387754,0.0002873606],"about_ca_topic_score_codex":0.00011117375,"about_ca_topic_score_gemma":0.000021785336,"teacher_disagreement_score":0.7789354,"about_ca_system_score_codex":0.0004440851,"about_ca_system_score_gemma":0.0025440122,"threshold_uncertainty_score":0.9331585},"labels":[],"label_agreement":null},{"id":"W2060699754","doi":"10.2165/11586460-000000000-00000","title":"Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram","year":2011,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Pfizer; Eli Lilly and Company","keywords":"Escitalopram; Hamilton Anxiety Rating Scale; Hamilton Rating Scale for Depression; Rating scale; Major depressive disorder; Internal medicine; Medicine; Psychology; Psychiatry; Anxiety; Antidepressant; Mood","score_opus":0.03580251983203029,"score_gpt":0.3033590042213166,"score_spread":0.2675564843892863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060699754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883456,0.00023915016,0.00018094147,0.0010717429,0.000064956315,0.005292469,0.00014264334,0.00021169009,0.003961863],"genre_scores_gemma":[0.95207936,0.00011813913,0.023217414,0.0004160531,0.00007095078,0.0036692694,0.00014224827,0.0002574493,0.020029118],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9956682,0.0001517703,0.0005893611,0.0015159915,0.0007446283,0.0013300912],"domain_scores_gemma":[0.99704045,0.00017660922,0.00030828995,0.0013919144,0.00018131969,0.000901387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021134841,0.0011031639,0.001370205,0.0009815603,0.0002973794,0.00013841112,0.0005050762,0.00019042447,0.00047574416],"category_scores_gemma":[0.000025081714,0.0005648271,0.0000458781,0.0015572897,0.0002112489,0.0005979144,0.0002656152,0.0002420454,0.00013453412],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47595057,0.035659034,0.24416733,0.00019013687,0.0073065483,0.025925346,0.054134417,0.000059605296,0.026295539,0.00026143694,0.00023206027,0.12981798],"study_design_scores_gemma":[0.27643937,0.40661925,0.17146915,0.0039789593,0.005119938,0.0032539936,0.0083735315,0.00010360958,0.109610766,0.000075916665,0.011616664,0.0033388615],"about_ca_topic_score_codex":0.0010509999,"about_ca_topic_score_gemma":0.0014470202,"teacher_disagreement_score":0.3709602,"about_ca_system_score_codex":0.002276038,"about_ca_system_score_gemma":0.00074865046,"threshold_uncertainty_score":0.99968034},"labels":[],"label_agreement":null},{"id":"W2061805713","doi":"10.1007/s40263-013-0098-2","title":"Comment on: “Publication Bias, with a Focus on Psychiatry: Causes and Solutions”","year":2013,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Clinical Reasoning and Diagnostic Skills","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Psychopharmacology; Focus (optics); Psychiatry; Clinical psychiatry; Psychology; Medicine","score_opus":0.04215796801755811,"score_gpt":0.30514262517499013,"score_spread":0.262984657157432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061805713","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029621192,0.0003307441,0.000018038396,0.9858459,0.0003895306,0.00061326247,0.000053598567,0.00010845133,0.009678316],"genre_scores_gemma":[0.007863365,0.00020933076,0.00045235213,0.9838442,0.0025837368,0.00020639549,0.0006583426,0.000058152895,0.0041241026],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836487,0.00007286053,0.00030901452,0.00048345607,0.0004258287,0.00034396994],"domain_scores_gemma":[0.99432814,0.0044624317,0.00019849619,0.00067542563,0.00015442235,0.00018111218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019699761,0.00028892478,0.00044364744,0.00016057998,0.00011272779,0.00007681616,0.00009705492,0.0004408809,0.00020717463],"category_scores_gemma":[0.003927691,0.00019739196,0.00008662257,0.00014026274,0.00015155063,0.00002712917,0.00003688827,0.0011432264,0.0004638355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046691308,0.00022701961,0.0011235476,0.000037719015,0.00010129095,0.000016807999,0.000060186198,2.576139e-7,1.1902415e-7,0.001157191,0.9927221,0.004507086],"study_design_scores_gemma":[0.0017621996,0.0011956547,0.0048461915,0.003526533,0.0003088038,0.000032814343,0.000038884176,0.000017786884,0.0000064137607,0.0006544497,0.98734117,0.00026909815],"about_ca_topic_score_codex":0.00024483012,"about_ca_topic_score_gemma":0.0000073338715,"teacher_disagreement_score":0.0055542137,"about_ca_system_score_codex":0.00008784041,"about_ca_system_score_gemma":0.00021418586,"threshold_uncertainty_score":0.80494106},"labels":[],"label_agreement":null},{"id":"W2062129453","doi":"10.1007/s40263-014-0175-1","title":"A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Lakehead University; START Clinic; University of Toronto; Adler","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Stimulant; Dosing; Atomoxetine; Psychiatry; Psychological intervention; Psychology; Substance abuse; Amphetamine; Clinical psychology; Medicine; Pharmacology","score_opus":0.0693815236239787,"score_gpt":0.39657237474306134,"score_spread":0.32719085111908264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062129453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0078003285,0.98692316,0.00004321353,0.00035172107,0.00014815785,0.0033921378,0.00009888991,0.000024343535,0.0012180606],"genre_scores_gemma":[0.0018900688,0.9962156,0.000081768005,0.00014157574,0.00008473845,0.00056386506,0.00036734404,0.000085405656,0.000569628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99590665,0.00097266864,0.0015631795,0.0006149773,0.00058359926,0.00035895262],"domain_scores_gemma":[0.99582714,0.0010919508,0.001345236,0.0014359716,0.00022077934,0.00007891789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087612035,0.0006490279,0.004544808,0.00030006716,0.000054830016,0.000011984124,0.00033824585,0.00029458734,0.00039902944],"category_scores_gemma":[0.00036178596,0.0003924328,0.0017498331,0.00095291797,0.00019218598,0.000108963926,0.000048570826,0.00043775453,0.0001268798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019386092,0.0025070158,0.0015145366,0.15506607,0.00047343457,0.000008478649,0.00017706012,5.4105544e-7,0.0000047018443,0.000078598365,0.00012240643,0.84002775],"study_design_scores_gemma":[0.0011457455,0.0003533913,0.0005803085,0.08926507,0.0043738433,0.000058790378,0.00037087974,0.0000066794078,4.8098e-7,0.000005655294,0.9035218,0.00031738175],"about_ca_topic_score_codex":0.00031840117,"about_ca_topic_score_gemma":0.000045679208,"teacher_disagreement_score":0.90339935,"about_ca_system_score_codex":0.0001950798,"about_ca_system_score_gemma":0.0003832592,"threshold_uncertainty_score":0.9998528},"labels":[],"label_agreement":null},{"id":"W2062401860","doi":"10.2165/00023210-200620020-00002","title":"Media Portrayal of Mental Illness and its Treatments","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":298,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Mental illness; Mental health; Blame; Psychological intervention; Psychology; Stigma (botany); Psychiatry; Public health; Social stigma; Mentally ill; Medicine; Nursing","score_opus":0.06200841973063581,"score_gpt":0.4169263110639009,"score_spread":0.35491789133326507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062401860","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003217645,0.9630822,1.207357e-7,0.000010547295,0.0013206784,0.0012691802,0.00063275266,0.00003374603,0.030433122],"genre_scores_gemma":[0.002702591,0.9852731,0.000014599764,0.00001638679,0.00020241503,0.00031490187,0.0014743177,0.00006132943,0.009940348],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980623,0.00014539342,0.00069288985,0.00049612054,0.00021805541,0.00038520482],"domain_scores_gemma":[0.9989327,0.00015311834,0.0004522412,0.00029887693,0.000016791362,0.00014623646],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012304823,0.00046026977,0.0014476837,0.00018392867,0.00012965658,0.000013595444,0.00021189604,0.0003210744,0.0011882654],"category_scores_gemma":[0.0000031754673,0.0003457035,0.00025638202,0.00018826735,0.00007673877,0.000054854565,0.00006887241,0.00016189691,0.00026965977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012149872,0.00036930954,0.00004785671,0.0036759574,0.00026288818,0.000043894528,0.0007881039,2.0481983e-9,5.3139008e-8,0.0007231821,0.0019644862,0.9921121],"study_design_scores_gemma":[0.0012377515,0.0000959123,0.0002638326,0.0028072528,0.0011069971,0.000059530743,0.00018570054,2.3152225e-7,0.0000056633753,0.000032077944,0.99382883,0.00037623884],"about_ca_topic_score_codex":0.00019385251,"about_ca_topic_score_gemma":0.000015108808,"teacher_disagreement_score":0.9918643,"about_ca_system_score_codex":0.00012415693,"about_ca_system_score_gemma":0.0000480675,"threshold_uncertainty_score":0.9998995},"labels":[],"label_agreement":null},{"id":"W2067903360","doi":"10.2165/00023210-200923020-00002","title":"Current Considerations in the Treatment of Generalized Anxiety Disorder","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"START Clinic","funders":"H. Lundbeck A/S; AstraZeneca","keywords":"Escitalopram; Generalized anxiety disorder; Paroxetine; Venlafaxine; Psychiatry; Duloxetine; Sertraline; Major depressive disorder; Anxiety; Antidepressant; Psychology; Anxiety disorder; Psychopharmacology; Major depressive episode; Medicine; Mood","score_opus":0.09963729924192531,"score_gpt":0.4303686466600599,"score_spread":0.3307313474181346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067903360","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012670003,0.9888769,0.000082763545,0.00011342845,0.0012652547,0.0021661343,0.000287336,0.000051665134,0.007029836],"genre_scores_gemma":[0.00061863655,0.9960301,0.00014436348,0.00008995845,0.00041668833,0.001581784,0.00043022272,0.00006424457,0.00062401325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964223,0.0008970689,0.0010059704,0.0008589368,0.0003384106,0.0004773514],"domain_scores_gemma":[0.9972249,0.00088496157,0.00063507305,0.0009966393,0.00016914772,0.00008924188],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002784695,0.0007191029,0.0016680917,0.0006651824,0.00015665233,0.000058483078,0.0003824033,0.00033798532,0.0009747449],"category_scores_gemma":[0.0001197253,0.00043772694,0.0007447297,0.0014010369,0.00017720158,0.00007127231,0.000028032726,0.00033191827,0.00027188333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008519715,0.0034269053,0.00054610026,0.0005356546,0.00025490118,0.0000062483778,0.0038691624,4.2977027e-7,1.9575708e-8,0.0012396023,0.0077848854,0.9823276],"study_design_scores_gemma":[0.0013813782,0.00021621438,0.0005193024,0.0010538665,0.00097303145,0.000028806906,0.00038852904,4.7273986e-7,5.136484e-7,0.0013226637,0.9937407,0.00037451525],"about_ca_topic_score_codex":0.00012030631,"about_ca_topic_score_gemma":0.000046905072,"teacher_disagreement_score":0.98595583,"about_ca_system_score_codex":0.00019606845,"about_ca_system_score_gemma":0.00024206426,"threshold_uncertainty_score":0.9999385},"labels":[],"label_agreement":null},{"id":"W2072202743","doi":"10.2165/11533130-000000000-00000","title":"Juvenile Parkinsonism","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai; Parkinson Society Canada; Merz Pharmaceuticals; Teva Pharmaceutical Industries","keywords":"Parkinsonism; Psychopharmacology; Neurology; Medicine; Juvenile; Psychiatry; Neuroscience; Psychology; Internal medicine; Biology; Genetics; Disease","score_opus":0.034179649571433275,"score_gpt":0.32810438152230426,"score_spread":0.293924731950871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072202743","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026122943,0.9780129,0.000009795462,0.0000425105,0.0008714996,0.0009504094,0.00017024366,0.0001584115,0.019758113],"genre_scores_gemma":[0.000058300873,0.98804986,0.0005658796,0.00016234998,0.0005727506,0.00032743273,0.00055137754,0.00013226978,0.009579751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980661,0.00006053161,0.0004574408,0.00062915764,0.0003450926,0.00044164967],"domain_scores_gemma":[0.99827904,0.00006552661,0.00025324218,0.0008853893,0.000051360243,0.0004654213],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014747569,0.00056243845,0.0019802502,0.00020834467,0.000113311566,0.000039882772,0.00020894258,0.000573367,0.0007980446],"category_scores_gemma":[0.000042159507,0.00041346948,0.0009606154,0.00022176107,0.00006127944,0.000041497184,0.00008816094,0.0006881683,0.0028131097],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055606765,0.00024003012,0.0000028450083,0.0040495032,0.00024824348,0.00027120562,0.00003361952,2.6646039e-9,4.967998e-7,0.00023405832,0.002421489,0.992493],"study_design_scores_gemma":[0.00065307075,0.00006687345,0.000010490546,0.0049923733,0.0033359441,0.00016584703,0.0000069395196,0.0000010509206,0.000006334965,0.00013346998,0.99030125,0.00032636372],"about_ca_topic_score_codex":0.000013461175,"about_ca_topic_score_gemma":0.0000018111757,"teacher_disagreement_score":0.9921666,"about_ca_system_score_codex":0.00015056694,"about_ca_system_score_gemma":0.0006926103,"threshold_uncertainty_score":0.99983174},"labels":[],"label_agreement":null},{"id":"W2073820341","doi":"10.2165/00023210-200216080-00003","title":"Telepsychiatry","year":2002,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine","funders":"","keywords":"Telepsychiatry; Telemedicine; Videoconferencing; Modalities; Medicine; Medical education; Telehealth; Interpersonal communication; The Internet; Psychology; Multimedia; Health care; Computer science; World Wide Web","score_opus":0.07704153654559204,"score_gpt":0.41233227808422324,"score_spread":0.3352907415386312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073820341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004614033,0.97868115,0.000012789051,0.00049642334,0.0007442729,0.0011425756,0.000033400887,0.00013576093,0.01874903],"genre_scores_gemma":[0.0000033702406,0.98901623,0.0005447448,0.0011179623,0.0016937057,0.00012464792,0.00044382774,0.00007624246,0.0069792625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815667,0.000055417957,0.00074485975,0.00035518483,0.00031089465,0.0003769837],"domain_scores_gemma":[0.9988487,0.000077981626,0.0002940459,0.00047895452,0.000044703625,0.00025564875],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016462085,0.00033013825,0.001450996,0.0002902558,0.000069410264,0.00001083819,0.00011441869,0.00023597738,0.0021006917],"category_scores_gemma":[0.00003898463,0.00024699967,0.0003732501,0.00037435707,0.00003756614,0.00003477128,0.00003047636,0.00050459744,0.0013483487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016851078,0.00004926332,0.000020873233,0.019459961,0.00007345385,0.000016865988,0.000082463084,1.0034171e-9,1.0582317e-8,0.00008060162,0.09737078,0.88284403],"study_design_scores_gemma":[0.0005645788,0.00014788227,0.000016043241,0.006448779,0.0013791003,0.0002233062,0.00006794377,6.847492e-7,1.18335315e-7,0.00001600734,0.99094796,0.00018762297],"about_ca_topic_score_codex":0.000015712456,"about_ca_topic_score_gemma":0.0000015943248,"teacher_disagreement_score":0.89357716,"about_ca_system_score_codex":0.00013502296,"about_ca_system_score_gemma":0.00033078846,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W2074119907","doi":"10.1007/s40263-014-0196-9","title":"QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"QT interval; Prolongation; Medicine; Torsades de pointes; Long QT syndrome; Ziprasidone; Escitalopram; Anesthesia; Intensive care medicine; Pharmacology; Internal medicine; Antipsychotic; Psychiatry; Schizophrenia (object-oriented programming); Antidepressant","score_opus":0.02742319594895679,"score_gpt":0.317847807261046,"score_spread":0.2904246113120892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074119907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024061233,0.97435004,0.00002346788,0.00016249831,0.00009654912,0.0011190937,0.00003151173,0.00004558798,0.000110012006],"genre_scores_gemma":[0.0055835918,0.9922053,0.00010840853,0.00092320744,0.00032053312,0.000060540937,0.00057587534,0.000045221877,0.00017728478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842244,0.00038033546,0.00040450454,0.00042906537,0.000117018324,0.00024660688],"domain_scores_gemma":[0.9989152,0.00021151172,0.00036622272,0.00025259773,0.00014910988,0.000105383995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026319167,0.00034267068,0.0018085307,0.000090905945,0.00008977962,0.000025064623,0.0000462813,0.00026670433,0.000021816228],"category_scores_gemma":[0.00018121084,0.00024847352,0.00018338718,0.00015489449,0.00016048044,0.00006413641,0.0000376391,0.00049280276,0.0000063673497],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018603886,0.00014745485,0.00023632924,0.14151011,0.0023776812,0.0001869105,0.00053990463,7.880061e-7,0.00031251484,0.00012873646,0.013472905,0.8409006],"study_design_scores_gemma":[0.0022748047,0.0015658289,0.0036516401,0.2340236,0.0090340385,0.0037293367,0.00003880155,0.0001371559,0.000058413512,0.000073490584,0.74440145,0.0010114395],"about_ca_topic_score_codex":0.0000024529288,"about_ca_topic_score_gemma":0.0000050701888,"teacher_disagreement_score":0.83988917,"about_ca_system_score_codex":0.000063462445,"about_ca_system_score_gemma":0.00013505625,"threshold_uncertainty_score":0.9999967},"labels":[],"label_agreement":null},{"id":"W2074289679","doi":"10.2165/11533280-000000000-00000","title":"The Association between Conventional Antidepressants and the Metabolic Syndrome","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Metabolic syndrome; Medicine; Psychopharmacology; Disease; Abdominal obesity; Antidepressant; Type 2 Diabetes Mellitus; Diabetes mellitus; Major depressive disorder; Type 2 diabetes; Bioinformatics; Obesity; Internal medicine; Psychiatry; Endocrinology; Mood; Biology","score_opus":0.02977379898294423,"score_gpt":0.36987220265307574,"score_spread":0.3400984036701315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074289679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000602137,0.9917846,0.0000010322567,0.0010576901,0.00095809007,0.0018819626,0.00014847067,0.00002608056,0.0035399548],"genre_scores_gemma":[0.0009228725,0.99425834,0.000010531898,0.00031375972,0.0007484265,0.00017283502,0.0002104695,0.00003103052,0.003331739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979106,0.00039759613,0.00058473344,0.0002486412,0.0004626131,0.00039581102],"domain_scores_gemma":[0.9972767,0.0015686714,0.00046475828,0.00036238125,0.00006588521,0.00026157466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026944657,0.00022103717,0.0015674992,0.00006105843,0.00042646294,0.0000431504,0.00012471277,0.00032686398,0.000018481034],"category_scores_gemma":[0.00028144656,0.000106692336,0.0004861417,0.00016450707,0.00015980071,0.000031669988,0.00007437622,0.0010151551,0.0001103073],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013518535,0.000012798595,0.00087275414,0.0038838487,0.00022460787,0.0000035675414,0.000059804155,6.850443e-10,1.3195108e-8,0.0010671504,0.0014033724,0.9924586],"study_design_scores_gemma":[0.0011549506,0.000015432064,0.008241501,0.0017575687,0.0020608497,0.00017800779,0.000021089098,2.913836e-7,1.3091328e-7,0.000081205566,0.986399,0.000090006004],"about_ca_topic_score_codex":0.00008308819,"about_ca_topic_score_gemma":0.000005872886,"teacher_disagreement_score":0.9923686,"about_ca_system_score_codex":0.00013729958,"about_ca_system_score_gemma":0.00068238913,"threshold_uncertainty_score":0.44104},"labels":[],"label_agreement":null},{"id":"W2076034178","doi":"10.2165/00023210-200822060-00003","title":"Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Diet and metabolism studies","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"","keywords":"Psychopharmacology; Antipsychotic; Atypical antipsychotic; Medicine; Clozapine; Neurology; Psychiatry; Schizophrenia (object-oriented programming); Risperidone; Bipolar disorder; Psychology; Pharmacology; Mood","score_opus":0.08652114572492818,"score_gpt":0.3905713029207254,"score_spread":0.3040501571957972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076034178","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038459705,0.9543816,0.000006478955,0.0000891063,0.0011823991,0.0011152207,0.00001244734,0.00006551997,0.042762622],"genre_scores_gemma":[0.00030115392,0.99434865,0.0005083118,0.00011629644,0.00055174244,0.00011128799,0.000041914274,0.00004553905,0.003975137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799067,0.00009506462,0.000688701,0.00046070127,0.0003828247,0.0003820591],"domain_scores_gemma":[0.9990729,0.00008267589,0.00023902535,0.0003648445,0.000067445995,0.00017308112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014499198,0.0004373285,0.0025288134,0.00016887148,0.00006265626,0.0000049315704,0.00022698008,0.0002593159,0.00026766723],"category_scores_gemma":[0.000016062048,0.00028851719,0.000820079,0.00037257053,0.00015273367,0.00002280016,0.00016098664,0.00043399513,0.00029037037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000781098,0.00047188328,0.00000851499,0.010970192,0.0013875947,0.00027958033,0.000114207185,8.44707e-9,0.000003339625,0.0006956293,0.033280484,0.95271045],"study_design_scores_gemma":[0.001033885,0.00008213348,0.00030417423,0.006038865,0.0043963683,0.000037097983,0.000045003333,4.3543605e-7,0.000009448755,0.000017112048,0.9877888,0.00024666177],"about_ca_topic_score_codex":9.90853e-7,"about_ca_topic_score_gemma":6.1951496e-8,"teacher_disagreement_score":0.9545083,"about_ca_system_score_codex":0.000049639708,"about_ca_system_score_gemma":0.000087462664,"threshold_uncertainty_score":0.9999567},"labels":[],"label_agreement":null},{"id":"W2077234386","doi":"10.2165/00023210-200418090-00003","title":"What are the Treatment Options for Patients with Severe Alzheimer???s Disease?","year":2004,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Donepezil; Rivastigmine; Galantamine; Memantine; Medicine; Alzheimer's disease; Disease; Clinical trial; Dementia; Psychology; Internal medicine","score_opus":0.05913915693612195,"score_gpt":0.34566652089798316,"score_spread":0.28652736396186124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077234386","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001084824,0.99290437,0.0000027535948,0.00030472074,0.0003016544,0.0041622226,0.0011704224,0.000043439628,0.00002557006],"genre_scores_gemma":[0.00020757822,0.99273956,0.000028125796,0.00034357703,0.00044383763,0.001733114,0.0035632723,0.00008773815,0.00085320027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987189,0.000059250156,0.00028192956,0.00046950698,0.000224672,0.00024574876],"domain_scores_gemma":[0.99856156,0.00015706234,0.00020293747,0.0006344469,0.00016823737,0.00027576872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000022677163,0.00047586512,0.0009073846,0.000076230914,0.00020521799,0.000095229545,0.00011879972,0.00007564432,0.000032872547],"category_scores_gemma":[0.000020448942,0.00022754222,0.0006740512,0.0001654946,0.000076550314,0.00012997042,0.000020438318,0.000111497786,0.00004728462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036809352,0.0037550756,0.0006087507,0.009591544,0.0020554294,0.00006585853,0.00040356882,0.000014096179,1.9507338e-8,0.00009992445,0.0021838362,0.9808538],"study_design_scores_gemma":[0.0019113988,0.0003625461,0.00052156765,0.018884005,0.0137256645,0.000007572913,0.000096635194,9.545447e-7,8.098377e-7,0.000011994684,0.9641816,0.00029521968],"about_ca_topic_score_codex":0.000002205746,"about_ca_topic_score_gemma":0.000003315104,"teacher_disagreement_score":0.9805586,"about_ca_system_score_codex":0.000169268,"about_ca_system_score_gemma":0.0005820201,"threshold_uncertainty_score":0.92789024},"labels":[],"label_agreement":null},{"id":"W2084441956","doi":"10.2165/11592230-000000000-00000","title":"Transdermal Rivastigmine","year":2011,"lang":"pl","type":"review","venue":"CNS Drugs","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"H. Lundbeck A/S; Exelon Corporation; Novartis Pharmaceuticals Corporation","keywords":"Rivastigmine; Transdermal patch; Transdermal; Medicine; Adverse effect; Nausea; Dermatology; Anesthesia; Skin patch; Pharmacology; Internal medicine; Dementia; Disease; Donepezil","score_opus":0.0857148668066361,"score_gpt":0.34183602177969635,"score_spread":0.25612115497306026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084441956","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004825222,0.9808591,0.000040199466,0.00016268794,0.0015045342,0.001402127,0.0006384638,0.000114166476,0.010453474],"genre_scores_gemma":[0.004083721,0.9751013,0.000042824344,0.0012751727,0.0034854158,0.00016266179,0.001259144,0.00020787696,0.0143819],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961295,0.0003331496,0.0011659672,0.0011336431,0.00042176974,0.0008159645],"domain_scores_gemma":[0.99721414,0.0002442193,0.00035495393,0.0011290035,0.00021921724,0.00083847175],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00019386684,0.0011469029,0.0026986557,0.00033844504,0.00018531925,0.00005438633,0.00045147046,0.00045205938,0.005958813],"category_scores_gemma":[0.00014104931,0.00092268747,0.0015439768,0.0005023124,0.000284379,0.00014593956,0.00010108358,0.0008834431,0.004254609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024099003,0.0017598066,0.00017530011,0.03787222,0.0011417265,0.0010833514,0.0028079797,4.758828e-7,0.00015577763,0.00044722308,0.023476407,0.93083876],"study_design_scores_gemma":[0.0014648642,0.00021627723,0.00024941945,0.01383404,0.00609661,0.0001832532,0.00005632307,0.0000069731996,0.000408172,0.000008100778,0.976647,0.0008289732],"about_ca_topic_score_codex":0.000024784753,"about_ca_topic_score_gemma":0.000003750833,"teacher_disagreement_score":0.9531706,"about_ca_system_score_codex":0.000088469154,"about_ca_system_score_gemma":0.00085981144,"threshold_uncertainty_score":0.99932235},"labels":[],"label_agreement":null},{"id":"W2084487135","doi":"10.2165/00023210-200721120-00003","title":"Recommendations for the Use of Pharmacological Smoking Cessation Strategies in Pregnant Women","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Varenicline; Bupropion; Medicine; Smoking cessation; Nicotine replacement therapy; Pregnancy; Pharmacotherapy; Psychiatry; Obstetrics","score_opus":0.29853549716316513,"score_gpt":0.4485880852321022,"score_spread":0.15005258806893707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084487135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004047116,0.9884506,0.0015286441,0.0003461976,0.00094530307,0.004135496,0.00013365704,0.00007685071,0.00033616772],"genre_scores_gemma":[0.0052937907,0.99302536,0.00013566826,0.000061008544,0.0001332797,0.0007541131,0.0003538944,0.00002659203,0.0002163107],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987148,0.00008285233,0.00057386264,0.00021093106,0.00019337142,0.00022418372],"domain_scores_gemma":[0.99846864,0.0008749027,0.00032853129,0.0001963204,0.00009120756,0.000040410898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006263039,0.00018129457,0.00062351016,0.0002231606,0.000070091446,0.000039328163,0.000115476614,0.00023043153,0.00015767782],"category_scores_gemma":[0.00008086646,0.000111847825,0.00018011707,0.00034755268,0.00006258065,0.0001320648,0.000026871687,0.00033832534,6.597519e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016364429,0.00012632138,0.00016805709,0.0019408559,0.00009779224,0.0000016427049,0.0009845771,0.000005031355,0.000001359801,0.00021488179,0.0005335325,0.9959096],"study_design_scores_gemma":[0.0005565815,0.00008093976,0.0006833924,0.006243143,0.0014168225,0.000006416725,0.0010380783,0.0000209571,0.000009970818,0.00004724677,0.9897679,0.00012854076],"about_ca_topic_score_codex":0.000028074572,"about_ca_topic_score_gemma":0.0000036416811,"teacher_disagreement_score":0.99578106,"about_ca_system_score_codex":0.00033406683,"about_ca_system_score_gemma":0.0002669335,"threshold_uncertainty_score":0.4561022},"labels":[],"label_agreement":null},{"id":"W2086306474","doi":"10.2165/11631310-000000000-00000","title":"Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder","year":2012,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Risperidone; Depot; Olanzapine; Treatment of bipolar disorder; Bipolar disorder; Medicine; Antipsychotic; Extrapyramidal symptoms; Fluphenazine; Psychiatry; Mania; Bipolar I disorder; Paliperidone; Schizophrenia (object-oriented programming); Atypical antipsychotic; Haloperidol; Pharmacology; Internal medicine; Mood; Dopamine","score_opus":0.059190963956804406,"score_gpt":0.34792862736692887,"score_spread":0.28873766341012447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086306474","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000117316185,0.9947859,0.0009969563,0.00009435543,0.00046440063,0.0028353436,0.00014780422,0.00003681838,0.00062666135],"genre_scores_gemma":[0.0006723081,0.9950878,0.00033334226,0.00001526199,0.0002827994,0.0004377463,0.00021114945,0.000106665095,0.0028529363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839437,0.000050767496,0.00052551925,0.00034158613,0.00018577304,0.00050196383],"domain_scores_gemma":[0.99825037,0.0004062553,0.0003587066,0.0007851234,0.000085862834,0.0001136863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016634744,0.00048231336,0.0015727916,0.000106730266,0.00015340478,0.00001646636,0.00015807491,0.00022444363,0.000070144524],"category_scores_gemma":[0.000028138624,0.00025092147,0.0009217863,0.0002741787,0.000101776415,0.000044455235,0.000030066285,0.00016573959,0.000044356813],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039074745,0.0008300067,0.0013494377,0.007032594,0.001186704,0.0000011014145,0.00042160056,2.5453272e-7,1.3422296e-7,0.00012923736,0.000087333494,0.98892254],"study_design_scores_gemma":[0.0012390931,0.0003925529,0.00022915775,0.002505377,0.007887977,0.00004863517,0.00013799776,0.000007960616,0.0000047990466,0.000013758587,0.9873209,0.00021177506],"about_ca_topic_score_codex":0.00009918446,"about_ca_topic_score_gemma":0.000052491243,"teacher_disagreement_score":0.98871076,"about_ca_system_score_codex":0.00019641343,"about_ca_system_score_gemma":0.00022488683,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W2090314549","doi":"10.1007/s40263-014-0190-2","title":"Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Micronutrient; Attention deficit hyperactivity disorder; Psychopharmacology; Randomized controlled trial; Psychiatry; Medicine; Broad spectrum; Intensive care medicine; Surgery","score_opus":0.07538574041162764,"score_gpt":0.37931202038508316,"score_spread":0.3039262799734555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090314549","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01734985,0.96929336,0.003292234,0.0023837201,0.00035097357,0.0068546846,0.00022110144,0.00011068648,0.00014339945],"genre_scores_gemma":[0.0020550715,0.98684174,0.00076529395,0.00014974573,0.00034247965,0.0019933549,0.0007163834,0.00014460414,0.006991301],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969362,0.00019861266,0.00075838325,0.0011856611,0.00039569655,0.00052547123],"domain_scores_gemma":[0.99711615,0.001077677,0.000450253,0.0008726186,0.00016231874,0.00032096612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003878979,0.00073508074,0.002257261,0.00036442254,0.00030919805,0.00011450843,0.0001723729,0.0002993853,0.00012008086],"category_scores_gemma":[0.00041471177,0.0006090292,0.00079171197,0.00036189304,0.00009028066,0.00023715518,0.00013066146,0.00030106923,0.00042927612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015079613,0.0011256922,0.0014455377,0.015698398,0.00060747773,0.00000847301,0.00014545329,0.0000050866947,0.000037681046,0.0003678505,0.0006954191,0.9797121],"study_design_scores_gemma":[0.0014440345,0.0005038013,0.00048309757,0.008704506,0.0022538735,0.00011763542,0.00019567397,0.000047154004,0.0000014170685,0.0000131723655,0.9856699,0.0005657088],"about_ca_topic_score_codex":0.000084547966,"about_ca_topic_score_gemma":0.000053450985,"teacher_disagreement_score":0.9849745,"about_ca_system_score_codex":0.00040096417,"about_ca_system_score_gemma":0.00043771308,"threshold_uncertainty_score":0.9996361},"labels":[],"label_agreement":null},{"id":"W2092504356","doi":"10.1007/s40263-013-0097-3","title":"Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Moclobemide; Tranylcypromine; Phenelzine; Psychiatry; Depression (economics); Atypical depression; Monoamine oxidase inhibitor; PsycINFO; Medicine; Mood; Monoamine oxidase; Psychology; MEDLINE; Antidepressant; Anxiety; Chemistry","score_opus":0.04994602142880084,"score_gpt":0.36116447529369905,"score_spread":0.3112184538648982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092504356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018415332,0.97794527,0.0000011901695,0.00003421375,0.00022972823,0.002798146,0.00004373902,0.000020922027,0.000511436],"genre_scores_gemma":[0.0031285097,0.9955069,0.00009522465,0.0000035890932,0.00015294182,0.0004900152,0.00022701068,0.000047212798,0.0003486216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997789,0.00023859314,0.0008782048,0.00039526692,0.00046335778,0.00023556325],"domain_scores_gemma":[0.997908,0.0004007692,0.0006167849,0.0009256369,0.000054058622,0.00009476628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015898906,0.00047025466,0.0018725095,0.00032711762,0.000023788061,0.000006773844,0.00021373425,0.00023293919,0.0000632662],"category_scores_gemma":[0.000047565172,0.00022604527,0.0005631328,0.00031840827,0.00008620739,0.000048260554,0.00005318595,0.00022335834,0.000044000477],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030413516,0.0024059021,0.0003738745,0.0076589263,0.0000952276,0.000016582791,0.0007997622,6.2581364e-7,0.0000123721,0.0000040889427,0.0012181957,0.987384],"study_design_scores_gemma":[0.002220207,0.0006043741,0.00034768516,0.036915883,0.0016500326,0.000024331268,0.00010713785,0.000007051788,0.0005050495,0.0000054927996,0.9574292,0.00018358715],"about_ca_topic_score_codex":0.00010269323,"about_ca_topic_score_gemma":0.000003826053,"teacher_disagreement_score":0.98720044,"about_ca_system_score_codex":0.0002701997,"about_ca_system_score_gemma":0.00018266132,"threshold_uncertainty_score":0.92178583},"labels":[],"label_agreement":null},{"id":"W2095273611","doi":"10.2165/00023210-200923060-00004","title":"Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Child and Family Research Institute","keywords":"Pregnancy; Medicine; Depression (economics); Low birth weight; Psychopharmacology; Pediatrics; Adverse effect; Antidepressant; Psychiatry; Obstetrics; Medical prescription; Sertraline; Internal medicine; Anxiety; Pharmacology","score_opus":0.03129358299483017,"score_gpt":0.34310695860110213,"score_spread":0.311813375606272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095273611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110391564,0.9746783,4.853813e-7,0.000049709342,0.0003346471,0.002815,0.000051373212,0.00004456969,0.021915566],"genre_scores_gemma":[0.00057332753,0.99554986,0.00011128222,0.000060432518,0.00013447105,0.00018851653,0.00008302398,0.000052433923,0.003246683],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99743205,0.00018563333,0.0012069066,0.00044315087,0.00029601628,0.00043625914],"domain_scores_gemma":[0.9987027,0.00011015036,0.00050399854,0.00045518327,0.000054990545,0.00017299489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025927497,0.00041367067,0.0020831116,0.0003224043,0.00004064788,0.000005541551,0.00017401158,0.0004052673,0.00005316312],"category_scores_gemma":[0.00004588815,0.0003385523,0.00035537698,0.000495324,0.000055934324,0.000051572097,0.00005566623,0.00076728605,0.00006813248],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011516115,0.00022429742,0.00019263827,0.16773082,0.000055142198,0.00008717762,0.0005656168,1.1913791e-7,2.1799808e-7,0.000224363,0.000066950066,0.8307375],"study_design_scores_gemma":[0.00065327936,0.00029195088,0.00036103808,0.5660508,0.00023406543,0.000082753664,0.000018531,4.9097497e-7,0.00009623506,0.000056836507,0.43192694,0.00022707046],"about_ca_topic_score_codex":0.00004478733,"about_ca_topic_score_gemma":0.0000083448085,"teacher_disagreement_score":0.83051044,"about_ca_system_score_codex":0.00038131353,"about_ca_system_score_gemma":0.0005214777,"threshold_uncertainty_score":0.99990666},"labels":[],"label_agreement":null},{"id":"W2135586697","doi":"10.1007/s40263-015-0291-6","title":"Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial","year":2015,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Evening; Placebo; Attention deficit hyperactivity disorder; Guanfacine; Randomized controlled trial; Morning; Rating scale; Population; Medicine; Psychiatry; Clinical trial; Pediatrics; Psychology; Internal medicine; Developmental psychology","score_opus":0.01570401413637458,"score_gpt":0.28776217564195755,"score_spread":0.272058161505583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135586697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865965,0.00019929592,0.0005405682,0.0025324165,0.00046541012,0.008620804,0.00021769165,0.00017958545,0.00064772967],"genre_scores_gemma":[0.9953556,0.000043450782,0.0002163369,0.00011185169,0.0004029363,0.00089394714,0.001122189,0.00007284534,0.0017808187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99529123,0.00083585636,0.0012324617,0.0009201806,0.0011577163,0.0005625344],"domain_scores_gemma":[0.99668986,0.0010529533,0.00065877306,0.00077159656,0.00038222285,0.00044458336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018122805,0.0005920148,0.002607329,0.00040690444,0.0001314018,0.000083483275,0.0001300359,0.00021899327,0.00042868583],"category_scores_gemma":[0.002477573,0.00031350885,0.0008436062,0.00047449794,0.00021981951,0.0004662356,0.00007293446,0.0006410705,0.00013873726],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.849463,0.0035646223,0.14412785,0.0000062323925,0.0012348114,0.000024216899,0.00023146466,0.00045786938,0.00015564052,0.000015043262,0.00013783015,0.000581446],"study_design_scores_gemma":[0.7331972,0.00064915424,0.2618861,0.00008167399,0.00076355366,0.000033609853,0.001273952,0.0016738254,0.0000034670961,0.00008883753,0.00002120199,0.0003274573],"about_ca_topic_score_codex":0.0029798283,"about_ca_topic_score_gemma":0.00021936819,"teacher_disagreement_score":0.11775824,"about_ca_system_score_codex":0.00042350515,"about_ca_system_score_gemma":0.00069707434,"threshold_uncertainty_score":0.9999317},"labels":[],"label_agreement":null},{"id":"W2227626307","doi":"10.1007/s40263-015-0288-1","title":"The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"National Institute of Mental Health; National Institutes of Health; Bristol-Myers Squibb","keywords":"Hypoactive sexual desire disorder; Sexual desire; Libido; Sexual function; Female sexual dysfunction; Sexual dysfunction; Psychiatry; Medicine; Distress; Psychology; Psychosocial; Clinical psychology; Human sexuality; Internal medicine","score_opus":0.3786873442893229,"score_gpt":0.42366875460578396,"score_spread":0.04498141031646108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227626307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004643455,0.9887627,0.0014709239,0.0004816549,0.0010507504,0.0033573764,0.00011950978,0.000065883076,0.00004778412],"genre_scores_gemma":[0.00065796723,0.9912666,0.00004195516,0.00013898489,0.00029738594,0.0011151837,0.00024283421,0.000057328005,0.006181757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977402,0.00042320325,0.00061699183,0.00059187284,0.00031638422,0.00031133156],"domain_scores_gemma":[0.9960942,0.0025712834,0.0004342099,0.0004451189,0.00029022337,0.00016493093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005700879,0.0005097118,0.001153533,0.000105900624,0.00047128965,0.000047538462,0.00013084788,0.00020254104,0.00000919001],"category_scores_gemma":[0.00033462624,0.00021536856,0.00018559166,0.0003123622,0.0005588488,0.00006710507,0.00008453036,0.000271193,0.000008181403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020770794,0.00038580399,0.00004688665,0.0014129528,0.0007303541,9.160603e-7,0.0017408832,0.000025779365,7.683586e-7,0.00025279226,0.0051969835,0.9881288],"study_design_scores_gemma":[0.0018385056,0.002656624,0.00019563547,0.00036277357,0.0019366469,0.000026153071,0.0072341776,0.0005788851,7.3409194e-7,0.00022328093,0.9847085,0.00023812204],"about_ca_topic_score_codex":0.000022702476,"about_ca_topic_score_gemma":0.000009327907,"teacher_disagreement_score":0.98789066,"about_ca_system_score_codex":0.00026576463,"about_ca_system_score_gemma":0.0006006345,"threshold_uncertainty_score":0.8782475},"labels":[],"label_agreement":null},{"id":"W2251665514","doi":"10.1007/s40263-015-0295-2","title":"The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Mental Health & Substance Use Services; University of British Columbia","funders":"Institute of Health Services and Policy Research; Canadian Institutes of Health Research","keywords":"Medicine; Pharmacokinetics; Tolerability; Medical physics; Intensive care medicine; Clinical trial; Clinical pharmacology; Pharmacology; Adverse effect; Internal medicine","score_opus":0.18668574639683075,"score_gpt":0.4065359293962108,"score_spread":0.21985018299938006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2251665514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024047545,0.9943932,0.000022444312,0.000049956045,0.00027315688,0.0009832878,0.000067634785,0.000018840594,0.0017867035],"genre_scores_gemma":[0.005528523,0.99202454,0.0011338759,0.0000068499535,0.00024365347,0.00007779465,0.00026815318,0.000038593185,0.0006780384],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833286,0.00017000189,0.00061239104,0.0002209918,0.0004218643,0.00024191588],"domain_scores_gemma":[0.9980132,0.00052179635,0.00041662902,0.00046005507,0.00044053124,0.00014779497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004953111,0.00022959402,0.00088423153,0.0002450189,0.00010158117,0.00002586372,0.00016629141,0.0001127867,0.00003529708],"category_scores_gemma":[0.0002223634,0.00014349476,0.00036208995,0.0005072896,0.00014389273,0.000048863778,0.000042317366,0.0002826778,0.000017313501],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015844153,0.00017568505,0.000024790463,0.0030086024,0.0007542552,0.0000049429955,0.00030548923,0.0000026543257,0.00002150092,0.0001203283,0.0028200825,0.99260324],"study_design_scores_gemma":[0.0030253541,0.00077205326,0.00013287496,0.0056676343,0.0037141808,0.00005139906,0.0005707566,0.00019654089,0.0011198714,0.0003803445,0.98403186,0.0003371475],"about_ca_topic_score_codex":0.000008246237,"about_ca_topic_score_gemma":0.000027845346,"teacher_disagreement_score":0.99226606,"about_ca_system_score_codex":0.00007364824,"about_ca_system_score_gemma":0.0007439604,"threshold_uncertainty_score":0.58515465},"labels":[],"label_agreement":null},{"id":"W2275911658","doi":"10.1007/s40263-016-0310-2","title":"The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective","year":2016,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Substance Abuse Treatment and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Nalmefene; Psychosocial; Medicine; Environmental health; Population; Public health; Cost effectiveness; Psychiatry; Naltrexone; Risk analysis (engineering); Internal medicine","score_opus":0.030771094258223962,"score_gpt":0.2995111677444613,"score_spread":0.26874007348623735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275911658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754053,0.00014496146,0.00018020885,0.0000866224,0.00025739998,0.0015906969,0.00015215095,0.000019905745,0.00002751514],"genre_scores_gemma":[0.99918497,0.00019159103,0.00022256609,0.0000075051826,0.000055623543,0.00014257617,0.000049857743,0.000021771824,0.00012354403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878716,0.00010967705,0.0002744918,0.00030126263,0.0003200571,0.0002073687],"domain_scores_gemma":[0.9980352,0.0010670968,0.0002762998,0.00026944786,0.00030886373,0.00004310172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029321614,0.00018204367,0.00041415065,0.00008507964,0.000081699225,0.0000067129813,0.000082102124,0.00008762444,0.000052984247],"category_scores_gemma":[0.00012859359,0.00008983182,0.00011338824,0.00013458914,0.00021150922,0.0001150529,0.000017077868,0.00008456261,0.0000052399446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009672125,0.0003180292,0.9761166,0.000036832138,0.00066767,0.0000031398215,0.0027247835,0.000010851384,0.0042163976,0.0002826029,0.00001685157,0.0059341365],"study_design_scores_gemma":[0.021896712,0.0004573188,0.90524787,0.00062780245,0.00034314248,0.0000014505854,0.0015713255,0.000003513712,0.06893234,0.00080145884,0.0000036912982,0.00011338308],"about_ca_topic_score_codex":0.00048775948,"about_ca_topic_score_gemma":0.00026824916,"teacher_disagreement_score":0.07086872,"about_ca_system_score_codex":0.00042001347,"about_ca_system_score_gemma":0.0000889398,"threshold_uncertainty_score":0.36632353},"labels":[],"label_agreement":null},{"id":"W2291484568","doi":"10.1007/s40263-015-0293-4","title":"Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Cabergoline; Internal medicine; valvular heart disease; Hazard ratio; Cohort study; Pergolide; Cohort; Heart failure; Observational study; Dopamine agonist; Confidence interval; Dopamine","score_opus":0.07807149264030631,"score_gpt":0.33521396006356047,"score_spread":0.25714246742325414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291484568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06124717,0.93337035,0.0000011260101,0.000030000469,0.000033523986,0.004309073,0.0009876828,0.0000151929835,0.0000058715214],"genre_scores_gemma":[0.024523586,0.97213465,0.00037081182,0.0000417136,0.0000145713,0.0006686144,0.0021333417,0.00006127939,0.00005144677],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99722767,0.000347948,0.0009629544,0.0004975958,0.0007428757,0.00022094774],"domain_scores_gemma":[0.9968647,0.00033418668,0.0012446699,0.00043150462,0.0008735851,0.0002513871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005022375,0.0005139555,0.004091926,0.00019718664,0.00005169252,0.000019715839,0.000067902976,0.00011852395,0.0000023628224],"category_scores_gemma":[0.0007173609,0.0003232938,0.00026081584,0.00044166777,0.00015629127,0.00015804399,0.0000609461,0.00014925994,0.000001040087],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015107381,0.00048627614,0.052758988,0.940746,0.0038849586,0.0000148268455,0.00019610158,2.883613e-7,1.6332808e-7,0.000010581452,0.0002836473,0.0014670703],"study_design_scores_gemma":[0.0024183318,0.00043644523,0.1911501,0.7806219,0.0173148,0.0000025557677,0.00012554498,0.0000026114228,5.312434e-7,0.000008041344,0.0076081166,0.0003110322],"about_ca_topic_score_codex":0.00002597012,"about_ca_topic_score_gemma":0.000017138367,"teacher_disagreement_score":0.16012414,"about_ca_system_score_codex":0.00029168045,"about_ca_system_score_gemma":0.00053523027,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W2328547247","doi":"10.2165/11587900-000000000-00000","title":"The Pharmacology of New Antiepileptic Drugs","year":2011,"lang":"en","type":"editorial","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"UCB Pharma; Agenzia Italiana del Farmaco, Ministero della Salute; Valeant Pharmaceuticals International; Eisai; Upsher-Smith; Johnson and Johnson; Pfizer","keywords":"Psychopharmacology; Antiepileptic drug; Medicine; Pharmacology; Clinical pharmacology; Epilepsy; Psychiatry","score_opus":0.018903417531976822,"score_gpt":0.3340876267090464,"score_spread":0.3151842091770696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328547247","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004272342,0.006288791,0.0000042372535,0.0010692669,0.94879943,0.0011172614,0.00011424812,0.000075396856,0.038259007],"genre_scores_gemma":[0.009163686,0.014273211,0.00011890726,0.00007779001,0.9004246,0.000091514936,0.00033968932,0.00009389634,0.07541668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997553,0.000116977615,0.00044123107,0.00039398254,0.00089106004,0.00060376804],"domain_scores_gemma":[0.997251,0.0011140247,0.0002356406,0.00063641643,0.00034395308,0.00041896894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043456283,0.00031818973,0.00069957896,0.00013862144,0.00013182884,0.00001802031,0.00040353904,0.00050245575,0.0007648746],"category_scores_gemma":[0.000338486,0.000196145,0.00030723008,0.0001796285,0.00035531676,0.000034413446,0.00015242878,0.0010214251,0.0004897096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006509592,0.00021831626,0.00012943985,0.00018530269,0.0007082072,0.000058333317,0.00080252567,3.8465537e-8,0.000106508676,0.00007222171,0.98639005,0.010678098],"study_design_scores_gemma":[0.0032022088,0.00080343883,0.000113069946,0.00015975283,0.0005913106,0.0000032512912,0.00015393866,0.0000024896854,0.002430226,0.00030156347,0.9920917,0.00014705728],"about_ca_topic_score_codex":0.00050071545,"about_ca_topic_score_gemma":0.0000120090335,"teacher_disagreement_score":0.048374824,"about_ca_system_score_codex":0.00015845946,"about_ca_system_score_gemma":0.0022069705,"threshold_uncertainty_score":0.8374841},"labels":[],"label_agreement":null},{"id":"W2344267538","doi":"10.1007/s40263-016-0334-7","title":"The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Occupational Therapy Practice and Research","field":"Health Professions","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Centre for Movement Disorders; University of British Columbia","funders":"","keywords":"Meta-analysis; Medicine; Randomized controlled trial; Placebo; Major depressive disorder; Systematic review; Psychiatry; MEDLINE; Internal medicine; Mood; Alternative medicine; Pathology","score_opus":0.11877144229701035,"score_gpt":0.5124727009310429,"score_spread":0.39370125863403255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344267538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013472078,0.95933837,0.000028233611,0.00040094985,0.00011879857,0.039597612,0.00030710656,0.0000074863246,0.00018798634],"genre_scores_gemma":[0.00013500966,0.9777536,0.000012163636,0.0001850302,0.00003486519,0.01982578,0.00005514347,0.00003223009,0.0019661942],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9403934,0.051369004,0.0064170463,0.0004208693,0.0010371252,0.0003625521],"domain_scores_gemma":[0.77316993,0.21772914,0.0078089926,0.00072618213,0.0004863655,0.000079382495],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03880921,0.0005053329,0.038144145,0.00081919355,0.0002925293,0.000017294537,0.00045349335,0.00030986295,0.00047741717],"category_scores_gemma":[0.05621838,0.00017266872,0.0073619094,0.0007703159,0.00017117836,0.00008801698,0.00013897501,0.0005760288,0.000027957756],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010308141,0.00016679637,0.000008575904,0.66960746,0.31743336,0.0000018031587,0.0001545864,3.967013e-7,1.8953368e-7,0.00059706473,0.00031623326,0.0014054052],"study_design_scores_gemma":[0.065925755,0.000048518425,0.000009134759,0.14886498,0.78251404,3.3455174e-7,0.00004046538,0.000006488135,3.0933745e-7,0.00011401762,0.0023137457,0.00016221867],"about_ca_topic_score_codex":0.00008130518,"about_ca_topic_score_gemma":0.00001966327,"teacher_disagreement_score":0.5207425,"about_ca_system_score_codex":0.00008814766,"about_ca_system_score_gemma":0.0007685102,"threshold_uncertainty_score":0.9897482},"labels":[],"label_agreement":null},{"id":"W2345643776","doi":"10.1007/s40263-016-0338-3","title":"Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"B.C. Women's Hospital & Health Centre; University of British Columbia","funders":"","keywords":"Psychopharmacology; Serotonin Uptake Inhibitors; Medicine; Reuptake inhibitor; Serotonin; Citalopram; Pregnancy; Pharmacology; Psychiatry; Fluoxetine; Internal medicine; Biology","score_opus":0.06956686618572296,"score_gpt":0.4006472551019375,"score_spread":0.33108038891621455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345643776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017597056,0.99358726,0.0000019817555,0.000110931134,0.00047169696,0.0046340274,0.00009245781,0.000020758525,0.0010632646],"genre_scores_gemma":[0.00007259322,0.99848354,0.000038759237,0.000055895474,0.00009888859,0.0004899386,0.000025537394,0.0000462877,0.0006885557],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962574,0.0004100369,0.0019999316,0.00047760332,0.00046294005,0.00039207205],"domain_scores_gemma":[0.9973261,0.00040070084,0.0012907233,0.00064566924,0.00016698151,0.00016986925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007894765,0.00042106662,0.0029323609,0.00025112525,0.000024031951,0.0000021606638,0.0002655407,0.00021211736,0.00013347797],"category_scores_gemma":[0.00036101122,0.00028363228,0.0005008465,0.0005362269,0.00010932713,0.00009004716,0.000118127595,0.00056569936,0.000055751167],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044694345,0.00007706768,0.000113695176,0.54609704,0.00002740206,0.0000068876425,0.000121841986,3.580294e-9,2.3667975e-7,0.000047954298,0.00010050307,0.45336267],"study_design_scores_gemma":[0.0002451063,0.00014067831,0.00007594961,0.62719005,0.00024854887,0.000023559547,0.000002042638,5.8361103e-8,0.00009204974,0.000013285409,0.37183446,0.00013422377],"about_ca_topic_score_codex":0.000021927453,"about_ca_topic_score_gemma":0.0000025739616,"teacher_disagreement_score":0.45322844,"about_ca_system_score_codex":0.0003935958,"about_ca_system_score_gemma":0.0010932058,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W2531324366","doi":"10.1007/s40263-016-0386-8","title":"Novel Levodopa Formulations for Parkinson’s Disease","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Levodopa; Carbidopa; Entacapone; Prodrug; Pharmacology; Bioavailability; Medicine; Parkinson's disease; Dosage form; Chemistry; Internal medicine; Disease","score_opus":0.06355281078969582,"score_gpt":0.3509963170510967,"score_spread":0.28744350626140086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531324366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007059576,0.98653,0.004714438,0.00015340411,0.00043497872,0.0029553315,0.003545987,0.00013283076,0.001525985],"genre_scores_gemma":[0.00017131973,0.9840453,0.0018489719,0.00014113967,0.00063171855,0.0019003757,0.001438295,0.00015402146,0.009668845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802285,0.000025626568,0.0004958375,0.000676592,0.000291511,0.00048755042],"domain_scores_gemma":[0.9979429,0.00019955632,0.00027439793,0.00076075643,0.00010805256,0.00071434124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011621694,0.00055174396,0.0013971286,0.00024366716,0.00018020938,0.00003402212,0.00017518537,0.00020246302,0.00023830532],"category_scores_gemma":[0.00012195223,0.0003608079,0.0012762399,0.00016532354,0.000042743493,0.00008956271,0.000066013505,0.00012757302,0.0005139539],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005734492,0.00044036668,0.000013987949,0.008393699,0.0005178572,0.00003070571,0.000017798984,4.1345896e-8,6.5964497e-7,0.0023524864,0.0024758324,0.98569924],"study_design_scores_gemma":[0.0019050746,0.00006374857,0.00012010919,0.011747957,0.0044973767,0.000019915673,0.0000036515914,0.00001315841,0.0000010202259,0.000598773,0.9806657,0.0003635579],"about_ca_topic_score_codex":0.000004590128,"about_ca_topic_score_gemma":0.0000010660524,"teacher_disagreement_score":0.98533565,"about_ca_system_score_codex":0.00035507377,"about_ca_system_score_gemma":0.00086021173,"threshold_uncertainty_score":0.99988437},"labels":[],"label_agreement":null},{"id":"W2535539542","doi":"10.1007/s40263-016-0385-9","title":"Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Pharmacogenetics; Antidepressant; Neuroimaging; Medicine; Pharmacology; Psychology; Psychiatry; Biology; Genetics; Gene; Anxiety","score_opus":0.03917798352743512,"score_gpt":0.3908195862422717,"score_spread":0.3516416027148366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535539542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017559051,0.9946003,0.00013590745,0.0002663514,0.00024877387,0.000979719,0.00054143375,0.000069482885,0.0014021526],"genre_scores_gemma":[0.0049673393,0.9927837,0.001071993,0.000031870983,0.00022517465,0.000053833675,0.00011369125,0.00010672348,0.00064563274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750715,0.0002772908,0.00076989015,0.000542912,0.0005771495,0.00032558705],"domain_scores_gemma":[0.9984424,0.0003605343,0.0003782797,0.0004477975,0.00014625977,0.00022469356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033167185,0.00054675376,0.0014614345,0.0003271603,0.000058714497,0.00003176543,0.00020227197,0.00020500679,0.00028665314],"category_scores_gemma":[0.00003912507,0.00037054383,0.00039986408,0.00017198514,0.00030019108,0.00008722574,0.000097058146,0.00025946018,0.000025528221],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029008347,0.00013789497,0.0003295424,0.0077783633,0.00042605592,0.00008099045,0.00014432687,5.819409e-7,0.00047525734,0.000025242949,0.0007704769,0.9895412],"study_design_scores_gemma":[0.002484596,0.000097205695,0.0019740188,0.014301121,0.0035403334,0.00026811945,0.000031669155,0.000015907306,0.000741275,0.000072245646,0.97608405,0.00038943836],"about_ca_topic_score_codex":0.000004161209,"about_ca_topic_score_gemma":1.3307819e-7,"teacher_disagreement_score":0.9891517,"about_ca_system_score_codex":0.000052985517,"about_ca_system_score_gemma":0.0010233724,"threshold_uncertainty_score":0.99987465},"labels":[],"label_agreement":null},{"id":"W2596957891","doi":"10.1007/s40263-017-0418-z","title":"Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; National Institutes of Health; Pfizer","keywords":"Antidepressant; Major depressive disorder; Psychopharmacology; Monoamine neurotransmitter; Psychiatry; Medicine; microRNA; Reuptake inhibitor; Psychology; Bioinformatics; Pharmacology; Internal medicine; Receptor; Serotonin; Biology; Mood; Anxiety","score_opus":0.07909037364567921,"score_gpt":0.37371710061954705,"score_spread":0.2946267269738678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596957891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012763267,0.98452073,0.0006991805,0.000013217943,0.00047622074,0.0011303263,0.00037727578,0.000009394971,0.000010387749],"genre_scores_gemma":[0.01055799,0.9862805,0.0010149748,0.000012845281,0.0005620271,0.00014174389,0.00024822986,0.00010133045,0.001080354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986296,0.00015140692,0.00039543124,0.00045886837,0.00011715499,0.00024752415],"domain_scores_gemma":[0.9982836,0.00005149479,0.00042244242,0.0010051499,0.00013922292,0.000098036675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027212268,0.00028825548,0.00064381777,0.00010767318,0.00009840432,0.000063596475,0.00044561675,0.00032752778,0.0000038173976],"category_scores_gemma":[0.00022308282,0.0002701884,0.0005209004,0.000045966,0.00006001147,0.0000055134337,0.00018697248,0.000072448805,0.000009555869],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005149182,0.000056481174,0.000020949097,0.0036141544,0.00040299704,0.000003070431,0.000027491342,0.000011679419,0.20644374,0.0000021325338,0.0010175077,0.7878849],"study_design_scores_gemma":[0.00022736705,0.00006258983,0.00023374753,0.0021262458,0.00042057605,0.000007718958,0.000003376665,0.0000016366639,0.019009711,0.000004177818,0.9776294,0.0002734366],"about_ca_topic_score_codex":0.0000050677054,"about_ca_topic_score_gemma":3.2707354e-7,"teacher_disagreement_score":0.9766119,"about_ca_system_score_codex":0.000030499063,"about_ca_system_score_gemma":0.0002481254,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W2599168029","doi":"10.1007/s40263-017-0427-y","title":"Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations","year":2017,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Queen's University Belfast","keywords":"Dementia; Medicine; Intensive care medicine; Health care; MEDLINE; Antibiotics; Psychiatry; Disease; Internal medicine","score_opus":0.09171518263481573,"score_gpt":0.3899917614172138,"score_spread":0.2982765787823981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599168029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915831,0.000111533955,0.000009085468,0.0064120996,0.00053571304,0.00033786753,0.000033943215,0.000012297478,0.0009643466],"genre_scores_gemma":[0.99847436,0.0003470782,0.00026624685,0.00057346176,0.0001823298,0.0000048057886,0.000058021895,0.000009180941,0.000084503336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944973,0.000023224045,0.0001254392,0.00015566395,0.000102046055,0.00014387457],"domain_scores_gemma":[0.99948716,0.00004315015,0.00010773369,0.00021797499,0.000046600293,0.00009738564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006494566,0.00008803764,0.00013678988,0.00003776104,0.00016261249,0.000076279975,0.000060394723,0.000031274714,0.00011500986],"category_scores_gemma":[0.00004112916,0.00006519253,0.000020287685,0.00002877359,0.000067088724,0.00040578554,0.00006058685,0.00020556095,0.000010356505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016739508,0.00021490137,0.9671341,0.00003349384,0.00003544889,0.0000021707751,0.00022341384,1.219543e-7,0.000004547389,0.00008260707,0.002828816,0.02927297],"study_design_scores_gemma":[0.003754612,0.00006610214,0.73652387,0.00008136331,0.00010696606,7.029254e-7,0.00003599771,0.000039919723,0.000031626234,0.000005342768,0.25927228,0.000081234655],"about_ca_topic_score_codex":0.00003337187,"about_ca_topic_score_gemma":0.000026026906,"teacher_disagreement_score":0.25644347,"about_ca_system_score_codex":0.000021309941,"about_ca_system_score_gemma":0.000024691893,"threshold_uncertainty_score":0.26584744},"labels":[],"label_agreement":null},{"id":"W2607002700","doi":"10.1007/s40263-017-0439-7","title":"Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Lamotrigine; Medicine; In utero; Pregnancy; Pediatrics; Odds ratio; Carbamazepine; Population; Obstetrics; Epilepsy; Internal medicine; Fetus; Psychiatry","score_opus":0.17209415557151952,"score_gpt":0.4562765213663113,"score_spread":0.2841823657947918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607002700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009782334,0.98932505,0.0000094917095,0.0015281258,0.000119678116,0.008280978,0.000040046616,0.000045202232,0.00064167235],"genre_scores_gemma":[0.0005202506,0.98511463,0.000110344794,0.002732519,0.000018494437,0.0021288567,0.0000151722525,0.000037007296,0.009322731],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99684805,0.00041927226,0.0012079647,0.0007284137,0.00038083052,0.0004154776],"domain_scores_gemma":[0.9976354,0.0004916337,0.00045863085,0.0010212866,0.000061085426,0.00033192622],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.000988843,0.00069658307,0.01742524,0.00047732893,0.000119323035,0.00007258383,0.0003875025,0.00019017018,0.00004879855],"category_scores_gemma":[0.0015971906,0.00036044972,0.003896781,0.0007817193,0.000027914646,0.00006727285,0.00031835443,0.00042796886,0.00007429569],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.622868e-7,0.000069051326,0.000016979831,0.866373,0.12845811,0.00030965035,0.00013454213,1.7001358e-7,5.357215e-8,0.0000052292094,0.00079773983,0.0038345908],"study_design_scores_gemma":[0.00019440701,0.00010551892,0.000027937764,0.18334314,0.78048724,0.0000071102822,0.000008045967,2.9488513e-7,8.9365464e-8,0.0000032279218,0.035509206,0.00031377835],"about_ca_topic_score_codex":0.000017223367,"about_ca_topic_score_gemma":0.00001946372,"teacher_disagreement_score":0.6830299,"about_ca_system_score_codex":0.0001033966,"about_ca_system_score_gemma":0.000068079986,"threshold_uncertainty_score":0.9998847},"labels":[],"label_agreement":null},{"id":"W2621146233","doi":"10.1007/s40263-017-0440-1","title":"A Review of Adjunctive CNS Medications Used for the Treatment of Post-Surgical Pain","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Anesthesia and Pain Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; York University; University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Psychopharmacology; Medicine; Neurology; Adjunctive treatment; Neurosurgery; Intensive care medicine; Psychiatry; Internal medicine","score_opus":0.08613565472166292,"score_gpt":0.3917450842540957,"score_spread":0.3056094295324328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621146233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.9906157e-7,0.9905141,0.00012473622,0.0028477474,0.000049731825,0.0052439133,0.00005424402,0.000014054468,0.0011509884],"genre_scores_gemma":[0.0000034653003,0.9934887,0.0001355725,0.00058676687,0.00019157132,0.0013996733,0.00044812888,0.000033538483,0.0037125747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982687,0.00032950204,0.00069081277,0.00026763004,0.00026772512,0.0001755864],"domain_scores_gemma":[0.9956995,0.0020486375,0.0008199782,0.0011500263,0.0001925109,0.00008933583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015429182,0.00029048888,0.0021616,0.000086314845,0.00009492353,0.000004751311,0.0003072506,0.00013805804,0.00016915187],"category_scores_gemma":[0.00028637671,0.00014540169,0.0012508968,0.000121188445,0.00022356403,0.000015037868,0.000018921217,0.00009594881,0.000017476475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012758318,0.00028961131,0.000005835124,0.10741064,0.0009090989,0.0000073257497,0.0002746786,1.5426592e-8,1.7027597e-8,0.00048150198,0.006577435,0.88403106],"study_design_scores_gemma":[0.00052832766,0.00056509627,0.000012234816,0.092379354,0.008501142,0.000013028363,0.00007014493,0.000005505039,2.165709e-7,0.000011913899,0.89781183,0.00010118642],"about_ca_topic_score_codex":0.000031580348,"about_ca_topic_score_gemma":0.0000024065205,"teacher_disagreement_score":0.8912344,"about_ca_system_score_codex":0.00010043502,"about_ca_system_score_gemma":0.00045428568,"threshold_uncertainty_score":0.59293085},"labels":[],"label_agreement":null},{"id":"W2736248910","doi":"10.1007/s40263-017-0453-9","title":"Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cardiovascular Syncope and Autonomic Disorders","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Orthostatic vital signs; Baroreflex; Pure autonomic failure; Supine position; Blood pressure; Anesthesia; Cardiology; Midodrine; Internal medicine; Heart rate","score_opus":0.10340174153467674,"score_gpt":0.35388748833352446,"score_spread":0.2504857467988477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736248910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030049175,0.9917877,0.000036701833,0.0000679104,0.00029055952,0.0012611462,0.0000153949,0.000048339185,0.00619179],"genre_scores_gemma":[0.00036587022,0.99733555,0.0006085425,0.00006897202,0.00007055716,0.000047462643,0.00022054317,0.00008465416,0.0011978325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820614,0.00006912733,0.0006719207,0.0005059406,0.00028975637,0.00025713],"domain_scores_gemma":[0.997658,0.000053779255,0.00048097703,0.0016186842,0.00008392117,0.00010461512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029712383,0.00035376276,0.0023202265,0.0001563589,0.00010256704,0.000019732,0.00026455513,0.00013710935,0.000029010516],"category_scores_gemma":[0.000036673555,0.00028115624,0.0014816619,0.00013266079,0.00009811669,0.000036032525,0.0002563121,0.00024611398,0.00020061058],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000051552324,0.00006319281,0.0000012391087,0.016709587,0.0009605826,0.00019832993,0.000017277194,6.3400313e-7,0.0000022235204,0.000038092767,0.00047451118,0.9815292],"study_design_scores_gemma":[0.0006738964,0.000040247007,0.000081782244,0.020422617,0.0057023517,0.0002708733,0.00005475582,0.000024959105,0.0000020017471,0.00000865178,0.9724915,0.0002263712],"about_ca_topic_score_codex":0.000019356077,"about_ca_topic_score_gemma":3.2544966e-7,"teacher_disagreement_score":0.9813028,"about_ca_system_score_codex":0.0000573405,"about_ca_system_score_gemma":0.00013648173,"threshold_uncertainty_score":0.99996406},"labels":[],"label_agreement":null},{"id":"W27800376","doi":"10.2165/00023210-200115030-00002","title":"Psychotic and Mood Disorders Associated with the Perimenopausal Period","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Stress Responses and Cortisol","field":"Neuroscience","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Psychopharmacology; Psychiatry; Mood disorders; Mood; Medicine; Neurology; Period (music); Psychosis; Psychology; Anxiety","score_opus":0.03430845675862346,"score_gpt":0.31247137427328087,"score_spread":0.2781629175146574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W27800376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013901044,0.99080116,0.0000090182575,0.00029078906,0.00015578316,0.0007098904,0.000047990023,0.0000783738,0.006516881],"genre_scores_gemma":[0.007039853,0.9890253,0.0000017880308,0.000094339615,0.000051487918,0.00014376003,0.000006168509,0.000065460736,0.0035718584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99816686,0.00032870757,0.00023109851,0.0005762592,0.00030977873,0.0003872749],"domain_scores_gemma":[0.99886197,0.0003574673,0.00023201026,0.00044165744,0.000014227794,0.00009267659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004269824,0.00038570698,0.00067320414,0.0000753994,0.00031575034,0.0001709883,0.00043792024,0.0001420692,0.00010504047],"category_scores_gemma":[0.00015423448,0.00021355756,0.00013074363,0.0005360045,0.00032107532,0.00005615767,0.00008258638,0.0004056183,0.00004962455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023763243,0.00007464309,0.000008696277,0.00034496066,0.00003840322,0.000016265596,0.0003144502,4.0739812e-7,0.0000059386903,0.00012445537,0.00022964948,0.99881834],"study_design_scores_gemma":[0.0003160976,0.00021567619,0.00012356116,0.0016330568,0.00033375193,0.00010251817,0.00014094304,0.000014274448,0.0000025063985,0.000017144837,0.9967125,0.00038795942],"about_ca_topic_score_codex":0.000011587883,"about_ca_topic_score_gemma":0.000038164962,"teacher_disagreement_score":0.99843043,"about_ca_system_score_codex":0.00004468184,"about_ca_system_score_gemma":0.00013436009,"threshold_uncertainty_score":0.8708625},"labels":[],"label_agreement":null},{"id":"W2791111957","doi":"10.1007/s40263-018-0507-7","title":"Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Intracerebral and Subarachnoid Hemorrhage Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Reuptake inhibitor; Medicine; Serotonin Uptake Inhibitors; Reuptake; Serotonin; Serotonin reuptake inhibitor; Pharmacology; Internal medicine; Psychiatry; Fluoxetine","score_opus":0.05731548868257076,"score_gpt":0.3207594309603097,"score_spread":0.26344394227773893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791111957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033043376,0.9879299,0.000034983204,0.000086926906,0.000055596647,0.0079587605,0.00029168607,0.000054313114,0.00028349744],"genre_scores_gemma":[0.0006344239,0.9963004,0.00088168256,0.000097634314,0.00015348825,0.00035258732,0.00013998506,0.00012252123,0.0013172956],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99403375,0.0015294204,0.0020513968,0.000553471,0.0012323709,0.00059958245],"domain_scores_gemma":[0.99314547,0.0016010444,0.0028176473,0.0013328705,0.00093851,0.00016447739],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033043786,0.00062747474,0.0057588313,0.00023042764,0.00016675021,0.000041288527,0.00054529525,0.00043113163,0.00013245552],"category_scores_gemma":[0.006246655,0.0003114132,0.0009065537,0.0012040619,0.00048657606,0.00013499137,0.00020810142,0.0014087801,0.00005933287],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003149218,0.00015693442,0.000022701095,0.9326657,0.00083280366,0.00019792542,0.00016532492,1.3691803e-7,0.0000024038313,0.000007023687,0.00068546354,0.0652321],"study_design_scores_gemma":[0.0005866813,0.00029347942,0.000007661248,0.97975796,0.015238335,0.00051188626,0.00008695409,0.00094245444,0.00004385161,0.0000022773427,0.0021670351,0.00036141448],"about_ca_topic_score_codex":0.00007838817,"about_ca_topic_score_gemma":0.000012015345,"teacher_disagreement_score":0.06487068,"about_ca_system_score_codex":0.00015915566,"about_ca_system_score_gemma":0.0006526528,"threshold_uncertainty_score":0.9999338},"labels":[],"label_agreement":null},{"id":"W2791860867","doi":"10.1007/s40263-018-0490-z","title":"Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; St. Michael's Hospital; University Health Network","funders":"","keywords":"Modafinil; Major depressive disorder; Pharmacotherapy; Atomoxetine; Medicine; Psychiatry; Psychopharmacology; Psychological intervention; Clinical psychology; Psychology; Cognition; Methylphenidate; Attention deficit hyperactivity disorder","score_opus":0.07535872882892011,"score_gpt":0.32116784511316976,"score_spread":0.24580911628424965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791860867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010143597,0.9787082,0.000027682896,0.00012230403,0.0001010578,0.0069451677,0.000054939504,0.00007784244,0.0038191893],"genre_scores_gemma":[0.0028178422,0.99075395,0.0015553541,0.000049390183,0.00020654491,0.0015791664,0.0002468992,0.00008573227,0.0027051107],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977036,0.0001398089,0.00042269562,0.00089579856,0.00045417956,0.00038387862],"domain_scores_gemma":[0.99898845,0.000079759804,0.00020463791,0.00044812358,0.000033172568,0.00024587588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000121067176,0.0005313445,0.0012023529,0.00032620702,0.0000715328,0.000030533363,0.00023962445,0.00022193657,0.000104623185],"category_scores_gemma":[0.000020119292,0.00032005575,0.00011927672,0.0003082863,0.00012054412,0.00007181488,0.00036854437,0.00028709145,0.00007171779],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019648614,0.00052854617,0.009863017,0.018751526,0.0005055871,0.00006526711,0.00024296375,9.825096e-7,3.2122212e-8,0.000017070264,0.00093359203,0.96889496],"study_design_scores_gemma":[0.010524938,0.0013265192,0.027224544,0.04870897,0.008344905,0.000011843708,0.00009055488,0.000008689286,0.0000038652724,0.000020418323,0.9028299,0.0009048909],"about_ca_topic_score_codex":0.0000082349225,"about_ca_topic_score_gemma":0.0000019618253,"teacher_disagreement_score":0.96799004,"about_ca_system_score_codex":0.00016390969,"about_ca_system_score_gemma":0.00004484337,"threshold_uncertainty_score":0.99992514},"labels":[],"label_agreement":null},{"id":"W2803533112","doi":"10.1007/s40263-018-0526-4","title":"Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ceritinib; Anaplastic lymphoma kinase; Alectinib; Pembrolizumab; Atezolizumab; Lung cancer; Crizotinib; Nivolumab; Epidermal growth factor receptor; Radiation therapy; Oncology; Immunotherapy; Cancer; Cancer research; Internal medicine","score_opus":0.05160550864221264,"score_gpt":0.3612285686345384,"score_spread":0.30962305999232576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803533112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0108096,0.98602694,0.000064795866,0.00002350984,0.00043619238,0.0021082636,0.00044033647,0.00003613041,0.000054235712],"genre_scores_gemma":[0.0035562487,0.9945761,0.00081378786,0.00004824537,0.0002550374,0.00017127393,0.00032682,0.00012418155,0.00012832886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972345,0.00030232014,0.0011017104,0.0005780863,0.00040190958,0.00038145893],"domain_scores_gemma":[0.998052,0.00007660323,0.00083437347,0.0006662097,0.0001770943,0.00019369613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048366524,0.0006293303,0.002638367,0.0002954029,0.00009430978,0.000032095595,0.00014199248,0.00023259521,0.00018119387],"category_scores_gemma":[0.000044085416,0.00043302626,0.00087859813,0.0004004577,0.00017856559,0.00006223077,0.00010542748,0.0002573685,0.00000733061],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017537668,0.00091537595,0.0002455369,0.09132133,0.018589575,0.0004218366,0.0016513523,0.000003145507,0.0011293546,0.000058853475,0.0012097155,0.88427854],"study_design_scores_gemma":[0.0064632716,0.00077363424,0.00010540188,0.14445707,0.023393705,0.0009079823,0.0003746485,0.00018677805,0.004054445,0.000016268965,0.8178127,0.0014541199],"about_ca_topic_score_codex":0.0006659236,"about_ca_topic_score_gemma":0.000002253967,"teacher_disagreement_score":0.8828244,"about_ca_system_score_codex":0.00032151118,"about_ca_system_score_gemma":0.00053969066,"threshold_uncertainty_score":0.9998121},"labels":[],"label_agreement":null},{"id":"W2841591265","doi":"10.1007/s40263-018-0536-2","title":"Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Biogen","keywords":"Medicine; Multiple sclerosis; 4-Aminopyridine; Context (archaeology); Intensive care medicine; Clinical Practice; Clinical trial; Neurology; Clinical research; Approved drug; Drug; Physical therapy; Pharmacology; Internal medicine; Psychiatry; Potassium channel","score_opus":0.25025202403471297,"score_gpt":0.40428571449465667,"score_spread":0.1540336904599437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2841591265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009505777,0.98631585,0.000010417625,0.00010824819,0.00042767185,0.0019843432,0.000036289293,0.000091535556,0.0015198833],"genre_scores_gemma":[0.0032883685,0.99363315,0.0006682221,0.000058991496,0.0013692923,0.00022636565,0.00010317326,0.00010415329,0.00054825743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618125,0.00032507014,0.0010390057,0.00105066,0.00076604995,0.00063796196],"domain_scores_gemma":[0.99657315,0.0017836667,0.00030896813,0.00074614404,0.00020670924,0.0003813513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015109109,0.00056475383,0.0023844754,0.0004749212,0.00019083581,0.00005458856,0.00020041304,0.00042281984,0.000053810734],"category_scores_gemma":[0.0019545327,0.00039448397,0.0003514433,0.00063628267,0.00069945847,0.00011099303,0.00035302326,0.0012137718,0.00012308818],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032570414,0.00038477374,0.005356535,0.0068216375,0.00041542048,0.000019557761,0.00016210064,1.6261937e-7,0.000002878551,0.0000070142964,0.0038261074,0.9826781],"study_design_scores_gemma":[0.004386804,0.00082150946,0.06819892,0.026147993,0.00079651916,0.000021472139,0.00009933894,0.000032533077,0.0000019534782,0.0000014087408,0.8990562,0.00043532584],"about_ca_topic_score_codex":0.000050899747,"about_ca_topic_score_gemma":0.000069249305,"teacher_disagreement_score":0.98224276,"about_ca_system_score_codex":0.0002977368,"about_ca_system_score_gemma":0.0004036182,"threshold_uncertainty_score":0.9998507},"labels":[],"label_agreement":null},{"id":"W2885631557","doi":"10.1007/s40263-018-0559-8","title":"Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Tics; Discontinuation; Antipsychotic; Tourette syndrome; Psychiatry; Olanzapine; Pediatrics; Medicine; PsycINFO; Psychology; Schizophrenia (object-oriented programming); MEDLINE","score_opus":0.019711716712524797,"score_gpt":0.3369957751390928,"score_spread":0.317284058426568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885631557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030747786,0.97798586,0.000010584216,0.00006984624,0.0022157773,0.0057907025,0.00021043884,0.00019091142,0.01349513],"genre_scores_gemma":[0.00012610154,0.99370915,0.000018637118,0.0003552185,0.00009833385,0.000713092,0.00023621802,0.00025503975,0.004488197],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9925325,0.0019204858,0.0028117073,0.0011653448,0.0006616046,0.0009083915],"domain_scores_gemma":[0.9925083,0.00071145693,0.003790744,0.002511084,0.00027314224,0.0002052612],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011706385,0.0011008949,0.008614266,0.0005204293,0.00010380745,0.000041632487,0.0017260269,0.00079758134,0.003099665],"category_scores_gemma":[0.0006337297,0.000891722,0.0020241984,0.0017514221,0.00036665125,0.00008165012,0.00015886464,0.0007857834,0.005500724],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000031636114,0.00030306244,0.000004134754,0.96305686,0.0032725858,0.00008654626,0.0003220101,9.98901e-9,1.8912939e-8,0.0006712842,0.019737467,0.012542873],"study_design_scores_gemma":[0.00048069423,0.00023687884,0.000022930828,0.89302397,0.011341706,0.00030984898,0.00006868893,4.5156702e-7,4.7524793e-8,0.000088974535,0.09357796,0.00084786967],"about_ca_topic_score_codex":0.000029125042,"about_ca_topic_score_gemma":0.0000047385697,"teacher_disagreement_score":0.07384049,"about_ca_system_score_codex":0.00027800264,"about_ca_system_score_gemma":0.00024014694,"threshold_uncertainty_score":0.99935335},"labels":[],"label_agreement":null},{"id":"W2895953827","doi":"10.1007/s40263-018-0579-4","title":"From LBR-101 to Fremanezumab for Migraine","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Calcitonin gene-related peptide; Migraine; Chronic Migraine; Medicine; Calcitonin; Monoclonal antibody; Drug development; Pharmacology; In vivo; Receptor; Bioinformatics; Neuroscience; Antibody; Neuropeptide; Immunology; Drug; Internal medicine; Biology","score_opus":0.08518251319761845,"score_gpt":0.40393790446252364,"score_spread":0.3187553912649052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895953827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023543122,0.9860271,0.0000921299,0.0011791487,0.00017952386,0.002321536,0.00052167894,0.00010616393,0.009549136],"genre_scores_gemma":[0.0000037248597,0.9225251,0.002575447,0.00091027253,0.0058460445,0.0005470203,0.0008355981,0.000112498245,0.06664427],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791104,0.000038423026,0.0006308245,0.000677698,0.0002580614,0.0004839411],"domain_scores_gemma":[0.99817306,0.00037047398,0.00017721111,0.0008105248,0.00019073037,0.000277997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024048374,0.00053270895,0.0025919771,0.0002260783,0.00012842595,0.000020977375,0.00024796353,0.0003214055,0.00047668364],"category_scores_gemma":[0.00041852772,0.00038806084,0.0011166878,0.0002759651,0.00008426948,0.00002258494,0.00014916019,0.0002819472,0.0013685874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019453686,0.000049808146,9.572884e-7,0.009255104,0.00048049042,0.000008192319,0.0014003353,2.311538e-9,4.32362e-7,0.000044787063,0.76906043,0.21968001],"study_design_scores_gemma":[0.0005542579,0.00029914718,0.000004231609,0.013529083,0.0026209007,0.000014305418,0.00024351427,9.465279e-7,0.0000029527687,0.00014456619,0.9822185,0.0003675938],"about_ca_topic_score_codex":0.00019718049,"about_ca_topic_score_gemma":0.00012414159,"teacher_disagreement_score":0.21931243,"about_ca_system_score_codex":0.00013954558,"about_ca_system_score_gemma":0.0003059572,"threshold_uncertainty_score":0.9998571},"labels":[],"label_agreement":null},{"id":"W2902232281","doi":"10.1007/s40263-018-0593-6","title":"Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Weston Brain Institute","keywords":"Neuroprotection; Neuroscience; Parkinson's disease; Disease; Medicine; Clinical trial; Neurology; Bioinformatics; Psychology; Internal medicine; Biology","score_opus":0.0666686767453187,"score_gpt":0.3375970176882603,"score_spread":0.2709283409429416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902232281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060205127,0.99310684,0.000002423836,0.000048355738,0.00023987604,0.0017000488,0.00010139101,0.000052581876,0.00414642],"genre_scores_gemma":[0.0014734687,0.99652344,0.00008800368,0.000060471666,0.00016225739,0.0003710999,0.0002489946,0.000053506097,0.0010187583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850607,0.000101100544,0.00043344536,0.00049265707,0.00019509789,0.00027165056],"domain_scores_gemma":[0.99897194,0.00011168761,0.00026008254,0.000454833,0.000056622564,0.00014482526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010206658,0.00037402165,0.0013573663,0.0004436081,0.00004943453,0.000019949246,0.00011531339,0.00012317396,0.00004995548],"category_scores_gemma":[0.000048789523,0.00028879638,0.0003192173,0.00037271014,0.00019494252,0.00007757836,0.00013876356,0.00018851888,0.000060351067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025651978,0.0004431623,0.00036838543,0.006417763,0.001838506,0.000045062006,0.00023049241,8.6138854e-8,3.635331e-7,0.000089246816,0.005097541,0.9854437],"study_design_scores_gemma":[0.0005141194,0.0002534317,0.0016657519,0.006203181,0.007983217,0.000005000732,0.00009679598,0.000003007186,0.0000029332757,0.00004167804,0.98301846,0.00021241924],"about_ca_topic_score_codex":0.00008884598,"about_ca_topic_score_gemma":0.000029162678,"teacher_disagreement_score":0.98523134,"about_ca_system_score_codex":0.00009331868,"about_ca_system_score_gemma":0.0001358003,"threshold_uncertainty_score":0.9999564},"labels":[],"label_agreement":null},{"id":"W2902974546","doi":"10.1007/s40263-018-0588-3","title":"Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; University of Toronto","funders":"","keywords":"Tolerability; Psychopharmacology; Schizophrenia (object-oriented programming); Psychiatry; Antipsychotic; Psychology; Antipsychotic drug; Psychotherapist; Medicine; Pharmacology; Adverse effect","score_opus":0.13617126211709812,"score_gpt":0.48317644373907936,"score_spread":0.34700518162198124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902974546","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06322545,0.93189067,0.0000022818185,0.001474454,0.00003761769,0.0027424244,0.00005381924,0.00001635697,0.0005569634],"genre_scores_gemma":[0.061486315,0.9370731,0.0004775089,0.00003208088,0.0003251485,0.0003408127,0.000025759928,0.00004070464,0.00019854332],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971405,0.00087066967,0.0007235312,0.0005985289,0.0003498404,0.0003168878],"domain_scores_gemma":[0.9964747,0.0021277915,0.00013988874,0.0006949379,0.00026102443,0.00030165483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026725854,0.00018449668,0.0009821921,0.00031788734,0.00010154379,0.000028087228,0.0002104327,0.00018545821,0.0001215511],"category_scores_gemma":[0.0017012912,0.0001174935,0.00012665728,0.0007342251,0.00072699727,0.000032080632,0.00020560987,0.0006703945,0.00012328179],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002294382,0.00011196186,0.002475329,0.0015030727,0.00020745324,0.000007269934,0.0005038385,8.674747e-9,6.4470385e-7,0.0015435655,0.00033596723,0.99308145],"study_design_scores_gemma":[0.00621189,0.0009110311,0.68438464,0.035117432,0.001078669,0.00016021715,0.00051705877,0.000017925302,0.000014151221,0.0024507674,0.26861337,0.00052281277],"about_ca_topic_score_codex":0.000026111824,"about_ca_topic_score_gemma":0.000019937186,"teacher_disagreement_score":0.99255866,"about_ca_system_score_codex":0.000079965335,"about_ca_system_score_gemma":0.0007148627,"threshold_uncertainty_score":0.4791246},"labels":[],"label_agreement":null},{"id":"W2910495852","doi":"10.1007/s40263-018-0597-2","title":"Phytomedicines in the Treatment of Migraine","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary; Women and Children’s Health Research Institute; University of Alberta","funders":"","keywords":"Migraine; Psychopharmacology; Neurology; Medicine; Psychiatry; Psychology","score_opus":0.11595345186461525,"score_gpt":0.4122082481325315,"score_spread":0.29625479626791623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910495852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010525299,0.9837369,2.6246556e-7,0.0006464899,0.000043872864,0.001327133,0.000021977816,0.000011305787,0.014106826],"genre_scores_gemma":[0.00010721083,0.9836467,0.000019126834,0.00013889417,0.0004802178,0.00014809032,0.00009856499,0.000024504616,0.015336719],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987792,0.000070840746,0.00048771518,0.00022850264,0.00022579194,0.00020794765],"domain_scores_gemma":[0.9988832,0.00033996717,0.00016763102,0.0005353181,0.00003982782,0.000034052624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018319437,0.00030351707,0.0022379167,0.0002138063,0.00002035695,0.0000027230922,0.00012320318,0.00012441397,0.00006553535],"category_scores_gemma":[0.000042535125,0.00013648454,0.000650196,0.00037774272,0.00009621249,0.000009731835,0.0000147698665,0.00015804394,0.00008653088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012404443,0.0005652519,0.00010690305,0.030166423,0.00041623478,0.000036945337,0.009199486,1.326959e-8,2.5041425e-7,0.00008370499,0.047900077,0.9115123],"study_design_scores_gemma":[0.0006908623,0.00060611765,0.000100491474,0.008855753,0.001828637,0.000032174634,0.00087513303,3.8719077e-7,4.556742e-7,0.000008753606,0.9869,0.00010127091],"about_ca_topic_score_codex":0.00010490252,"about_ca_topic_score_gemma":0.00004095867,"teacher_disagreement_score":0.9389999,"about_ca_system_score_codex":0.00008042711,"about_ca_system_score_gemma":0.00018164357,"threshold_uncertainty_score":0.5565678},"labels":[],"label_agreement":null},{"id":"W2910561017","doi":"10.1007/s40263-018-0599-0","title":"Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"Royal Melbourne Hospital","keywords":"Schizophrenia (object-oriented programming); Psychosis; Psychiatry; Mood disorders; Dystonia; Neurology; Psychology; Disease; Cognition; Mood; Bipolar disorder; Medicine; Anxiety; Internal medicine","score_opus":0.029798970696599817,"score_gpt":0.3348153211590439,"score_spread":0.3050163504624441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910561017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035910655,0.9903319,0.0000021537815,0.00012497373,0.00014665865,0.0026445922,0.00007299857,0.00005684547,0.0030288517],"genre_scores_gemma":[0.0017196464,0.99096453,0.000010925473,0.00017576257,0.000064208914,0.00010902387,0.0005823823,0.00008456005,0.006288965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813396,0.00019371959,0.00027866263,0.0006995291,0.00027904895,0.00041505918],"domain_scores_gemma":[0.99888545,0.00022204484,0.00017349259,0.00031257526,0.00013397622,0.00027243112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015050232,0.00040263927,0.0012419005,0.00032941884,0.00008168377,0.000037449103,0.0001251777,0.00021104595,0.000062789644],"category_scores_gemma":[0.000115817136,0.00028228556,0.00011818096,0.0006006024,0.00020772126,0.000039958974,0.00021255469,0.00044657936,0.00013000198],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003609973,0.00038104312,0.0057684933,0.053123597,0.0028561987,0.00037372444,0.00012325299,7.7116695e-8,7.243311e-8,0.0003040176,0.0024695692,0.934239],"study_design_scores_gemma":[0.0051162057,0.0015965938,0.0205469,0.024645641,0.01576195,0.00012522758,0.00014564217,0.0000135032105,6.169971e-8,0.000066387525,0.9310062,0.0009756978],"about_ca_topic_score_codex":0.0000060611114,"about_ca_topic_score_gemma":0.0000025989648,"teacher_disagreement_score":0.93326324,"about_ca_system_score_codex":0.000082774895,"about_ca_system_score_gemma":0.000226139,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W2920380976","doi":"10.1007/s40263-019-00618-2","title":"Expanding Role of NMDA Receptor Antagonists in the Management of Pain","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Anesthesia and Sedative Agents","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; St. Joseph's Hospital; St Joseph's Health Care","funders":"","keywords":"Dextromethorphan; Ketamine; NMDA receptor; Memantine; Medicine; Chronic pain; Pharmacology; Anesthesia; Intensive care medicine; Receptor; Psychiatry; Internal medicine","score_opus":0.0472936803371561,"score_gpt":0.3455623342468386,"score_spread":0.2982686539096825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920380976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012175707,0.9895265,0.000012342056,0.000046687994,0.00005869378,0.0013153899,0.000010889382,0.0000066936864,0.007805246],"genre_scores_gemma":[0.0017568483,0.9962667,0.00015628552,0.000064095875,0.000041249088,0.00005192427,0.00011843093,0.000024026669,0.0015204425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866533,0.00027331867,0.00045848012,0.00019426082,0.00025758418,0.00015101077],"domain_scores_gemma":[0.999087,0.00015461756,0.00029189215,0.00041735562,0.000022819293,0.000026326112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086601585,0.00018315414,0.0010677455,0.00012591318,0.000014820493,0.0000039858523,0.00023953644,0.000104128114,0.00010847817],"category_scores_gemma":[0.00001399508,0.00010904089,0.00026624082,0.00025405845,0.000050107803,0.000019203075,0.000041921434,0.00016787021,0.00006337235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012965334,0.00012576261,0.00027647556,0.031576604,0.00019456478,0.0000100752895,0.0013661535,4.9004672e-8,0.0000053092217,0.0004711492,0.00074026623,0.96522063],"study_design_scores_gemma":[0.0002817266,0.00007573675,0.00013172443,0.020253569,0.00039613503,0.0000032904234,0.0024483828,0.0000012527879,0.000023007044,0.0000134169095,0.97627395,0.000097827586],"about_ca_topic_score_codex":0.000012359784,"about_ca_topic_score_gemma":2.3650293e-7,"teacher_disagreement_score":0.97553366,"about_ca_system_score_codex":0.000056111243,"about_ca_system_score_gemma":0.00005984955,"threshold_uncertainty_score":0.44465587},"labels":[],"label_agreement":null},{"id":"W2928038989","doi":"10.1007/s40263-019-00622-6","title":"The Effect of Non-Gabapentinoid Anticonvulsants on Sensorimotor Recovery After Human Spinal Cord Injury","year":2019,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; International Collaboration On Repair Discoveries; University of British Columbia","funders":"Canadian Institutes of Health Research; Wings for Life; Craig H. Neilsen Foundation","keywords":"Spinal cord injury; Pregabalin; Gabapentin; Medicine; Anesthesia; Anticonvulsant; Neurology; Spinal cord; Psychopharmacology; Epilepsy; Pharmacology; Psychiatry","score_opus":0.01473338062620074,"score_gpt":0.3675172022363786,"score_spread":0.3527838216101779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928038989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877681,0.00010453299,0.0000018595351,0.00017879553,0.0005899724,0.0012190024,0.000013514206,0.000030052533,0.010094183],"genre_scores_gemma":[0.9923689,0.00003486652,0.000021697058,0.00015968215,0.00025537948,0.000053262043,0.000007854887,0.00004529266,0.007053091],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979972,0.00015437171,0.00034589204,0.00036102004,0.00066796545,0.0004735061],"domain_scores_gemma":[0.99850243,0.00022894189,0.000121756464,0.0008750964,0.00013033098,0.00014143733],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007495934,0.00022767528,0.00045717575,0.00017348911,0.00011224434,0.000036863963,0.00025541615,0.000102035985,0.0004638025],"category_scores_gemma":[0.00016969543,0.00014654778,0.00022242736,0.00023717315,0.00017801287,0.000079012585,0.00013249232,0.00049095,0.0016336998],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19425343,0.0002393241,0.21823499,0.0010978595,0.00025910587,0.00011799529,0.000047356178,3.0473072e-7,0.4819741,0.000054351825,0.0048680888,0.098853104],"study_design_scores_gemma":[0.0029546758,0.11341771,0.52226555,0.00091426267,0.00012598305,0.000029944313,0.00008681575,0.00004550465,0.35316673,0.00002881159,0.0066673975,0.00029664396],"about_ca_topic_score_codex":0.00003580062,"about_ca_topic_score_gemma":0.0000012273248,"teacher_disagreement_score":0.30403054,"about_ca_system_score_codex":0.00009704035,"about_ca_system_score_gemma":0.00007216012,"threshold_uncertainty_score":0.99914366},"labels":[],"label_agreement":null},{"id":"W2940332174","doi":"10.1007/s40263-019-00629-z","title":"Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia","funders":"","keywords":"Aripiprazole; Risperidone; Bipolar disorder; Paliperidone; Olanzapine; Medicine; Randomized controlled trial; Psychiatry; Quetiapine; Treatment of bipolar disorder; Cochrane Library; Antipsychotic; Bipolar I disorder; Atypical antipsychotic; Mood; Pediatrics; Schizophrenia (object-oriented programming); Internal medicine; Mania","score_opus":0.05585145500879804,"score_gpt":0.3455361583013354,"score_spread":0.28968470329253737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940332174","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023058515,0.986017,0.0008257136,0.00009890514,0.00037078527,0.0122206025,0.00008486498,0.000030917716,0.00034891945],"genre_scores_gemma":[0.00006818907,0.9950988,0.00036209365,0.00010745961,0.00010010654,0.0011712842,0.00037385858,0.00008600253,0.0026321777],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768597,0.00013478816,0.0011257759,0.0004295072,0.00031515321,0.00030880238],"domain_scores_gemma":[0.9977411,0.00028947092,0.00063148385,0.0011567154,0.00010800608,0.00007323777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056896923,0.00044971937,0.0028687161,0.00010079898,0.00012829267,0.000029663875,0.00028353813,0.00017771729,0.00012551366],"category_scores_gemma":[0.00004186192,0.00025457164,0.0009951527,0.00036648568,0.000043256336,0.00004376793,0.00007647218,0.0002713977,0.00010285121],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010431389,0.00017052116,0.000012167678,0.8215676,0.0023454505,0.0000013102716,0.000052305364,1.7911269e-7,4.9455494e-8,0.00033105502,0.00039623125,0.17511271],"study_design_scores_gemma":[0.00049944344,0.00009480607,0.000011072452,0.40787077,0.02698874,0.000039309656,0.000064260916,0.000023672586,5.143475e-7,0.000005396681,0.56421316,0.000188875],"about_ca_topic_score_codex":0.0000030509589,"about_ca_topic_score_gemma":0.000014478318,"teacher_disagreement_score":0.5638169,"about_ca_system_score_codex":0.00010186505,"about_ca_system_score_gemma":0.00015420768,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W2942949442","doi":"10.1007/s40263-019-00636-0","title":"Authors’ Reply to Diener: “Phytomedicines in the Treatment of Migraine”","year":2019,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary; Women and Children’s Health Research Institute; University of Alberta","funders":"","keywords":"Diener; Migraine; Medicine; Psychopharmacology; Neurology; Psychiatry; Psychology; Psychotherapist","score_opus":0.034174075225902795,"score_gpt":0.31575787617181605,"score_spread":0.2815838009459133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942949442","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030398794,0.0029119833,0.0000020446876,0.9482449,0.00018010153,0.0013336663,0.000046538513,0.000031232452,0.016850688],"genre_scores_gemma":[0.016169647,0.0009703317,0.00012450042,0.8400949,0.0061695096,0.00024353064,0.00024078734,0.00006028328,0.13592646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980075,0.00008947905,0.0005086483,0.00045597277,0.0005052614,0.00043316538],"domain_scores_gemma":[0.998299,0.00040252597,0.0001420604,0.0009979322,0.0001083285,0.00005017869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002733459,0.00038290265,0.0010852151,0.00037683526,0.000041997842,0.000007673419,0.00020987826,0.00027836792,0.00007766391],"category_scores_gemma":[0.00014038828,0.00020843983,0.00036229644,0.00040922087,0.00011290396,0.00001574608,0.000033314736,0.0005414119,0.00010831862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047762507,0.00015359242,0.0019618557,0.00037331012,0.00015488359,0.00020292673,0.02617193,2.6410737e-7,0.00003266871,0.000009466514,0.96992886,0.00096245675],"study_design_scores_gemma":[0.0010548615,0.0014998325,0.005212194,0.00046207802,0.00030620396,0.000023275235,0.001675502,0.0000025949737,0.000062638595,0.00003168835,0.98948836,0.00018077646],"about_ca_topic_score_codex":0.0009314323,"about_ca_topic_score_gemma":0.00010343991,"teacher_disagreement_score":0.119075775,"about_ca_system_score_codex":0.0001244159,"about_ca_system_score_gemma":0.000116651645,"threshold_uncertainty_score":0.84999293},"labels":[],"label_agreement":null},{"id":"W2946911722","doi":"10.1007/s40263-019-00641-3","title":"Methylene Blue in the Treatment of Neuropsychiatric Disorders","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Methylene blue; Antidepressant; Anxiolytic; Bipolar disorder; Neuroprotection; Pharmacology; Medicine; Psychiatry; Mania; Psychology; Neuroscience; Lithium (medication); Anxiety; Chemistry","score_opus":0.05658665457901436,"score_gpt":0.3316590149100579,"score_spread":0.27507236033104354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946911722","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060011167,0.9907262,0.0000030004496,0.000121046,0.0005775407,0.001396636,0.000046090114,0.00002766644,0.0065017114],"genre_scores_gemma":[0.00064080604,0.9983623,0.000011712938,0.00015909824,0.00006217332,0.00011597398,0.000009428143,0.000048211878,0.00059027155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977005,0.0006369182,0.0004830264,0.00057020545,0.00028518523,0.0003241712],"domain_scores_gemma":[0.9979338,0.00094443775,0.00028689214,0.00079182565,0.000006277851,0.000036780875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012700974,0.0003960137,0.0010241072,0.0003304311,0.00004851593,0.000028439725,0.00080513925,0.00014134409,0.000044578723],"category_scores_gemma":[0.00008132138,0.00022768525,0.00062759913,0.0012467464,0.00012324772,0.000046115634,0.00003548043,0.0002113601,0.00022437926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034269244,0.0004724436,0.000002846486,0.0016888226,0.000009405431,0.0000032490725,0.00094546104,0.0000029069327,0.0000030246936,0.00041692457,0.0001640258,0.99628747],"study_design_scores_gemma":[0.00039027893,0.00021419469,0.000022898725,0.00033345324,0.00012248724,0.000004937366,0.0001351395,0.000003387876,0.000015303618,0.000107607884,0.99843216,0.00021814348],"about_ca_topic_score_codex":0.000031478467,"about_ca_topic_score_gemma":0.000017133707,"teacher_disagreement_score":0.9982681,"about_ca_system_score_codex":0.000051597366,"about_ca_system_score_gemma":0.00015402374,"threshold_uncertainty_score":0.92847353},"labels":[],"label_agreement":null},{"id":"W2948421871","doi":"10.1007/s40263-019-00643-1","title":"Endolysosome and Autolysosome Dysfunction in Alzheimer’s Disease: Where Intracellular and Extracellular Meet","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alzheimer Nederland; ZonMw; EU Joint Programme – Neurodegenerative Disease Research; Weston Brain Institute; Alzheimer's Association","keywords":"Proteostasis; Intracellular; Lysosome; Endosome; Autophagy; Extracellular; Cell biology; Neuroscience; Disease; Biology; Secretion; Medicine; Pathology; Genetics; Biochemistry","score_opus":0.037134919561475375,"score_gpt":0.3097020473000599,"score_spread":0.27256712773858455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948421871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024268215,0.994448,0.000012127631,0.00016494858,0.00038053712,0.0019920927,0.00007636422,0.00011179766,0.0003872854],"genre_scores_gemma":[0.0019462688,0.99478424,0.000051292645,0.00009057022,0.00036555482,0.00017719435,0.00030053602,0.0001428567,0.0021414794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972195,0.00020139663,0.00074786786,0.00094240526,0.00038267442,0.0005061696],"domain_scores_gemma":[0.9981218,0.00017270853,0.0002987199,0.0008058509,0.000041270196,0.00055965706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031866017,0.00071172655,0.0021318907,0.00043363584,0.000079214406,0.000068723246,0.00015769576,0.0004844538,0.0003277826],"category_scores_gemma":[0.000036073485,0.000594845,0.00036831727,0.00033463872,0.00018456773,0.00018576822,0.0001148114,0.0005897317,0.00014732778],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001196306,0.0002504617,0.00022816588,0.020973623,0.0007964628,0.00071029353,0.0002691356,5.7780966e-7,0.000025953454,0.0012171369,0.00060585234,0.97480273],"study_design_scores_gemma":[0.0017263887,0.000111800524,0.00029331542,0.012387502,0.0056858067,0.0001326287,0.000051184874,0.00009892493,0.00001110828,0.000253106,0.97861737,0.0006308375],"about_ca_topic_score_codex":0.000020100382,"about_ca_topic_score_gemma":0.0000023198304,"teacher_disagreement_score":0.97801155,"about_ca_system_score_codex":0.00011171699,"about_ca_system_score_gemma":0.0004469259,"threshold_uncertainty_score":0.9996503},"labels":[],"label_agreement":null},{"id":"W2963057845","doi":"10.1007/s40263-019-00651-1","title":"Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets","year":2019,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"European Commission","keywords":"Amantadine; Pharmacokinetics; Renal function; Medicine; Pharmacology; Dosing; Creatinine; Population; Urology; Oral administration; Internal medicine","score_opus":0.005505265742242169,"score_gpt":0.24411152707068612,"score_spread":0.23860626132844395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963057845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98413616,0.0003371777,0.000027872455,0.0009085186,0.00018261728,0.0008899475,0.000011363924,0.000017278457,0.0134890815],"genre_scores_gemma":[0.9953489,0.00019981917,0.00003712296,0.0007987653,0.0000942785,0.000025519515,0.000013896199,0.000017913904,0.0034637873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987384,0.000066313754,0.00029383835,0.00020668229,0.0004914472,0.00020332482],"domain_scores_gemma":[0.99909323,0.00015306225,0.00016325843,0.00039103167,0.00007795956,0.000121476754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023236172,0.00015312721,0.00035235847,0.00010765512,0.000023663384,0.000007007255,0.00014660294,0.00003145646,0.00050477986],"category_scores_gemma":[0.000037266294,0.00008838726,0.00021947736,0.00021555128,0.0000796368,0.000021917838,0.00007947919,0.000110219415,0.000107852386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003949592,0.010531732,0.0029173119,0.0069765775,0.0032844534,0.00023499524,0.0025127865,0.0021332242,0.7791218,0.011564511,0.10107565,0.07569735],"study_design_scores_gemma":[0.014844469,0.0036642062,0.13238189,0.0026426704,0.0035616038,0.0000052463056,0.0006077052,0.00845989,0.79131913,0.00028041852,0.041729,0.0005037885],"about_ca_topic_score_codex":0.00001995141,"about_ca_topic_score_gemma":2.98434e-7,"teacher_disagreement_score":0.12946458,"about_ca_system_score_codex":0.000038764883,"about_ca_system_score_gemma":0.000046066783,"threshold_uncertainty_score":0.55269855},"labels":[],"label_agreement":null},{"id":"W2968219865","doi":"10.1007/s40263-019-00657-9","title":"Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia; University of British Columbia Hospital","funders":"Alberta Prion Research Institute; Canadian Institutes of Health Research; Consortium canadien en neurodégénérescence associée au vieillissement; Fondation Brain Canada","keywords":"Proteotoxicity; Frontotemporal lobar degeneration; Neurodegeneration; Protein aggregation; Disease; Neuroscience; Biology; Frontotemporal dementia; Medicine; Pathology; Dementia; Cell biology","score_opus":0.057841898429623166,"score_gpt":0.38011929955339896,"score_spread":0.3222774011237758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968219865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023357088,0.9922607,0.0000010252817,0.000027839025,0.00010407487,0.004053869,0.00009601902,0.000039224396,0.0010815284],"genre_scores_gemma":[0.004472476,0.9930632,0.0001551529,0.00004439243,0.00010465061,0.001045051,0.00080501114,0.000087884284,0.00022214204],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970418,0.0003283282,0.00068519084,0.00074172334,0.00051133404,0.0006916314],"domain_scores_gemma":[0.99891776,0.00012034495,0.00019410173,0.00035771585,0.00006339894,0.00034666999],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021125711,0.0005076215,0.0016858062,0.00057931326,0.00006415461,0.000032180036,0.00019296566,0.0001669849,0.00008667336],"category_scores_gemma":[0.00020692442,0.00039724036,0.00030674,0.0007395474,0.00005506905,0.00012256014,0.00018826754,0.0005991108,0.00036410597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013584444,0.0017099341,0.020578943,0.032545242,0.0037285185,0.0018805913,0.00059717864,0.000004450367,0.0000013112494,0.000034989203,0.0005863915,0.9381966],"study_design_scores_gemma":[0.00878398,0.00039594236,0.013453058,0.10194001,0.00473105,0.000050560582,0.00042876287,0.00014309467,0.00006679223,0.00007694677,0.86744523,0.0024845377],"about_ca_topic_score_codex":0.00005488346,"about_ca_topic_score_gemma":0.00000841312,"teacher_disagreement_score":0.93571204,"about_ca_system_score_codex":0.0005677778,"about_ca_system_score_gemma":0.0018419822,"threshold_uncertainty_score":0.99984795},"labels":[],"label_agreement":null},{"id":"W2986981536","doi":"10.1007/s40263-019-00682-8","title":"Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"Ministry of Science and Technology, Taiwan","keywords":"Discontinuation; Antipsychotic; Schizophrenia (object-oriented programming); Medicine; Psychosis; Psychiatry; Dosing; Psychology; Algorithm; Internal medicine; Computer science","score_opus":0.034362615392149326,"score_gpt":0.35708397992175117,"score_spread":0.3227213645296019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986981536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047720135,0.9597428,0.00011825954,0.00039860889,0.0010343723,0.03330041,0.00021006545,0.00015732292,0.0002661463],"genre_scores_gemma":[0.0014612889,0.98453355,0.0051700915,0.000065700326,0.0009179882,0.004368654,0.0019803722,0.0002832945,0.0012190848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676573,0.0003042655,0.00059550354,0.0009482095,0.00072764803,0.00065861247],"domain_scores_gemma":[0.99730676,0.00037863513,0.0004446556,0.001174902,0.0004302446,0.00026480464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004432193,0.00070926343,0.0017030832,0.00032266643,0.00026195263,0.00009105041,0.00031996836,0.00029444584,0.000028660366],"category_scores_gemma":[0.00015765126,0.00035692568,0.00068448635,0.00074353087,0.00015908862,0.00010575968,0.000053916043,0.0006789503,0.00020315057],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021439625,0.00091053505,0.000073726835,0.0077464064,0.0015786561,0.000009047385,0.0001455673,1.7618054e-7,5.8254955e-7,0.000013266056,0.001961041,0.985417],"study_design_scores_gemma":[0.049316593,0.009361911,0.011578464,0.07399524,0.017380672,0.000360594,0.00020305872,0.000098449374,0.000014088694,0.000100987876,0.83586854,0.0017213793],"about_ca_topic_score_codex":0.000027949196,"about_ca_topic_score_gemma":0.000003232487,"teacher_disagreement_score":0.9836956,"about_ca_system_score_codex":0.00052767684,"about_ca_system_score_gemma":0.0005959936,"threshold_uncertainty_score":0.9998883},"labels":[],"label_agreement":null},{"id":"W2998920613","doi":"10.1007/s40263-020-00700-0","title":"Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study","year":2020,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Biogen","keywords":"Tolerability; Dimethyl fumarate; Medicine; Adverse effect; Nausea; Internal medicine; Gastroenterology; Multiple sclerosis; Diarrhea; Abdominal pain; Immunology","score_opus":0.07551401859164208,"score_gpt":0.3057251555602757,"score_spread":0.2302111369686336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998920613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860868,0.000117533185,0.00023856683,0.0009634699,0.000057308018,0.011750442,0.0003277963,0.00022057489,0.00023749788],"genre_scores_gemma":[0.9929973,0.0000127085605,0.004932076,0.00015871321,0.0001887623,0.00097570254,0.00060996757,0.000092545146,0.000032215336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99328643,0.0012187395,0.0016090389,0.0016184447,0.0012297096,0.0010376567],"domain_scores_gemma":[0.9941723,0.002347368,0.00073292106,0.0011683764,0.00093331723,0.00064573355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025034046,0.00077512534,0.001973877,0.00013819963,0.0005903747,0.00024259635,0.0005595964,0.00009416574,0.000053170905],"category_scores_gemma":[0.00238011,0.00045171403,0.00018635909,0.0009913652,0.0009956848,0.0005177228,0.00033183064,0.001291434,0.00001968612],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6288922,0.0035838436,0.35131028,0.000046950343,0.00037929014,0.000013283232,0.011438354,0.000183152,0.0026562128,4.245696e-7,0.000091975475,0.0014040183],"study_design_scores_gemma":[0.66657555,0.0030742374,0.27889338,0.0008746569,0.0002968352,0.0000014923265,0.008923892,0.040015567,0.0009244117,0.0000020553898,0.000003868881,0.00041402603],"about_ca_topic_score_codex":0.0036447477,"about_ca_topic_score_gemma":0.0010850714,"teacher_disagreement_score":0.0724169,"about_ca_system_score_codex":0.00022950623,"about_ca_system_score_gemma":0.00035687812,"threshold_uncertainty_score":0.99979347},"labels":[],"label_agreement":null},{"id":"W3013166411","doi":"10.1007/s40263-020-00713-9","title":"Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Medicine; Meta-analysis; Medication adherence; Antipsychotic; Confidence interval; Schizophrenia (object-oriented programming); Internal medicine; Regimen; MEDLINE; Psychiatry","score_opus":0.11520425710561334,"score_gpt":0.3935842397463182,"score_spread":0.27837998264070485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013166411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021662043,0.99256843,0.000025358193,0.00038248143,0.00003583409,0.0067510246,0.000119344746,0.0000656868,0.000030179188],"genre_scores_gemma":[0.0014343836,0.9943307,0.00083211437,0.00012547069,0.00003991199,0.0025755728,0.00010055697,0.000078408375,0.0004828688],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947534,0.0007616425,0.0015006401,0.0011767015,0.0009729843,0.00083460024],"domain_scores_gemma":[0.9971497,0.0002884518,0.00046199534,0.0011516268,0.00018232924,0.00076591625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001021829,0.0008912258,0.012214029,0.00057202845,0.000073187985,0.00010327067,0.00050076446,0.00024098904,0.00014143944],"category_scores_gemma":[0.00064875383,0.0005900349,0.002116825,0.0035855905,0.00005719717,0.000082250204,0.00014668005,0.0010842872,0.00028655498],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030095555,0.00019526624,0.000010608974,0.8119451,0.15124623,0.00017616892,0.00008233721,1.378119e-7,6.291751e-7,0.000047951282,0.0004270496,0.03556757],"study_design_scores_gemma":[0.00097291305,0.00061461795,0.0000061944897,0.07874821,0.9112467,0.00007264373,0.00002553165,0.0000046131704,0.0000031028471,0.000027819518,0.007737195,0.0005404299],"about_ca_topic_score_codex":0.000069779446,"about_ca_topic_score_gemma":0.00008249042,"teacher_disagreement_score":0.76000047,"about_ca_system_score_codex":0.0005011739,"about_ca_system_score_gemma":0.0009715356,"threshold_uncertainty_score":0.9996551},"labels":[],"label_agreement":null},{"id":"W3031692871","doi":"10.1007/s40263-020-00737-1","title":"Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer’s Disease","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Institute of Aging; Institute of Nutrition, Metabolism and Diabetes; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Neuroinflammation; Senile plaques; Immune system; Neurodegeneration; Dementia; Immunology; Alzheimer's disease; Disease; Amyloid (mycology); Inflammation; Biochemistry of Alzheimer's disease; Biology; Innate immune system; Neuroscience; Medicine; Amyloid precursor protein; Pathology","score_opus":0.08595807630187191,"score_gpt":0.3982246360576957,"score_spread":0.3122665597558238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031692871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000065115986,0.99230534,0.0000011988101,0.000116529016,0.00009730491,0.0025172222,0.00010311359,0.00013495087,0.0046592024],"genre_scores_gemma":[0.014085781,0.9836884,0.0000057244765,0.00023637082,0.00028793863,0.0005374718,0.00091943616,0.00014520473,0.00009364757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969281,0.00032327248,0.00062662706,0.00077875843,0.0006201418,0.00072307704],"domain_scores_gemma":[0.99781036,0.00013731532,0.00020866768,0.0005032447,0.00006887996,0.0012715497],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015436663,0.0006534029,0.0016955783,0.0003292939,0.000103557555,0.000072717616,0.00022906813,0.00021943933,0.00061877083],"category_scores_gemma":[0.000101322556,0.0005095994,0.00068990816,0.0006947749,0.00010119428,0.0001007425,0.00013551525,0.0007593285,0.0024851607],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011095703,0.00076451496,0.00055084866,0.0047829896,0.013881678,0.0045898147,0.00009833186,0.0000017863777,4.319732e-8,0.00007899725,0.00092650746,0.97421354],"study_design_scores_gemma":[0.0021200648,0.0003489302,0.00033183442,0.008157359,0.015961442,0.00006122468,0.00008273043,0.000094084084,4.1287726e-7,0.00030296308,0.9718825,0.0006564335],"about_ca_topic_score_codex":0.00010191924,"about_ca_topic_score_gemma":0.0000021623202,"teacher_disagreement_score":0.9735571,"about_ca_system_score_codex":0.00030529854,"about_ca_system_score_gemma":0.0026334398,"threshold_uncertainty_score":0.99973553},"labels":[],"label_agreement":null},{"id":"W3036420635","doi":"10.1007/s40263-020-00743-3","title":"Methadone for Pain Management: A Pharmacotherapeutic Review","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; St Joseph's Health Care; London Health Sciences Centre; St. Joseph's Hospital","funders":"","keywords":"Methadone; Medicine; Cancer pain; Opioid; Chronic pain; Analgesic; Intensive care medicine; Addiction; Morphine; Anesthesia; Psychiatry; Cancer; Internal medicine","score_opus":0.06837846230751701,"score_gpt":0.39302345922953075,"score_spread":0.32464499692201376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036420635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.3862773e-9,0.97894126,0.0018948558,0.0018842001,0.00021280613,0.007767222,0.00002902809,0.00019622556,0.009074382],"genre_scores_gemma":[5.6835585e-8,0.9631897,0.0021085998,0.016952612,0.00050228287,0.0016559198,0.00042578834,0.00014597941,0.015019037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975982,0.00032778713,0.0007092805,0.0006345548,0.00031301336,0.0004172104],"domain_scores_gemma":[0.99851656,0.00032359263,0.00031121416,0.0005984311,0.00004280277,0.00020742642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016081727,0.00055378827,0.0025596658,0.00022161876,0.00006472468,0.000025890458,0.00038662265,0.00013189981,0.0003894083],"category_scores_gemma":[0.00009761386,0.00043716584,0.0012390533,0.00065848196,0.000038770013,0.000038795613,0.000112965936,0.00033797932,0.0005040275],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000069332727,0.00003524372,2.2220479e-7,0.31352007,0.0008843232,0.000035516125,0.000018120269,4.076923e-9,4.3492687e-8,0.0001713379,0.086584955,0.59874326],"study_design_scores_gemma":[0.00069855066,0.00006063843,2.6741125e-7,0.100883104,0.014875088,0.0000023879043,0.000013501612,0.000031194744,1.7072618e-7,0.00004904098,0.8830403,0.0003457589],"about_ca_topic_score_codex":7.7538976e-7,"about_ca_topic_score_gemma":7.192787e-8,"teacher_disagreement_score":0.7964553,"about_ca_system_score_codex":0.00012616123,"about_ca_system_score_gemma":0.00009054005,"threshold_uncertainty_score":0.999808},"labels":[],"label_agreement":null},{"id":"W3037461942","doi":"10.1007/s40263-020-00744-2","title":"Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial","year":2020,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Jazz Pharmaceuticals","keywords":"Cataplexy; Narcolepsy; Epworth Sleepiness Scale; Placebo; Subgroup analysis; Excessive daytime sleepiness; Psychology; Modafinil; Anesthesia; Internal medicine; Medicine; Sleep disorder; Confidence interval; Psychiatry; Polysomnography; Insomnia","score_opus":0.06475190533656593,"score_gpt":0.3432362906212195,"score_spread":0.2784843852846536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037461942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949933,0.00061366096,0.0008298423,0.0005740417,0.000021487314,0.0076377927,0.00079332595,0.000010507123,0.000020032088],"genre_scores_gemma":[0.99794066,0.00051492715,0.000051923267,0.000051103307,0.000022451763,0.0012650953,0.00010667328,0.000021442092,0.000025721096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969203,0.00068862445,0.0007467928,0.0007140218,0.0004435652,0.0004866907],"domain_scores_gemma":[0.99343234,0.0053368537,0.00038748808,0.0005914494,0.00007235573,0.00017950499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009663227,0.00026065603,0.0022206726,0.00024030989,0.00009506104,0.00005067758,0.0003792019,0.00005541114,0.0000151587765],"category_scores_gemma":[0.0015992789,0.00013436443,0.00009213701,0.0012138134,0.00077166065,0.00018664655,0.00010855066,0.00010574406,2.3819153e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97936285,0.0007430417,0.0064217956,0.000046942583,0.0009415529,0.0000071991526,0.008029681,0.0004317548,0.001237772,0.00004560753,0.000010178956,0.0027216244],"study_design_scores_gemma":[0.9067415,0.0011530652,0.0017137378,0.00004351147,0.0017989074,6.425034e-7,0.0008443048,0.08353438,0.0039161807,0.000006373277,0.00007413097,0.00017328715],"about_ca_topic_score_codex":0.0012272097,"about_ca_topic_score_gemma":0.0009917866,"teacher_disagreement_score":0.08310263,"about_ca_system_score_codex":0.000040950945,"about_ca_system_score_gemma":0.00024651014,"threshold_uncertainty_score":0.54792225},"labels":[],"label_agreement":null},{"id":"W3045363217","doi":"10.1007/s40263-020-00749-x","title":"Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study","year":2020,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Bayer HealthCare; Teva Pharmaceutical Industries; Biogen; Celgene; Sanofi","keywords":"Alemtuzumab; Medicine; Multiple sclerosis; Neurology; Interferon beta-1a; Internal medicine; Post-hoc analysis; Clinical trial; Interferon beta; Psychiatry","score_opus":0.017180481804925214,"score_gpt":0.2825230293991739,"score_spread":0.2653425475942487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045363217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980496,0.00020883403,5.985152e-7,0.00018562001,0.000010539162,0.001325717,0.00018290653,0.0000035962023,0.000032583404],"genre_scores_gemma":[0.9996661,0.00015991538,0.000025890848,0.00004724159,0.0000053193394,0.000015434829,0.000068059155,0.0000094000825,0.00000263102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847287,0.0001429535,0.00033454032,0.00028345303,0.0006175161,0.00014867017],"domain_scores_gemma":[0.9989404,0.00027374123,0.00014211281,0.0002619153,0.00030797036,0.000073845076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011822168,0.00012134048,0.00057968986,0.00016482615,0.00003869846,0.0000033228798,0.00009237285,0.000026230218,0.0000050670387],"category_scores_gemma":[0.0005677327,0.00008031751,0.00005545362,0.0007986751,0.00018220853,0.00007198904,0.00019848744,0.0001192742,1.3071595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010483031,0.0010568888,0.89032024,0.00011973997,0.00042834174,0.0000030568574,0.09016942,0.0000213118,0.00008646469,0.0000019521458,0.000013443982,0.0072961086],"study_design_scores_gemma":[0.0138298925,0.0030919178,0.97164196,0.00015344797,0.00048290312,1.16694645e-8,0.010621773,0.000042018124,0.000057521203,5.674471e-7,0.000012096757,0.00006590065],"about_ca_topic_score_codex":0.0005802601,"about_ca_topic_score_gemma":0.00026417724,"teacher_disagreement_score":0.08132171,"about_ca_system_score_codex":0.00004678337,"about_ca_system_score_gemma":0.000045142133,"threshold_uncertainty_score":0.32752532},"labels":[],"label_agreement":null},{"id":"W3048893740","doi":"10.1007/s40263-020-00754-0","title":"Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; University Health Network","funders":"","keywords":"Dopaminergic; Parkinson's disease; Psychopharmacology; Medicine; Neurology; Neuroscience; Physical medicine and rehabilitation; Apomorphine; Motor control; Disease; Psychology; Dopamine; Psychiatry; Internal medicine","score_opus":0.030008998222642153,"score_gpt":0.32352673857504793,"score_spread":0.2935177403524058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048893740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004608227,0.99261564,0.000014245281,0.00053212064,0.00015512793,0.004862422,0.0009674021,0.00006689451,0.0003253128],"genre_scores_gemma":[0.0031209998,0.9899165,0.00006627359,0.0015926393,0.00018996338,0.0024958625,0.0015655207,0.00010042995,0.0009518329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979577,0.000080363716,0.0005111666,0.00082068803,0.00019691471,0.00043318752],"domain_scores_gemma":[0.99867237,0.00009852835,0.00018661277,0.0004642785,0.000028629443,0.0005495605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000552571,0.0005819984,0.0021160846,0.00013977142,0.000053089556,0.000025855064,0.00018643646,0.00019104604,0.00008083742],"category_scores_gemma":[0.000043548163,0.0003895768,0.00069768465,0.00020730316,0.000048376525,0.000055406712,0.000035655044,0.00022781098,0.0001759118],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006604664,0.0017502414,0.0008799386,0.0047188047,0.0006947138,0.0013257505,0.000028398234,3.0924738e-7,5.643061e-7,0.000045575416,0.001458938,0.9884363],"study_design_scores_gemma":[0.0061285654,0.0009332757,0.00089866854,0.0013199591,0.0040482655,0.000004789091,0.000005299861,0.00012775318,1.10878865e-7,0.00018259928,0.9860638,0.0002869117],"about_ca_topic_score_codex":0.0000120985405,"about_ca_topic_score_gemma":0.0000025896775,"teacher_disagreement_score":0.9881494,"about_ca_system_score_codex":0.00014971184,"about_ca_system_score_gemma":0.00022267897,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W3134827765","doi":"10.1007/s40263-021-00801-4","title":"Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Gambling Behavior and Treatments","field":"Psychology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bibliothèque et Archives nationales du Québec; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; Centre de Santé et de Services Sociaux de la Vieille-Capitale; Centre Hospitalier Universitaire de Sherbrooke; Université Laval; Institut Universitaire en Santé Mentale de Québec","funders":"","keywords":"Aripiprazole; Psychiatry; Psychology; Odds ratio; Population; Nested case-control study; Confidence interval; Psychosis; Comorbidity; Medicine; Clinical psychology; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.06074770325621788,"score_gpt":0.3763586047743851,"score_spread":0.31561090151816723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134827765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412644,0.00017066817,0.000024740373,0.00025666654,0.00029054427,0.0023339516,0.000044985496,0.0003350632,0.0024169267],"genre_scores_gemma":[0.9957104,0.0000026955195,0.00035921787,0.000098192555,0.000037592657,0.0024708812,0.000043859607,0.0000741963,0.0012029834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732006,0.00035961732,0.0005153776,0.000800048,0.00030623097,0.0006986598],"domain_scores_gemma":[0.99861205,0.00020985042,0.00019391868,0.0006366397,0.00019184618,0.00015572125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000426358,0.0003557204,0.000504133,0.00022516109,0.00019216898,0.00013328329,0.00016485713,0.0001992755,0.0003205758],"category_scores_gemma":[0.00006032898,0.00031549323,0.000109079294,0.0012825809,0.000051522995,0.000108783854,0.00003538467,0.00042176055,0.00008824179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001627302,0.011136568,0.9443104,0.000010168385,0.000493935,0.011910465,0.009823692,0.000036560872,0.0000061599467,0.000020502737,0.0001754688,0.021913325],"study_design_scores_gemma":[0.017315272,0.0010570036,0.9724261,0.0001579237,0.000650376,0.0006839315,0.0064930166,0.00011867727,0.000023395,0.00003242422,0.0005760354,0.00046583946],"about_ca_topic_score_codex":0.0022205096,"about_ca_topic_score_gemma":0.01835804,"teacher_disagreement_score":0.028115682,"about_ca_system_score_codex":0.00017046231,"about_ca_system_score_gemma":0.000045890305,"threshold_uncertainty_score":0.9999297},"labels":[],"label_agreement":null},{"id":"W3134994261","doi":"10.1007/s40263-021-00793-1","title":"Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; McMaster University; BC Mental Health & Substance Use Services; St. Joseph’s Healthcare Hamilton; University of British Columbia; University of Toronto; TRIUMF; University of British Columbia Hospital","funders":"Canadian Institutes of Health Research; Ontario Brain Institute","keywords":"Escitalopram; Aripiprazole; Major depressive disorder; Neurocognitive; Psychology; Psychiatry; Cognition; Adjunctive treatment; Bipolar disorder; Psychomotor learning; Medicine; Internal medicine; Schizophrenia (object-oriented programming); Anxiety","score_opus":0.014135780871600319,"score_gpt":0.2788517343189797,"score_spread":0.26471595344737936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134994261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99315,0.001971621,0.00021300511,0.0011746683,0.00014638566,0.0013619501,0.00005617734,0.00004594653,0.0018802797],"genre_scores_gemma":[0.9967538,0.00023847379,0.0006335941,0.00026932446,0.000049357506,0.00041209947,0.00076257915,0.000053056992,0.0008276936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997881,0.00014876356,0.000430196,0.0007618656,0.00029259708,0.0004855995],"domain_scores_gemma":[0.99887145,0.0001628276,0.00018289339,0.00035573047,0.00013468735,0.0002924423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001394903,0.00038696188,0.0005643644,0.00032599046,0.00013193484,0.00005509212,0.0000503409,0.00020486096,0.00007276836],"category_scores_gemma":[0.000113027585,0.00027658464,0.000083121224,0.00045812005,0.00010689962,0.0001930557,0.00003956797,0.00023083492,0.000003991629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010123032,0.00047627767,0.9225875,0.000013504166,0.00025274852,0.0048413794,0.0020546238,0.000043218628,0.0005228207,0.000012530131,0.000049384715,0.068133704],"study_design_scores_gemma":[0.01597715,0.00029120705,0.9729351,0.0008521055,0.00024412459,0.00038917945,0.0019368823,0.00041885502,0.005999425,0.0001459843,0.000487657,0.00032233642],"about_ca_topic_score_codex":0.06866823,"about_ca_topic_score_gemma":0.4483152,"teacher_disagreement_score":0.37964696,"about_ca_system_score_codex":0.000696556,"about_ca_system_score_gemma":0.00082135905,"threshold_uncertainty_score":0.99996865},"labels":[],"label_agreement":null},{"id":"W3147565333","doi":"10.1007/s40263-021-00798-w","title":"Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Fingolimod; Sphingosine-1-phosphate receptor; S1PR1; Sphingosine-1-phosphate; Sphingosine kinase; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Pharmacology; Immune system; Medicine; Receptor; Sphingosine; Functional selectivity; Immunology; Neuroscience; Biology; G protein-coupled receptor; Cancer research; Internal medicine","score_opus":0.05276628998028735,"score_gpt":0.29557527165513836,"score_spread":0.24280898167485102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147565333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007131381,0.9957139,0.0008599611,0.000016792485,0.0014623586,0.00077318575,0.00034557004,0.00003421688,0.000080897626],"genre_scores_gemma":[0.00021922977,0.9902314,0.002432299,0.00013237873,0.002075455,0.000339034,0.0029256986,0.00016580723,0.0014786973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977934,0.00008964553,0.0005873373,0.00087367924,0.00016759832,0.0004883681],"domain_scores_gemma":[0.99853474,0.000071798175,0.00030975527,0.0007531863,0.00015589327,0.00017461918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034791068,0.000534791,0.0013497127,0.000084347375,0.00016686534,0.000086944274,0.00043211156,0.00056891394,0.000059691065],"category_scores_gemma":[0.0003574609,0.00048942986,0.0010689602,0.00022708997,0.000059804534,0.000004939832,0.00022061671,0.00019490355,0.00003320312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017788363,0.00008319971,0.000006626647,0.004535201,0.00044719508,0.0000010830045,0.00006843023,0.000013024181,0.0034869432,0.00012136667,0.015783835,0.9754353],"study_design_scores_gemma":[0.0004951878,0.000031122712,9.5367096e-7,0.0026299078,0.00042907725,0.0000042393904,0.000026971169,0.0000138490905,0.0070402925,0.000004124439,0.98877674,0.0005475575],"about_ca_topic_score_codex":0.000015865187,"about_ca_topic_score_gemma":0.0000024036017,"teacher_disagreement_score":0.9748877,"about_ca_system_score_codex":0.000033082197,"about_ca_system_score_gemma":0.00029159483,"threshold_uncertainty_score":0.99975574},"labels":[],"label_agreement":null},{"id":"W3156392683","doi":"10.1007/s40263-021-00808-x","title":"Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Takeda (Canada)","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Pharmacotherapy; Discontinuation; Medicine; Pediatrics; Attention deficit hyperactivity disorder; Comorbidity; Methylphenidate; Retrospective cohort study; Young adult; McNemar's test; Psychiatry; Internal medicine","score_opus":0.012183851937043863,"score_gpt":0.30060121251875166,"score_spread":0.2884173605817078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156392683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938608,0.00006840814,0.0035163597,0.0013095799,0.00005967338,0.0007028128,0.00044904792,0.000022916005,0.000010412988],"genre_scores_gemma":[0.9990948,0.000054309523,0.00012172652,0.00021906072,0.00003943528,0.00006683177,0.00031358213,0.000028429818,0.00006186477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980044,0.00026021167,0.00035699573,0.00048322527,0.0005994148,0.00029578898],"domain_scores_gemma":[0.99868304,0.00013465308,0.00017117796,0.0006568668,0.00027194753,0.00008230577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002242244,0.00021228206,0.00038871288,0.00011396608,0.00023142976,0.000049192015,0.00014593902,0.00006001242,0.00020008071],"category_scores_gemma":[0.00004368324,0.00013842699,0.00020356289,0.0015572064,0.000097513155,0.00037949046,0.00005143338,0.00037451094,0.000024772797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077129115,0.0012807545,0.9701747,0.000042690466,0.00032415512,0.000007503072,0.0033368191,0.0006434652,0.020897506,0.0000032062317,0.0000012891653,0.0025166296],"study_design_scores_gemma":[0.0037396618,0.00006390611,0.98769337,0.00015196484,0.00047527053,0.0000020459752,0.0067349444,0.0004910651,0.0004701129,0.000001919443,0.000014391915,0.0001613768],"about_ca_topic_score_codex":0.0010791755,"about_ca_topic_score_gemma":0.001997795,"teacher_disagreement_score":0.020427393,"about_ca_system_score_codex":0.000081870465,"about_ca_system_score_gemma":0.00005575369,"threshold_uncertainty_score":0.5644888},"labels":[],"label_agreement":null},{"id":"W3156691689","doi":"10.1007/s40263-021-00803-2","title":"Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Queen's University; University of British Columbia; University of British Columbia Hospital","funders":"Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; H. Lundbeck A/S; Servier; Ontario Brain Institute","keywords":"Escitalopram; Aripiprazole; Quality of life (healthcare); Major depressive disorder; Clinical psychology; Psychology; Depression (economics); Psychiatry; Adjunctive treatment; Antidepressant; Medicine; Internal medicine; Anxiety; Schizophrenia (object-oriented programming); Mood; Psychotherapist","score_opus":0.007309110990366666,"score_gpt":0.24854670039845367,"score_spread":0.241237589408087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156691689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977305,0.00020714062,0.000018316441,0.00011666417,0.00005137522,0.0014903101,0.00007207568,0.000018152843,0.00029544687],"genre_scores_gemma":[0.99935436,0.0000076160895,0.00019324117,0.000029968325,0.000012837884,0.00009622738,0.00012364262,0.00002516599,0.00015696119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997931,0.000098153076,0.0005927591,0.0004854692,0.00069819787,0.00019443464],"domain_scores_gemma":[0.9983493,0.000091909606,0.0005062989,0.0005513481,0.00035250522,0.00014864762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022912088,0.00021267713,0.000608204,0.0001072254,0.000036592406,0.000007401738,0.000057121528,0.00006228315,0.000016673719],"category_scores_gemma":[0.0002702246,0.00014276542,0.000038293616,0.00026114553,0.00013299583,0.00009288512,0.00011174552,0.00014933811,2.238868e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020667952,0.004792053,0.98696655,0.0001708571,0.00052576844,0.00011693057,0.0033288626,0.000010261516,0.00037423152,0.0000034026373,0.000017564287,0.0016267301],"study_design_scores_gemma":[0.019620774,0.002605305,0.9676762,0.000257612,0.00030888707,0.0000047418393,0.0047557927,0.0000047198787,0.0046119466,0.000008184359,0.0000123936825,0.00013340621],"about_ca_topic_score_codex":0.0013548462,"about_ca_topic_score_gemma":0.0011312357,"teacher_disagreement_score":0.019290308,"about_ca_system_score_codex":0.00008077637,"about_ca_system_score_gemma":0.00036525782,"threshold_uncertainty_score":0.5821805},"labels":[],"label_agreement":null},{"id":"W3164200337","doi":"10.1007/s40263-021-00814-z","title":"Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Purdue Pharma (Canada); University of Alberta","funders":"Purdue Pharma; Purdue University","keywords":"Pittsburgh Sleep Quality Index; Methylphenidate; Placebo; Stimulant; Clinical trial; Medicine; Adverse effect; Randomized controlled trial; Open label; Attention deficit hyperactivity disorder; Insomnia; Internal medicine; Anesthesia; Psychiatry; Sleep quality","score_opus":0.0375773965351871,"score_gpt":0.3543715755283068,"score_spread":0.3167941789931197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164200337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97408795,0.0008606439,0.0017145885,0.00055542804,0.00030788963,0.021507645,0.000022826076,0.00008994453,0.00085305737],"genre_scores_gemma":[0.992534,0.000057838937,0.000960657,0.00020381714,0.00008224833,0.0033097721,0.00039617723,0.00011612579,0.0023393882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99479735,0.0013001885,0.0013018334,0.0010484969,0.00096817105,0.0005839331],"domain_scores_gemma":[0.99537075,0.0021828278,0.0007769453,0.00093352137,0.0004662334,0.0002697205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002760554,0.00063896173,0.0030017174,0.00043825622,0.00013909438,0.00008984185,0.00026319825,0.00032794024,0.00014562315],"category_scores_gemma":[0.0021028358,0.00046431556,0.0004877005,0.0008242611,0.000099544945,0.0005311949,0.00016512863,0.000600352,0.000042514726],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97423756,0.004555111,0.00004762378,0.00024649317,0.0005773551,0.00012249903,0.0010098492,0.00037521016,0.010761898,0.00006404341,0.00018795529,0.0078143915],"study_design_scores_gemma":[0.9317955,0.0036307494,0.000024419449,0.0009019422,0.0012697554,0.000025508743,0.0007895331,0.054600578,0.0064860918,0.000014791116,0.00003530883,0.00042582297],"about_ca_topic_score_codex":0.00036464597,"about_ca_topic_score_gemma":0.00019628041,"teacher_disagreement_score":0.054225367,"about_ca_system_score_codex":0.00018812326,"about_ca_system_score_gemma":0.0003016912,"threshold_uncertainty_score":0.99978083},"labels":[],"label_agreement":null},{"id":"W3185751141","doi":"10.1007/s40263-021-00840-x","title":"Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"EMD Serono; Teva Pharmaceutical Industries; Celgene; MedDay Pharmaceuticals; Biogen; Sanofi","keywords":"Medicine; Adverse effect; Multiple sclerosis; Incidence (geometry); Clinical Practice; Expanded Disability Status Scale; Physical therapy; Internal medicine; Psychiatry","score_opus":0.0465823873557548,"score_gpt":0.36075225756524093,"score_spread":0.3141698702094861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185751141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928322,0.00005190795,0.0000071415543,0.0008538323,0.00008034906,0.005771099,0.00007148887,0.000016454078,0.00031554926],"genre_scores_gemma":[0.99822474,0.0001229618,0.0010522461,0.000065940054,0.000029006575,0.0003444324,0.000088714594,0.000030053545,0.000041892803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537843,0.0007287821,0.0019204275,0.0007622533,0.00082796795,0.00038215873],"domain_scores_gemma":[0.99503744,0.0017267163,0.001072618,0.00089634274,0.0011458659,0.00012101945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018512633,0.00028496067,0.0010007755,0.00011630432,0.000105982836,0.000016088796,0.000096956544,0.00008412303,0.000003484258],"category_scores_gemma":[0.006615525,0.00018381546,0.00015185008,0.0006610788,0.0002300483,0.0001396511,0.00025962736,0.000324126,1.9012823e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006136375,0.015863333,0.9462493,0.00013283668,0.0006469998,0.000019449419,0.005558576,0.00009869473,0.0008870749,0.000001624054,0.000025366737,0.024380364],"study_design_scores_gemma":[0.038674936,0.003021925,0.94962275,0.00051900215,0.00031005786,8.272731e-7,0.003635728,0.0012815705,0.0026879841,0.0000045402057,0.00009783125,0.00014282134],"about_ca_topic_score_codex":0.0007071653,"about_ca_topic_score_gemma":0.0008639292,"teacher_disagreement_score":0.032538563,"about_ca_system_score_codex":0.0003361913,"about_ca_system_score_gemma":0.0004900414,"threshold_uncertainty_score":0.79198796},"labels":[],"label_agreement":null},{"id":"W3186046354","doi":"10.1007/s40263-021-00839-4","title":"Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Tuberous Sclerosis Complex Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Tuberous sclerosis; Subependymal giant cell astrocytoma; Tolerability; Everolimus; Medicine; Pediatrics; Internal medicine; Epilepsy; Surgery; Astrocytoma; Psychiatry; Glioma; Adverse effect","score_opus":0.06900239039779014,"score_gpt":0.2948978457487866,"score_spread":0.22589545535099642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186046354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979898,0.000031286654,0.000008167932,0.00012385269,0.000030828855,0.0015758824,0.00008186516,0.000032674725,0.00012564726],"genre_scores_gemma":[0.99949414,0.0000020238394,0.00015793591,0.00006600812,0.000011280204,0.000039100658,0.0001770189,0.00003473968,0.00001777446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968678,0.00071891723,0.0004509375,0.0006905086,0.00092087593,0.00035099522],"domain_scores_gemma":[0.9976418,0.00041978012,0.00011628395,0.0006805375,0.0009834177,0.00015819982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006109714,0.00022963922,0.00061144825,0.00022115896,0.0000895252,0.00003069223,0.00011282062,0.00006872213,0.00008623604],"category_scores_gemma":[0.00058777933,0.000197072,0.00007090361,0.0007215518,0.00020630297,0.00007128857,0.00010920049,0.00030243292,0.000006746603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002686949,0.009924094,0.9820989,0.00006445923,0.00006804103,0.0000032593775,0.0028646912,0.000035947043,0.00025650428,0.0000059778854,0.000038711536,0.0019525026],"study_design_scores_gemma":[0.01777247,0.0036230672,0.97621936,0.00023275903,0.000043813438,3.121285e-7,0.0015388282,0.00010871131,0.00028904446,0.0000038086507,0.0000026383104,0.0001651676],"about_ca_topic_score_codex":0.0005759701,"about_ca_topic_score_gemma":0.0004334265,"teacher_disagreement_score":0.015085521,"about_ca_system_score_codex":0.00037562553,"about_ca_system_score_gemma":0.0001809908,"threshold_uncertainty_score":0.8036363},"labels":[],"label_agreement":null},{"id":"W3188896843","doi":"10.1007/s40263-021-00846-5","title":"Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada; University of Alberta; University of Toronto; University Health Network","funders":"","keywords":"Adverse effect; Ketamine; Tolerability; Medicine; Intensive care medicine; Psychiatry; Major depressive disorder; Context (archaeology); Anxiety; Neurology; Mood; Internal medicine","score_opus":0.006728945509502953,"score_gpt":0.2747249285350123,"score_spread":0.26799598302550937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188896843","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13702878,0.86029655,0.0000042210704,0.00000825887,0.00003916574,0.0021604705,0.000010782938,0.00000901893,0.00044278338],"genre_scores_gemma":[0.037545517,0.96129197,0.00032482328,0.0000016697787,0.00000527239,0.000079934776,0.0003294835,0.00003167517,0.00038963126],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988415,0.00009870097,0.00038301785,0.00030295204,0.0002535002,0.00012029228],"domain_scores_gemma":[0.9992053,0.00008854349,0.00030534342,0.00031868217,0.000026315029,0.000055844048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007908603,0.0002565933,0.0013110286,0.00018691427,0.0000118571925,0.000002382514,0.00004628593,0.00010478673,0.000006385566],"category_scores_gemma":[0.000011478768,0.00018120377,0.00010152784,0.0002077437,0.00007167902,0.000044127777,0.00011760625,0.00011190087,5.050938e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051291572,0.0012094816,0.027414955,0.0966481,0.00046272203,0.000012652611,0.00006954957,1.6335979e-7,2.3786914e-7,0.000015122387,0.000011053792,0.8741047],"study_design_scores_gemma":[0.02194032,0.0026445189,0.5995546,0.33450365,0.01098556,0.000007934611,0.00012246323,0.000004380437,0.000034511126,0.000019045441,0.029718691,0.00046428555],"about_ca_topic_score_codex":0.000012326633,"about_ca_topic_score_gemma":0.000017291131,"teacher_disagreement_score":0.8736404,"about_ca_system_score_codex":0.000044497792,"about_ca_system_score_gemma":0.000023141338,"threshold_uncertainty_score":0.7389275},"labels":[],"label_agreement":null},{"id":"W3194250079","doi":"10.1007/s40263-021-00854-5","title":"Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Olfactory and Sensory Function Studies","field":"Neuroscience","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Physicians' Services Incorporated Foundation","keywords":"Frontotemporal dementia; Dementia; Neurology; Psychosis; Psychiatry; Psychopharmacology; Psychology; Cognition; Personality changes; Medicine; Disease; Neuropsychiatry; Clinical psychology; Internal medicine","score_opus":0.18773797303704354,"score_gpt":0.3700846432395017,"score_spread":0.18234667020245815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194250079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010011584,0.9941416,0.00005998051,0.000044502318,0.0033345749,0.0009689763,0.00010322006,0.0000815679,0.0011654572],"genre_scores_gemma":[0.00011505133,0.9961662,0.000036658184,0.0005312146,0.00042146823,0.00024638863,0.0000222205,0.00007164832,0.002389139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975802,0.0004197557,0.00060354505,0.000800832,0.00021108345,0.0003846096],"domain_scores_gemma":[0.99887943,0.00041756989,0.00027750165,0.00032062957,0.000030780568,0.00007409824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016137153,0.00041955238,0.0012114136,0.0002674766,0.00018901192,0.000068337875,0.00030025086,0.00013837266,0.0002487505],"category_scores_gemma":[0.00009633224,0.00035787912,0.0006031438,0.0006011145,0.000062069164,0.000111938294,0.000062398205,0.00033644374,0.000106273415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016004235,0.00015734081,0.00003907984,0.0028203754,0.000103170045,0.000022375176,0.00022784361,0.000001981266,0.000029921366,0.0002964999,0.008249079,0.98803633],"study_design_scores_gemma":[0.00052056974,0.000039503324,0.000003416931,0.0005710323,0.00028531876,0.000009398858,0.000027096483,0.000008460205,0.000023263274,0.000018634035,0.9981603,0.0003330112],"about_ca_topic_score_codex":0.0000025772301,"about_ca_topic_score_gemma":0.0000022717434,"teacher_disagreement_score":0.9899112,"about_ca_system_score_codex":0.00006105928,"about_ca_system_score_gemma":0.000153792,"threshold_uncertainty_score":0.99988735},"labels":[],"label_agreement":null},{"id":"W3200887443","doi":"10.1007/s40263-021-00860-7","title":"Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; Agence Nationale de la Recherche","keywords":"Fingolimod; Medicine; Natalizumab; Expanded Disability Status Scale; Multiple sclerosis; Internal medicine; Confidence interval; Cohort; Hazard ratio; Disease; Immunology","score_opus":0.03640744322808392,"score_gpt":0.2720628795888382,"score_spread":0.23565543636075426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200887443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967321,0.00031187985,0.00019358384,0.00045610074,0.0003058151,0.00034563147,0.00013896349,0.000068044,0.001447883],"genre_scores_gemma":[0.99645007,0.00010150376,0.0021458091,0.000093528695,0.00013395064,0.00006691882,0.0008818293,0.00003592121,0.000090456764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727905,0.00007692446,0.0004300484,0.000682348,0.0010770389,0.0004545794],"domain_scores_gemma":[0.9981142,0.0004961209,0.00013945272,0.0005674616,0.0005121499,0.00017055737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023024665,0.0002445843,0.00058723363,0.000397495,0.00013811373,0.00007854052,0.00020514544,0.000102631806,0.00028973533],"category_scores_gemma":[0.0015159074,0.00021612224,0.00019174877,0.0012251145,0.00012628031,0.00019227399,0.0003178935,0.00038619235,0.000027264206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013293942,0.00041432367,0.98762953,0.00002052642,0.0020341193,0.000034037203,0.0011402845,0.00013527274,0.00032321908,0.000008242658,0.0002037736,0.0067272987],"study_design_scores_gemma":[0.013639525,0.00009132596,0.9787629,0.00045093967,0.00039262828,3.613697e-7,0.0006866412,0.0050360826,0.00052667636,0.00000760922,0.00019391587,0.00021134944],"about_ca_topic_score_codex":0.0011249647,"about_ca_topic_score_gemma":0.0043738834,"teacher_disagreement_score":0.0123101305,"about_ca_system_score_codex":0.0004682135,"about_ca_system_score_gemma":0.00013565658,"threshold_uncertainty_score":0.88132095},"labels":[],"label_agreement":null},{"id":"W3213007658","doi":"10.1007/s40263-021-00877-y","title":"Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Psilocybin; Serotonergic; Neuroscience; Neurochemical; Antidepressant; Monoaminergic; Psychology; Hallucinogen; Pharmacology; Psychopharmacology; Serotonin; Medicine; Receptor; Psychiatry; Hippocampus; Internal medicine","score_opus":0.0834527158822608,"score_gpt":0.42685967313502526,"score_spread":0.3434069572527645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213007658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026906118,0.9935543,0.003149469,0.00014036047,0.00022562002,0.0008887876,0.00025887604,0.000006900862,0.0017488088],"genre_scores_gemma":[0.00044305873,0.99785507,0.00027809458,0.00001574183,0.000030270232,0.0009858387,0.000051759016,0.000025229348,0.00031495804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99912757,0.00006168461,0.0003477619,0.00028078258,0.00005330568,0.00012887653],"domain_scores_gemma":[0.99862367,0.00042060198,0.00026765416,0.0005878775,0.00007275864,0.000027434722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000930441,0.00018903555,0.00085306127,0.000053088108,0.00006838303,0.000005495514,0.00014148492,0.00012808938,0.000020805937],"category_scores_gemma":[0.000012236073,0.000110974026,0.00036794698,0.00012128641,0.00006269958,0.0000053678996,0.000039732255,0.000041209547,0.0000020531809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002503052,0.00021503384,0.0000016556867,0.0007139532,0.0006190757,3.6910882e-7,0.00059857796,2.561292e-7,0.000008761141,0.048840303,0.0006471974,0.94835234],"study_design_scores_gemma":[0.00031071994,0.000100409205,0.000024497125,0.00083058106,0.0012786799,0.0000061408587,0.00033072438,0.0000014205061,0.00005369115,0.0022054666,0.99474174,0.00011590709],"about_ca_topic_score_codex":0.000027593029,"about_ca_topic_score_gemma":0.0000026985454,"teacher_disagreement_score":0.99409455,"about_ca_system_score_codex":0.000019620462,"about_ca_system_score_gemma":0.000043018634,"threshold_uncertainty_score":0.45253894},"labels":[],"label_agreement":null},{"id":"W3215276948","doi":"10.1007/s40263-021-00879-w","title":"Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Technische Universität München","keywords":"Cannabidiol; Neuropathic pain; Medicine; Cannabis; Chronic pain; Pregabalin; Gabapentin; Dronabinol; Tetrahydrocannabinol; Duloxetine; Population; Psychiatry; Pharmacology; Cannabinoid; Internal medicine; Alternative medicine","score_opus":0.02875298202892851,"score_gpt":0.3593217910969135,"score_spread":0.33056880906798497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215276948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008938206,0.95459163,0.00032406332,0.04115707,0.0006082622,0.0027024492,0.00015569941,0.000112435584,0.00033946353],"genre_scores_gemma":[0.000011322692,0.96628016,0.00004555494,0.003001619,0.0024538438,0.0020565654,0.00080551486,0.00025203192,0.025093373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937365,0.0011539061,0.0011225453,0.0012832438,0.0015781149,0.0011256587],"domain_scores_gemma":[0.9963651,0.00029605682,0.0002918198,0.0010478008,0.00060363184,0.0013955921],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005663984,0.0008472607,0.0034649181,0.0005500182,0.0002468152,0.00009242736,0.00045538464,0.00094719225,0.0009071939],"category_scores_gemma":[0.00658766,0.000636606,0.001059818,0.0008572908,0.00065540365,0.0000448383,0.00022127955,0.0015562576,0.000019328134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014373262,0.00007410517,0.0000033473611,0.04122834,0.00010920109,0.00032506764,0.000047862362,1.344715e-7,8.316361e-7,0.000054345513,0.33668727,0.62145513],"study_design_scores_gemma":[0.0014486786,0.0006596384,0.0000072681346,0.02713991,0.0012042108,0.0004064227,0.00006866279,0.0006002646,0.0000044182802,0.0000081544595,0.96791816,0.0005342318],"about_ca_topic_score_codex":0.0002278077,"about_ca_topic_score_gemma":0.00018111475,"teacher_disagreement_score":0.6312309,"about_ca_system_score_codex":0.0006759299,"about_ca_system_score_gemma":0.01623284,"threshold_uncertainty_score":0.9996085},"labels":[],"label_agreement":null},{"id":"W3217624600","doi":"10.1007/s40263-021-00876-z","title":"Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Jewish General Hospital; Montreal Heart Institute","funders":"","keywords":"Randomized controlled trial; Neurocognitive; Medicine; Cognition; Systematic review; Meta-analysis; MEDLINE; Cochrane Library; Pediatrics; Clinical psychology; Psychology; Psychiatry; Internal medicine","score_opus":0.04656544141655883,"score_gpt":0.41076723611627863,"score_spread":0.3642017946997198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217624600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003291632,0.96210974,0.000011259482,0.00019403448,0.00007284267,0.036963314,0.00012948003,0.000012654345,0.0005033494],"genre_scores_gemma":[0.000031813215,0.9852711,0.00009294096,0.00008477134,0.000068476074,0.01298514,0.0009998948,0.000031638916,0.00043425814],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98452175,0.008827036,0.0053330776,0.0003733664,0.0007101119,0.00023465215],"domain_scores_gemma":[0.98155576,0.014891913,0.0025718915,0.00035910154,0.0005315174,0.000089802576],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.021574974,0.00041005376,0.03774466,0.0005182726,0.000029350242,0.000019771078,0.00008513526,0.00015473782,0.00019831532],"category_scores_gemma":[0.07589395,0.00022405948,0.0023219779,0.00043069466,0.00015358628,0.00004658657,0.0000824553,0.0002836873,0.000010232803],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022492798,0.000090246,1.4597076e-7,0.9759127,0.003064362,0.000026233853,0.0002229025,1.3987829e-9,3.1182768e-7,0.000031721873,0.00058176904,0.017820347],"study_design_scores_gemma":[0.21288683,0.000046597426,1.14552094e-7,0.75415,0.031245435,0.000024648567,0.00045704868,0.0000026938449,0.0000011078627,0.0000062142713,0.0010634115,0.000115908435],"about_ca_topic_score_codex":0.000012242578,"about_ca_topic_score_gemma":0.000003709436,"teacher_disagreement_score":0.22176267,"about_ca_system_score_codex":0.0001342583,"about_ca_system_score_gemma":0.00037660706,"threshold_uncertainty_score":0.97654104},"labels":[],"label_agreement":null},{"id":"W328786158","doi":"10.2165/11533120-000000000-00000","title":"For What Diagnoses Are Psychotropic Medications Being Prescribed?","year":2010,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thomson Reuters (Canada)","funders":"Substance Abuse and Mental Health Services Administration; Centers for Disease Control and Prevention; Australian Government; U.S. Department of Health and Human Services","keywords":"Psychiatry; Anxiety; Medicine; Psychotropic drug; Mood; Psychopharmacology; Antidepressant; Anti-Anxiety Agents; Mood disorders; Depression (economics); Drug; Medical prescription; Pharmacology","score_opus":0.013481992939070238,"score_gpt":0.3088238816607857,"score_spread":0.29534188872171546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W328786158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96529204,0.0010255225,0.00038325868,0.0261828,0.0016648724,0.0010638109,0.000015958745,0.0002268161,0.0041449224],"genre_scores_gemma":[0.990688,0.0004160511,0.0038133403,0.00072757015,0.00058146624,0.0004108965,0.00007964618,0.00003366647,0.0032493463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991368,0.00001189251,0.00016257676,0.0002643776,0.00021365908,0.00021066438],"domain_scores_gemma":[0.9989746,0.0001955269,0.000076909804,0.0004998414,0.00008376607,0.00016933738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071111856,0.00012349497,0.00018139022,0.00008127888,0.00012316467,0.00004552972,0.00011560202,0.00010594344,0.00023987226],"category_scores_gemma":[0.00021471527,0.000097333104,0.000090964895,0.00007938467,0.00008909112,0.00023461346,0.000026387495,0.00018088955,0.00007817512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031107327,0.0028077043,0.25236848,0.0005538491,0.0005421785,0.00005925326,0.0059498157,0.0000024527703,0.08410747,0.007777482,0.21572489,0.42979535],"study_design_scores_gemma":[0.008081264,0.00035945757,0.40932626,0.0013651116,0.00081624015,0.000053818694,0.0019414483,0.0001303445,0.057976823,0.0066002756,0.5129168,0.0004321714],"about_ca_topic_score_codex":0.000008536357,"about_ca_topic_score_gemma":0.000022804652,"teacher_disagreement_score":0.4293632,"about_ca_system_score_codex":0.000023483242,"about_ca_system_score_gemma":0.000045244098,"threshold_uncertainty_score":0.39691287},"labels":[],"label_agreement":null},{"id":"W33860922","doi":"10.1007/s40263-021-00803-2","title":"A critical appraisal of the added value of BiPV in atria","year":2006,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Building Energy and Comfort Optimization","field":"Engineering","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; Servier; Ontario Brain Institute","keywords":"Building-integrated photovoltaics; Glazing; Photovoltaic system; Architectural engineering; Atrium (architecture); Desk; Photovoltaics; Engineering; Mechanical engineering; Civil engineering; Electrical engineering","score_opus":0.003950654662513969,"score_gpt":0.21833486385308926,"score_spread":0.2143842091905753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W33860922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767954,0.00015576299,0.004916799,0.000061015555,0.0003797584,0.000037422495,0.0000042943157,0.000042988337,0.00672242],"genre_scores_gemma":[0.99886656,0.0000032371497,0.0010479109,0.0000044864164,0.000034339922,0.0000031491788,0.0000021660967,0.000008037294,0.000030125753],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996671,0.0000130161825,0.00013436758,0.000044392986,0.00006778857,0.000073345174],"domain_scores_gemma":[0.9997658,0.00009035497,0.000012460205,0.000109632114,0.000013917718,0.000007833469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005630657,0.000042057192,0.00007612344,0.000034982775,0.00000902839,0.0000025865195,0.00007935897,0.000043652755,0.000014297263],"category_scores_gemma":[0.00004024437,0.000034372504,0.000034866374,0.00017448736,0.000034521767,0.000032234242,0.00001439605,0.000054158594,3.6696244e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032487585,0.0000210077,0.0011289702,0.000030953433,0.000003817575,2.0390526e-7,0.00011347362,0.9385775,0.0015287102,0.057872545,0.00040605848,0.00031352625],"study_design_scores_gemma":[0.0009064152,0.000024356073,0.024851622,0.00016403815,0.000034323395,0.0000031169845,0.00012597075,0.882302,0.084142,0.004907922,0.0022928943,0.00024538164],"about_ca_topic_score_codex":0.000064670094,"about_ca_topic_score_gemma":0.000010510342,"teacher_disagreement_score":0.08261329,"about_ca_system_score_codex":0.000008851684,"about_ca_system_score_gemma":0.000009076844,"threshold_uncertainty_score":0.14016701},"labels":[],"label_agreement":null},{"id":"W38310539","doi":"10.2165/00023210-200115010-00004","title":"Glutamate Receptors and Nociception","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Metabotropic glutamate receptor; Metabotropic glutamate receptor 2; Metabotropic glutamate receptor 5; Ionotropic effect; Glutamate receptor; Metabotropic glutamate receptor 1; Metabotropic glutamate receptor 6; Kainate receptor; Metabotropic glutamate receptor 7; Metabotropic glutamate receptor 8; Pharmacology; Nociception; Neuroscience; Metabotropic receptor; Chemistry; Receptor; Biology; AMPA receptor; Biochemistry","score_opus":0.04115513688786963,"score_gpt":0.34376611217775704,"score_spread":0.3026109752898874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W38310539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005459459,0.99313456,0.000023825862,0.00003500594,0.00028710958,0.0005925718,0.0000125712395,0.00006991364,0.005789857],"genre_scores_gemma":[0.000006391288,0.98857385,0.00050945237,0.00007037274,0.0002165361,0.00006480776,0.00023118845,0.000048497634,0.010278916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990455,0.000053002186,0.00024598904,0.00030839717,0.00014315979,0.0002039513],"domain_scores_gemma":[0.9994204,0.000034888253,0.00012814582,0.0002503626,0.000022393171,0.00014378973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014262275,0.00027709472,0.0009673039,0.000120517485,0.000058680806,0.000017556245,0.000046541078,0.0002453421,0.00036512763],"category_scores_gemma":[0.000019689865,0.00019812338,0.00021009598,0.00017469788,0.00002946946,0.000031271116,0.000033232,0.0001871837,0.0005373622],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000028814075,0.000040528124,0.000007109619,0.0037505191,0.00012933186,0.000034633667,0.00005944332,2.9078508e-9,3.0114109e-7,0.00006990747,0.0006855708,0.99521977],"study_design_scores_gemma":[0.00037468417,0.000070366266,0.000007916776,0.0070713884,0.0013241364,0.00013863394,0.000027497526,0.0000012348743,9.0400005e-7,0.000075052776,0.99075645,0.0001517227],"about_ca_topic_score_codex":0.000013598275,"about_ca_topic_score_gemma":5.9027906e-7,"teacher_disagreement_score":0.9950681,"about_ca_system_score_codex":0.00012403277,"about_ca_system_score_gemma":0.000072582065,"threshold_uncertainty_score":0.8079237},"labels":[],"label_agreement":null},{"id":"W4206358361","doi":"10.1007/s40263-021-00883-0","title":"Pharmacological Management of Apathy in Dementia","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Neurological Disorders and Treatments","field":"Neuroscience","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Ontario Brain Institute; Sunnybrook Health Science Centre","funders":"","keywords":"Apathy; Dementia; Rivastigmine; Memantine; Dementia with Lewy bodies; Frontotemporal dementia; Rotigotine; Galantamine; Psychiatry; Medicine; Vascular dementia; Psychology; Internal medicine; Parkinson's disease; Disease; Donepezil","score_opus":0.11569123049786068,"score_gpt":0.3665872304137719,"score_spread":0.2508959999159112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206358361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036016043,0.9748258,0.0000012674694,0.000017254912,0.00027637844,0.0009902818,0.00005135685,0.000037160127,0.02344035],"genre_scores_gemma":[0.0016387209,0.99725187,0.000019579842,0.0002508649,0.000008431212,0.00046733374,0.0000147453975,0.00002103555,0.00032744568],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980132,0.0003487751,0.00044767582,0.0006072403,0.00028641915,0.00029670776],"domain_scores_gemma":[0.9993074,0.00020526095,0.00020834051,0.00022449624,0.0000025097975,0.000052008836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011369186,0.00026913884,0.0007740698,0.00013432733,0.00006500484,0.000011735325,0.0005386865,0.00007779133,0.0022126124],"category_scores_gemma":[0.000017056842,0.00019796538,0.00031037652,0.0005497689,0.000078148354,0.000031034597,0.0004970976,0.0003157996,0.00010413493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008335986,0.0007843055,0.0000059833264,0.001962182,0.00006513524,0.0006122518,0.000018902258,0.0000014335815,0.0000033245808,0.0013000206,0.00022745524,0.9950107],"study_design_scores_gemma":[0.00042375998,0.0001053966,0.000010603823,0.00024640668,0.0005211205,0.000003998708,0.000011838846,0.0000025246818,0.000015603666,0.00047771382,0.9980119,0.00016912135],"about_ca_topic_score_codex":0.0000025937982,"about_ca_topic_score_gemma":1.572161e-7,"teacher_disagreement_score":0.99778444,"about_ca_system_score_codex":0.000049913167,"about_ca_system_score_gemma":0.000021027943,"threshold_uncertainty_score":0.9986995},"labels":[],"label_agreement":null},{"id":"W4212826549","doi":"10.1007/s40263-022-00897-2","title":"Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Adler; START Clinic; Professional Engineers Ontario; Lakehead University; Grey Nuns Community Hospital; University of Calgary; Misericordia Community Hospital; NOSM University; Translational Research in Oncology; University of Saskatchewan; University of Alberta","funders":"","keywords":"Ketamine; Context (archaeology); Medicine; Addiction; Intensive care medicine; Psychiatry; Treatment-resistant depression; Depression (economics); Mood; Major depressive disorder","score_opus":0.02660666941866643,"score_gpt":0.3258086522865787,"score_spread":0.2992019828679123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212826549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8136535,0.0005442895,0.03139905,0.13704893,0.0040490027,0.01011595,0.001144678,0.00050922384,0.0015353349],"genre_scores_gemma":[0.98856866,0.0000223999,0.0056508277,0.00047069788,0.00033836174,0.0015153149,0.0011368821,0.000044293778,0.0022525548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987442,0.000051342176,0.0002499908,0.00042787511,0.000277205,0.00024940647],"domain_scores_gemma":[0.9992568,0.00017103624,0.00012489104,0.00025173507,0.00005379028,0.00014172825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019201051,0.00016596838,0.00022808024,0.00013610987,0.00065588887,0.000029513076,0.000053066902,0.000057877514,0.00016760008],"category_scores_gemma":[0.00012034239,0.000115322706,0.00012096541,0.000077519886,0.000028170922,0.00013980325,0.00013454481,0.0002082696,0.0000031799757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016053783,0.005048352,0.0073164767,0.00028376546,0.0005046204,0.000069282345,0.0032023466,0.00024212712,0.023433752,0.00030712938,0.57104874,0.37248963],"study_design_scores_gemma":[0.06980541,0.014109965,0.046729036,0.0018056626,0.0035027212,0.0010383393,0.006295857,0.09043007,0.02024238,0.0016337208,0.7430967,0.0013101033],"about_ca_topic_score_codex":0.000008673252,"about_ca_topic_score_gemma":0.0000014137125,"teacher_disagreement_score":0.37117952,"about_ca_system_score_codex":0.0001439961,"about_ca_system_score_gemma":0.000054136613,"threshold_uncertainty_score":0.5044633},"labels":[],"label_agreement":null},{"id":"W4214636256","doi":"10.1007/s40263-022-00903-7","title":"Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Substantia nigra; Pars compacta; Medicine; Immunization; Parkinson's disease; Disease; Neurotoxicity; Neurology; Neuroscience; Dopaminergic; Vaccination; Immunology; Dopamine; Antibody; Pathology; Biology; Internal medicine; Psychiatry; Toxicity","score_opus":0.01075353122992427,"score_gpt":0.2653492891887223,"score_spread":0.254595757958798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214636256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385536,0.0036343697,0.000069334885,0.00061832025,0.00006994208,0.00046425048,0.00003260851,0.00008735922,0.0011684544],"genre_scores_gemma":[0.997815,0.00003973103,0.00044113726,0.000562184,0.000036563564,0.00027371364,0.000030486503,0.000032760134,0.00076838897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991874,0.000042303378,0.00008846988,0.0002450492,0.0002796467,0.0001571352],"domain_scores_gemma":[0.99959254,0.00001316074,0.000049875358,0.00018479173,0.000020008214,0.00013961237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088166504,0.00012314874,0.0001314209,0.00007997388,0.0002791709,0.000023115233,0.000040974723,0.000014837999,0.00046450933],"category_scores_gemma":[0.00000533942,0.00009154492,0.000040501694,0.00011090462,0.00001584441,0.00006400542,0.000047723825,0.00007978995,0.000006986266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006298909,0.002258422,0.6306571,0.00025565468,0.0006811408,0.0006477668,0.006286547,0.000028085658,0.0021387376,0.0018165082,0.00083571265,0.34809545],"study_design_scores_gemma":[0.007825948,0.0006621823,0.56336105,0.00015157911,0.00034865335,0.000046191955,0.0014149797,0.00064720935,0.0008752203,0.000599213,0.4237758,0.00029197754],"about_ca_topic_score_codex":0.000013936789,"about_ca_topic_score_gemma":8.8931864e-7,"teacher_disagreement_score":0.42294008,"about_ca_system_score_codex":0.00008863903,"about_ca_system_score_gemma":0.00006503157,"threshold_uncertainty_score":0.5086051},"labels":[],"label_agreement":null},{"id":"W4232225695","doi":"10.2165/00023210-200620020-00008","title":"Augmenting Strategies in Clozapine-Resistant Schizophrenia","year":2006,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Clozapine; Psychopharmacology; Schizophrenia (object-oriented programming); Psychiatry; Medicine; Psychology; Pharmacology; Psychotherapist","score_opus":0.012831819847018061,"score_gpt":0.27935427258433976,"score_spread":0.26652245273732167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232225695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787547,0.0015865976,0.000021833046,0.0010350135,0.00006356772,0.00032926013,0.000007763794,0.00009157146,0.01810971],"genre_scores_gemma":[0.99527204,0.000048610225,0.0027802503,0.000041854924,0.00022788471,0.00005181486,0.000056012752,0.000022579243,0.0014989278],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99860954,0.000036786947,0.00027513824,0.00028431532,0.00035158906,0.00044263882],"domain_scores_gemma":[0.99945015,0.000051048257,0.00004423111,0.0002822598,0.000048824288,0.00012346153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017533432,0.00016442138,0.0002465795,0.00021838884,0.00007658731,0.000069845846,0.00008508391,0.00006150884,0.00019913867],"category_scores_gemma":[0.000028011655,0.00013380026,0.00008986813,0.00031960555,0.00007311446,0.0001155729,0.00004405705,0.00020457416,0.00017165775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06804582,0.0062590726,0.11823679,0.0011735079,0.00075699744,0.007827607,0.0018719988,0.00037992897,0.18107603,0.42143983,0.023187067,0.16974534],"study_design_scores_gemma":[0.037284262,0.00078122766,0.884043,0.0006597397,0.00015381377,0.00009181555,0.0025162841,0.00085246464,0.029851304,0.032046754,0.011020331,0.0006990139],"about_ca_topic_score_codex":0.0008873969,"about_ca_topic_score_gemma":0.00085694843,"teacher_disagreement_score":0.7658062,"about_ca_system_score_codex":0.00016380742,"about_ca_system_score_gemma":0.0003508125,"threshold_uncertainty_score":0.54562163},"labels":[],"label_agreement":null},{"id":"W4240725191","doi":"10.1007/s40263-017-0433-0","title":"Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Lamotrigine; Medicine; In utero; Pregnancy; Pediatrics; Odds ratio; Carbamazepine; Population; Obstetrics; Epilepsy; Internal medicine; Fetus; Psychiatry","score_opus":0.19486570779744306,"score_gpt":0.46526494203629903,"score_spread":0.270399234238856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240725191","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000071307645,0.99190646,0.0000065140057,0.000783164,0.00006209215,0.006739953,0.000034442633,0.00004082404,0.0004194385],"genre_scores_gemma":[0.00040751646,0.9912978,0.000068972484,0.0013843045,0.000013413785,0.0015850572,0.000015254342,0.000030726063,0.0051969686],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.997163,0.00040971482,0.0011315275,0.0006182275,0.00033169138,0.00034581136],"domain_scores_gemma":[0.9977329,0.000574052,0.0005243419,0.00090739917,0.00004658845,0.00021472012],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0009223985,0.00062617677,0.018022744,0.00038986682,0.00010608005,0.00005564521,0.00032035416,0.00017799306,0.0000621752],"category_scores_gemma":[0.001207495,0.00031352072,0.004424284,0.0005522652,0.000035177694,0.00006560005,0.00024353355,0.00038342425,0.000049667215],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[4.5450594e-7,0.0000554035,0.00001856124,0.84041184,0.15453573,0.0002813128,0.00006840639,6.447702e-8,1.565082e-8,0.000005374078,0.0001085153,0.0045143124],"study_design_scores_gemma":[0.00020417193,0.000063953245,0.00001985707,0.17654052,0.7999448,0.0000074678624,0.000005280602,3.1959195e-7,5.199538e-8,0.0000025259403,0.022961073,0.00024998316],"about_ca_topic_score_codex":0.000014754738,"about_ca_topic_score_gemma":0.000010852499,"teacher_disagreement_score":0.66387135,"about_ca_system_score_codex":0.000084420724,"about_ca_system_score_gemma":0.000055504006,"threshold_uncertainty_score":0.9999317},"labels":[],"label_agreement":null},{"id":"W42654371","doi":"10.2165/11587820-000000000-00000","title":"Targeting Progressive Neuroaxonal Injury","year":2011,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; McGill University","funders":"National Institutes of Health; Health Canada; Multiple Sclerosis Society; Canadian Institutes of Health Research; Teva Pharmaceutical Industries; Sanofi","keywords":"Neurodegeneration; Medicine; Neuroprotection; Amyotrophic lateral sclerosis; Multiple sclerosis; Disease; Neurology; Neuroscience; Parkinson's disease; Inflammation; Degenerative disease; Pathology; Progressive supranuclear palsy; Immunology; Biology; Internal medicine","score_opus":0.04339443308181088,"score_gpt":0.33550784726540683,"score_spread":0.29211341418359593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W42654371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003837186,0.9927779,0.0000058520236,0.000010813337,0.00043197407,0.0012028168,0.00015074668,0.00012615547,0.0052553657],"genre_scores_gemma":[0.000090929265,0.99612194,0.00044495272,0.00012388233,0.00047381048,0.0004119127,0.00051036733,0.000114088514,0.0017081351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982189,0.0000914558,0.00042416353,0.00059422414,0.0002544321,0.00041680096],"domain_scores_gemma":[0.9987713,0.00003506849,0.00033744468,0.00043918713,0.00007303723,0.00034395038],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010194936,0.00051083526,0.0014183616,0.0001815077,0.00009555299,0.00002385435,0.00017207443,0.0002518901,0.00075909134],"category_scores_gemma":[0.000053065818,0.00036652177,0.00060841354,0.00020878976,0.000057290967,0.00005037091,0.0001202437,0.00039145697,0.0010316754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002376487,0.00028813857,0.000014520558,0.005973127,0.000405116,0.00048368212,0.000051155905,3.4759489e-9,2.7104136e-7,0.0002133246,0.0025942973,0.9899526],"study_design_scores_gemma":[0.00034026772,0.00014515262,0.000015406606,0.0072253104,0.0025370629,0.00008912594,0.000010094401,0.0000015191583,0.0000035200512,0.00006055214,0.98929906,0.00027291718],"about_ca_topic_score_codex":0.00000505434,"about_ca_topic_score_gemma":4.7318537e-8,"teacher_disagreement_score":0.9896797,"about_ca_system_score_codex":0.000116657844,"about_ca_system_score_gemma":0.00049017393,"threshold_uncertainty_score":0.99987864},"labels":[],"label_agreement":null},{"id":"W4283592028","doi":"10.1007/s40263-022-00930-4","title":"Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Advanced Drug Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Milken Family Foundation; Milken Institute","keywords":"Medicine; Nasal administration; Intensive care medicine; Drug; Psychiatry; Pharmacology","score_opus":0.13988202627114982,"score_gpt":0.4464926226626209,"score_spread":0.3066105963914711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283592028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033868516,0.9824596,0.00013461524,0.004221387,0.004632786,0.0032518175,0.0005348921,0.00010463601,0.0012734141],"genre_scores_gemma":[0.00084849325,0.9872884,0.00027903033,0.0068296464,0.002727536,0.00064899377,0.00012409824,0.00010755167,0.0011462283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957911,0.0015449998,0.0008264032,0.0008857597,0.00033170223,0.0006200477],"domain_scores_gemma":[0.99694717,0.0016345972,0.0003360254,0.0004916294,0.000068988,0.0005215646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075044244,0.00076153845,0.0013711551,0.00048161543,0.0009942864,0.00012023796,0.00067811,0.0005846392,0.00079204456],"category_scores_gemma":[0.000071350085,0.0005397189,0.00023899204,0.0013844927,0.00020083717,0.00016131545,0.0005648341,0.0016187084,0.000044634944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024839453,0.00013218632,0.00009728845,0.0032225417,0.00023054915,0.00008439148,0.003877971,0.00020653964,0.000002160919,0.0013405599,0.00840788,0.98214954],"study_design_scores_gemma":[0.00041598498,0.00016767782,0.000008039739,0.00012007156,0.0011870726,0.00041060918,0.0010289273,0.00009782382,0.000001165713,0.000030039144,0.99594206,0.0005905395],"about_ca_topic_score_codex":0.000019464173,"about_ca_topic_score_gemma":0.000011458207,"teacher_disagreement_score":0.98753417,"about_ca_system_score_codex":0.00014335655,"about_ca_system_score_gemma":0.00033067723,"threshold_uncertainty_score":0.99970543},"labels":[],"label_agreement":null},{"id":"W4283660569","doi":"10.1007/s40263-022-00932-2","title":"A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cilag; H. Lundbeck A/S; Mylan; Biogen; Sunovion; Medical Research Council; Sanofi; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Clozapine; Tolerability; Guideline; Schizophrenia (object-oriented programming); Checklist; Medicine; Intensive care medicine; Psychopharmacology; Psychiatry; Adverse effect; Psychology; Internal medicine","score_opus":0.014328500738093691,"score_gpt":0.2785911916347042,"score_spread":0.2642626908966105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283660569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949065,0.0013600636,0.000014567742,0.001535772,0.000026287811,0.0016851852,0.00018176771,0.000039224004,0.00025062638],"genre_scores_gemma":[0.99096674,0.00015736677,0.0068451525,0.00012396375,0.000057065285,0.0008836061,0.00047500653,0.000040009454,0.0004510736],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99858713,0.00004968743,0.00029460408,0.00043510876,0.00026359243,0.00036989833],"domain_scores_gemma":[0.9993264,0.00009437076,0.00007754635,0.00023641493,0.00005863355,0.00020662663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014421214,0.00024761527,0.0003806867,0.00023513955,0.00030125538,0.00003515418,0.000042037937,0.000025551819,0.00005165386],"category_scores_gemma":[0.000029724428,0.00017616684,0.000051961342,0.00020335121,0.00006496954,0.00006369127,0.00007402715,0.00008786893,0.000001255912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112811774,0.0040563317,0.31082058,0.00020905229,0.0010778264,0.00042308192,0.0034161787,0.000044214805,0.00023291743,0.0013343756,0.00038706738,0.5651866],"study_design_scores_gemma":[0.29903603,0.038908914,0.6263743,0.00029116432,0.0009955249,0.00008820348,0.0042072525,0.0049613076,0.00091805065,0.0013340568,0.021930026,0.0009551733],"about_ca_topic_score_codex":0.00042138313,"about_ca_topic_score_gemma":0.0003176852,"teacher_disagreement_score":0.56423146,"about_ca_system_score_codex":0.00062828505,"about_ca_system_score_gemma":0.00019619329,"threshold_uncertainty_score":0.7183875},"labels":[],"label_agreement":null},{"id":"W4286491536","doi":"10.1007/s40263-022-00937-x","title":"Antiseizure Drugs and Movement Disorders","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; Ontario Neurotrauma Foundation; University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto","keywords":"Lacosamide; Oxcarbazepine; Lamotrigine; Medicine; Movement disorders; Tiagabine; Carbamazepine; Levetiracetam; Zonisamide; Felbamate; Perampanel; Epilepsy; Gabapentin; Primidone; Topiramate; Pharmacology; Adverse effect; Psychiatry; Internal medicine","score_opus":0.034637669936816176,"score_gpt":0.35363422266236744,"score_spread":0.3189965527255513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286491536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046490168,0.9774832,0.0000012719617,0.0004514507,0.0001453789,0.0016347369,0.00010586636,0.00006179453,0.020069787],"genre_scores_gemma":[0.000033114375,0.9890183,0.00006287195,0.00023628189,0.00012370553,0.0005496832,0.00058095966,0.00007425628,0.0093208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798703,0.00012246093,0.0003467823,0.00054154755,0.00055166637,0.00045053312],"domain_scores_gemma":[0.99881375,0.00017323898,0.00011565386,0.00053838844,0.000017543038,0.00034145644],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002343394,0.00039209184,0.001275331,0.00023031232,0.00017461233,0.00003309779,0.00014550715,0.00012803545,0.0017893233],"category_scores_gemma":[0.000039667317,0.00028817396,0.00040758005,0.00029968435,0.00010475975,0.00003426878,0.00026624955,0.00058639643,0.00013805504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000107180285,0.00021727727,0.00009471005,0.009318409,0.00044080734,0.00009208128,0.00022368348,1.8423458e-8,3.7320113e-8,0.00017104103,0.006386605,0.9830446],"study_design_scores_gemma":[0.00079618907,0.0002937253,0.000036482033,0.0023537474,0.00086678314,0.000017723334,0.00023468559,0.0000014195232,3.51899e-7,0.00018272578,0.99499243,0.00022372161],"about_ca_topic_score_codex":0.00007068725,"about_ca_topic_score_gemma":0.0000056584176,"teacher_disagreement_score":0.98860586,"about_ca_system_score_codex":0.0002747557,"about_ca_system_score_gemma":0.00041524976,"threshold_uncertainty_score":0.999957},"labels":[],"label_agreement":null},{"id":"W4292104378","doi":"10.1007/s40263-022-00947-9","title":"Correction to: Antiseizure Drugs and Movement Disorders","year":2022,"lang":"en","type":"erratum","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; Ontario Neurotrauma Foundation; University of Toronto; University Health Network","funders":"","keywords":"Psychopharmacology; Movement disorders; Neurology; Medicine; Psychology; Psychotherapist; Psychiatry; Neuroscience; Internal medicine","score_opus":0.00823056938266356,"score_gpt":0.28123803979069834,"score_spread":0.27300747040803475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292104378","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016955802,0.013322648,0.0000444155,0.023189113,0.09459914,0.0048810816,0.0004243307,0.00041614135,0.8461673],"genre_scores_gemma":[0.018807068,0.007183481,0.00007006556,0.0020341775,0.0010269647,0.00044841348,0.0017573078,0.00009931373,0.9685732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977939,0.00006990194,0.00024163132,0.0006209769,0.0007824623,0.0004911396],"domain_scores_gemma":[0.99883723,0.00007814079,0.00007938752,0.000493408,0.000063269734,0.00044857585],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019290515,0.00033594732,0.00049067964,0.00031424343,0.00025689887,0.00004763724,0.000120625875,0.00015689465,0.0018107619],"category_scores_gemma":[0.00009992738,0.00029918482,0.00015787086,0.0003244498,0.00007122958,0.000041459247,0.00025354384,0.0010946591,0.00012955586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001218623,0.00026593707,0.002073199,0.00018350146,0.00022097143,0.00006025092,0.0011291612,0.0000014292925,0.00001018316,0.000027509219,0.94921577,0.046690226],"study_design_scores_gemma":[0.0012397617,0.0010951699,0.01018193,0.0003168655,0.00017952984,0.000009609967,0.0015035457,0.00009303791,0.000036513113,0.00018932785,0.98488194,0.0002727749],"about_ca_topic_score_codex":0.00069779746,"about_ca_topic_score_gemma":0.0001635884,"teacher_disagreement_score":0.12240588,"about_ca_system_score_codex":0.0004462011,"about_ca_system_score_gemma":0.00041258562,"threshold_uncertainty_score":0.999946},"labels":[],"label_agreement":null},{"id":"W4293065740","doi":"10.1007/s40263-022-00946-w","title":"Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia","year":2022,"lang":"en","type":"erratum","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medical Research Council","keywords":"Clozapine; Guideline; Psychopharmacology; Schizophrenia (object-oriented programming); Checklist; Medicine; Psychiatry; MEDLINE; Psychology; Psychotherapist; Pathology; Political science","score_opus":0.013875041224964767,"score_gpt":0.28099551024642033,"score_spread":0.2671204690214556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293065740","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8539197,0.055954587,0.00009261171,0.010144195,0.01792209,0.02694418,0.0043605207,0.00072435144,0.029937755],"genre_scores_gemma":[0.31849357,0.025008399,0.026123136,0.0011308343,0.0065017026,0.014538843,0.06337363,0.0012913174,0.5435386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997351,0.000080385485,0.00057829823,0.0009216783,0.00047901683,0.00058965216],"domain_scores_gemma":[0.9986208,0.00017294577,0.00024223098,0.00046841401,0.00015527164,0.0003402998],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017250948,0.0006560891,0.0010055089,0.00054134114,0.00037843222,0.000091244445,0.0000774259,0.0001798294,0.00015875106],"category_scores_gemma":[0.00009450648,0.00047684027,0.00013519987,0.0003255554,0.00012319665,0.000088595945,0.000101931015,0.00040623348,0.0000028057088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1153923,0.004316035,0.03208463,0.0009841452,0.003300209,0.0008611943,0.0023858484,0.000012935839,0.0000087833905,0.00018577947,0.2596559,0.5808123],"study_design_scores_gemma":[0.15984526,0.034005657,0.12129002,0.002019538,0.0026893925,0.00012856086,0.0019827113,0.0034431568,0.00006694741,0.0002884534,0.6726882,0.0015521444],"about_ca_topic_score_codex":0.0009830215,"about_ca_topic_score_gemma":0.0015696589,"teacher_disagreement_score":0.5792601,"about_ca_system_score_codex":0.0016539684,"about_ca_system_score_gemma":0.0008424552,"threshold_uncertainty_score":0.9997683},"labels":[],"label_agreement":null},{"id":"W4295449270","doi":"10.1007/s40263-022-00944-y","title":"A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"National Institute of Mental Health; Universität Zürich","keywords":"Research Domain Criteria; Psilocybin; Psychology; PsycINFO; Valence (chemistry); Clinical psychology; Cognitive psychology; Cognition; Psychiatry; MEDLINE; Hallucinogen; Chemistry","score_opus":0.2240884902956888,"score_gpt":0.5258268709130501,"score_spread":0.30173838061736136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295449270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.67831e-7,0.88777995,0.00001723046,0.002211601,0.002143049,0.017493682,0.000452799,0.00022942534,0.08967202],"genre_scores_gemma":[1.4717388e-7,0.94231427,0.0005207827,0.008253735,0.0004814334,0.033610247,0.0003874359,0.00031533974,0.014116599],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9790567,0.010190393,0.004343733,0.0023805543,0.0020460756,0.0019825203],"domain_scores_gemma":[0.99060065,0.0021074838,0.001251127,0.0049563395,0.00044313405,0.0006412959],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.018276675,0.001502865,0.010980812,0.0010143499,0.00080518646,0.0001515438,0.003276851,0.00042921252,0.013671248],"category_scores_gemma":[0.002218828,0.0011826624,0.002176512,0.004421046,0.0002500415,0.000090474445,0.0017686742,0.0021691741,0.010972041],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035035055,0.00011395574,3.2580743e-8,0.5310983,0.00057066383,0.000106028725,0.000647065,7.3546587e-9,2.8469572e-8,0.002568473,0.45507103,0.009820906],"study_design_scores_gemma":[0.00015579068,0.0000770879,6.402896e-8,0.4602767,0.0014869081,0.00015346958,0.0003879017,6.3152e-8,6.7713155e-9,0.00028856235,0.5365566,0.0006168501],"about_ca_topic_score_codex":0.00009144358,"about_ca_topic_score_gemma":0.0000072021353,"teacher_disagreement_score":0.08148559,"about_ca_system_score_codex":0.0009965012,"about_ca_system_score_gemma":0.0005837387,"threshold_uncertainty_score":0.999772},"labels":[],"label_agreement":null},{"id":"W4297238194","doi":"10.1007/s40263-022-00952-y","title":"Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Medicine; Nephrogenic diabetes insipidus; Kidney disease; Lithium (medication); Adverse effect; Comorbidity; PsycINFO; Internal medicine; Intensive care medicine; Observational study; Psychiatry; Randomized controlled trial; MEDLINE; Kidney","score_opus":0.0393036728831198,"score_gpt":0.3819230748082708,"score_spread":0.342619401925151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297238194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008716487,0.9898321,5.9599444e-7,0.0002516757,0.00015722067,0.006732471,0.00007389059,0.000015248733,0.0029280744],"genre_scores_gemma":[0.00004697151,0.9973378,0.000024826568,0.00015199465,0.000042352618,0.0010933,0.00006525531,0.000052497737,0.001184976],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99609387,0.0013786327,0.00095799705,0.00038873623,0.00089938677,0.00028140593],"domain_scores_gemma":[0.99711084,0.00077180855,0.00052332255,0.0012921654,0.00011378483,0.00018805785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012163047,0.00033121696,0.0029981337,0.00024581677,0.00010701193,0.000004801452,0.00037349857,0.00014155457,0.00016124567],"category_scores_gemma":[0.000735786,0.00018084084,0.0007718466,0.0009842187,0.00023440312,0.000021330581,0.00024755244,0.0007099229,0.000022961505],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000049096902,0.0001831818,0.000048992195,0.9588965,0.00058663887,0.0000034227178,0.00033676004,1.2799335e-9,1.3975801e-7,0.0001377405,0.0012466708,0.038555026],"study_design_scores_gemma":[0.00043419254,0.000116170144,0.000024449419,0.61564773,0.005678441,0.00004817281,0.00009994182,1.512545e-7,8.4086565e-7,0.000013161905,0.3778531,0.000083661434],"about_ca_topic_score_codex":0.00003760072,"about_ca_topic_score_gemma":0.0000013076486,"teacher_disagreement_score":0.37660643,"about_ca_system_score_codex":0.00017687122,"about_ca_system_score_gemma":0.0005509581,"threshold_uncertainty_score":0.73744756},"labels":[],"label_agreement":null},{"id":"W4306292918","doi":"10.1007/s40263-022-00956-8","title":"The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Teva Pharmaceutical Industries","keywords":"Medicine; Chorea; Tolerability; Adverse effect; Somnolence; Huntington's disease; Akathisia; Pediatrics; Internal medicine; Anesthesia; Disease; Psychiatry","score_opus":0.059127159505417796,"score_gpt":0.3357942568526275,"score_spread":0.2766670973472097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306292918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967189,0.0001052676,0.000024153784,0.0004279192,0.00026521113,0.002062942,0.00020595647,0.000022616978,0.00016707777],"genre_scores_gemma":[0.9985314,0.000021513322,0.00004747761,0.00038199368,0.000027021499,0.00051313394,0.000014180818,0.000031115407,0.00043216452],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99782586,0.00057361583,0.0003251113,0.000590071,0.00040160172,0.00028376415],"domain_scores_gemma":[0.998574,0.0004491973,0.00012988853,0.00067150116,0.00006181324,0.00011358961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005606849,0.00014129655,0.0001815108,0.00007007842,0.0007061148,0.00007024609,0.0009988388,0.000009674159,0.000029272951],"category_scores_gemma":[0.0007787778,0.00011387046,0.000032576078,0.00042662208,0.000096630836,0.00012086228,0.00068796356,0.00012112834,0.0000022430181],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032850031,0.012072164,0.024210384,0.000046087996,0.000014570302,0.000023676506,0.0027450044,0.0046528704,0.9227883,0.004125111,0.0019673698,0.024069414],"study_design_scores_gemma":[0.014418846,0.004050641,0.49049512,0.00003636095,0.00013008254,0.0000027641436,0.005372538,0.012232801,0.4542982,0.0029916358,0.015104316,0.00086671946],"about_ca_topic_score_codex":0.000023525732,"about_ca_topic_score_gemma":0.000034213244,"teacher_disagreement_score":0.46849015,"about_ca_system_score_codex":0.00004622757,"about_ca_system_score_gemma":0.00012547287,"threshold_uncertainty_score":0.54309356},"labels":[],"label_agreement":null},{"id":"W4375859891","doi":"10.1007/s40263-023-01002-x","title":"Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis","year":2023,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Biogen","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Internal medicine; Confidence interval; Nuclear medicine; Relative risk; Gastroenterology; Fingolimod; Immunology","score_opus":0.12092613490396055,"score_gpt":0.3234922728062846,"score_spread":0.20256613790232408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375859891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960871,0.00043803127,0.0003046055,0.0009040819,0.00015019214,0.001118223,0.00016115583,0.0002148633,0.0006217684],"genre_scores_gemma":[0.99504364,0.00058009144,0.002997808,0.00006842904,0.00009124778,0.00017671191,0.00009568416,0.000057606427,0.0008887843],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99820507,0.00007275564,0.00044105196,0.00041444134,0.00034393344,0.0005227506],"domain_scores_gemma":[0.9981378,0.0009862853,0.00014211517,0.0003612684,0.00017923249,0.0001933015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058564486,0.00022905743,0.0007010499,0.00037283017,0.00027094013,0.000033506745,0.00013035056,0.00010757021,0.000019468569],"category_scores_gemma":[0.0005871443,0.00020369742,0.00014477261,0.0005567232,0.00026101753,0.000109762936,0.00023333586,0.00020825931,0.000028569655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017199387,0.000427742,0.23671071,0.0019101842,0.0006328297,0.000010553839,0.012414008,0.00011587308,0.6811898,0.00010736167,0.032869946,0.03189109],"study_design_scores_gemma":[0.005791257,0.00022478086,0.95048565,0.0008188176,0.00013343118,0.0000036914,0.0043143798,0.008577553,0.027468463,0.00006546726,0.0018415218,0.0002749665],"about_ca_topic_score_codex":0.00030926784,"about_ca_topic_score_gemma":0.00008078433,"teacher_disagreement_score":0.713775,"about_ca_system_score_codex":0.00007572285,"about_ca_system_score_gemma":0.000070345086,"threshold_uncertainty_score":0.83065397},"labels":[],"label_agreement":null},{"id":"W4378953505","doi":"10.1007/s40263-023-01010-x","title":"Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Management and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medizinische Universität Graz","keywords":"Medicine; Phantom limb pain; Calcitonin; Phantom limb; Amputation; Analgesic; Regimen; Randomized controlled trial; MEDLINE; Observational study; Physical therapy; Internal medicine; Anesthesia; Surgery","score_opus":0.09207663435731953,"score_gpt":0.3865501423956726,"score_spread":0.29447350803835304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378953505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001419944,0.9881205,0.000002872679,0.00027169564,0.000070639144,0.009710251,0.000016035185,0.000049753387,0.0017568389],"genre_scores_gemma":[0.000006388435,0.9909399,0.000016011387,0.00029387075,0.000083043,0.0033851531,0.00021847883,0.000049872197,0.005007246],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99690235,0.001033354,0.0010625897,0.0003298874,0.0003991267,0.00027267227],"domain_scores_gemma":[0.99741054,0.0010859853,0.0004477776,0.00096974435,0.000028779255,0.000057155397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017993479,0.00044193136,0.0038503571,0.00027055436,0.00002992503,0.000012670237,0.00024321987,0.00010883152,0.000026407635],"category_scores_gemma":[0.00019466467,0.0002078364,0.0010000927,0.00082101795,0.000039611044,0.000015370551,0.000024958119,0.00011365604,0.00036182432],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000020850396,0.0005658154,0.0000030117244,0.90495044,0.0008765311,0.00022946854,0.00036064157,1.2176523e-8,3.226909e-9,0.000075823096,0.0012606058,0.09167556],"study_design_scores_gemma":[0.00037264923,0.00033520424,0.0000014604535,0.612798,0.010242572,0.000011060669,0.000116682386,0.0000036865229,6.165057e-8,0.0000077905015,0.37600273,0.00010814905],"about_ca_topic_score_codex":0.00004004373,"about_ca_topic_score_gemma":0.000009951505,"teacher_disagreement_score":0.37474212,"about_ca_system_score_codex":0.00035928245,"about_ca_system_score_gemma":0.00012833961,"threshold_uncertainty_score":0.8475323},"labels":[],"label_agreement":null},{"id":"W4379114392","doi":"10.1007/s40263-023-01016-5","title":"BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Glioma; Targeted therapy; Clinical trial; Bioinformatics; Oncology; Internal medicine; Cancer research; Biology; Cancer","score_opus":0.046265265051207385,"score_gpt":0.3385630503462798,"score_spread":0.29229778529507244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379114392","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012439326,0.9956563,7.4298646e-7,0.0002576098,0.00014738883,0.0016376347,0.00006567844,0.0000896393,0.0009010452],"genre_scores_gemma":[0.004249208,0.9937176,0.00005440623,0.00009956788,0.00008047031,0.0007726842,0.00041554563,0.00009466509,0.0005158223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842614,0.000098665594,0.00047927818,0.00045226485,0.0002038937,0.00033973105],"domain_scores_gemma":[0.998661,0.0006880248,0.00014206147,0.00031336962,0.000033100023,0.0001624498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018191876,0.0003721981,0.0012659073,0.00045444872,0.000065589215,0.000034412937,0.00008536499,0.00017048346,0.00010665363],"category_scores_gemma":[0.00012739246,0.00027963254,0.0002707868,0.0006091303,0.00008415052,0.000024406592,0.000054866934,0.0002820206,0.0003630661],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066969105,0.00034547786,0.0015774993,0.010157366,0.00059264683,0.0010115029,0.00045650286,6.9469957e-7,3.2898453e-7,0.00020432532,0.00087121275,0.9847757],"study_design_scores_gemma":[0.0020278802,0.00025213748,0.012638694,0.03833706,0.005000946,0.00034151302,0.00042747235,0.00004391778,0.0000019144927,0.00044373987,0.93985987,0.00062486756],"about_ca_topic_score_codex":0.000060879072,"about_ca_topic_score_gemma":0.00003377143,"teacher_disagreement_score":0.9841509,"about_ca_system_score_codex":0.00015933588,"about_ca_system_score_gemma":0.00025150634,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W4385231015","doi":"10.1007/s40263-023-01028-1","title":"Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Paliperidone Palmitate; Paliperidone; Meta-analysis; Randomized controlled trial; Schizophrenia (object-oriented programming); Cochrane Library; Adverse effect; Positive and Negative Syndrome Scale; Discontinuation; Observational study; Internal medicine; Antipsychotic; Psychiatry; Psychosis","score_opus":0.08628787647540762,"score_gpt":0.3851335997236647,"score_spread":0.2988457232482571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385231015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011946966,0.98990595,0.000032123316,0.00024629128,0.00002107717,0.008154042,0.0003936887,0.000015867958,0.000036232155],"genre_scores_gemma":[0.0051294733,0.99239224,0.0011131506,0.000039106228,0.000010003727,0.0011086701,0.00012598075,0.00004447336,0.000036877715],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956391,0.0013133157,0.0014167286,0.00063784304,0.0006887193,0.00030428352],"domain_scores_gemma":[0.9968237,0.001300244,0.00052173214,0.0010881851,0.000095107476,0.00017102648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026416394,0.000519317,0.008884873,0.0005371292,0.000054130156,0.000031341417,0.00031317605,0.00011106502,0.000016015734],"category_scores_gemma":[0.00012891497,0.0002700202,0.0013439421,0.0020945861,0.00007279407,0.000038873364,0.00019634665,0.0003348275,0.000012094691],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054050656,0.00012888954,0.000011190997,0.8131984,0.1734539,0.00014438835,0.00021353293,0.0000015235779,1.4352867e-7,0.00016491757,0.000008449367,0.012134196],"study_design_scores_gemma":[0.0014660836,0.00015299513,0.001304909,0.19065432,0.8056185,0.00001062361,0.00018350914,0.000008742901,7.7312006e-7,0.00012336673,0.00026045876,0.0002156601],"about_ca_topic_score_codex":0.00017347986,"about_ca_topic_score_gemma":0.00010496729,"teacher_disagreement_score":0.63216466,"about_ca_system_score_codex":0.000085038366,"about_ca_system_score_gemma":0.000087889704,"threshold_uncertainty_score":0.9999752},"labels":[],"label_agreement":null},{"id":"W4386019723","doi":"10.1007/s40263-023-01008-5","title":"Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Anxiety; Anxiolytic; Lysergic acid diethylamide; Psychology; Psychopharmacology; Clinical trial; Randomized controlled trial; Pharmacology; Medicine; Psychiatry; Serotonin; Receptor; Internal medicine","score_opus":0.34593529662441314,"score_gpt":0.5418382729961186,"score_spread":0.1959029763717055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386019723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001142989,0.99309003,0.00004376163,0.00066244084,0.002493012,0.0022777615,0.00017347737,0.00006714803,0.0010780775],"genre_scores_gemma":[0.00012693618,0.99366945,0.00007180244,0.000048877282,0.00076661434,0.0015032437,0.000026332795,0.00008310284,0.0037036682],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965057,0.0004099845,0.0015100222,0.000928482,0.00018713869,0.0004587016],"domain_scores_gemma":[0.9872029,0.010890586,0.0006332782,0.001087527,0.00007212771,0.000113589806],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001397921,0.0005139445,0.0022465433,0.00007356388,0.0001860345,0.000029472154,0.0005041026,0.00051010493,0.00003929833],"category_scores_gemma":[0.0005307363,0.00029149247,0.0016495719,0.00029197408,0.00056216156,0.00003308682,0.00015657397,0.00030002042,0.00012418814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000617062,0.00042530932,0.00022877214,0.0019804095,0.0018868175,0.0000010260194,0.0012577765,8.409177e-8,1.4668659e-8,0.0005464764,0.0054571,0.98815453],"study_design_scores_gemma":[0.0006611995,0.00078123773,0.00053795625,0.0025821943,0.0024849516,0.000002502219,0.00049363,0.000008251989,6.991599e-8,0.0006132953,0.9915513,0.00028341435],"about_ca_topic_score_codex":0.00007730336,"about_ca_topic_score_gemma":0.00016035326,"teacher_disagreement_score":0.9878711,"about_ca_system_score_codex":0.00004969018,"about_ca_system_score_gemma":0.00012379745,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W4387326085","doi":"10.1007/s40263-023-01032-5","title":"Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University; Brain and Cognition Discovery Foundation; University Health Network","funders":"National Institute of Mental Health; National Institute on Aging","keywords":"Dextromethorphan; Bupropion; Medicine; Major depressive disorder; Internal medicine; Placebo; Adverse effect; Depression (economics); Randomized controlled trial; Meta-analysis; Rating scale; Hamilton Rating Scale for Depression; Psychiatry; Psychology; Smoking cessation; Alternative medicine","score_opus":0.2922463324314019,"score_gpt":0.533897522969662,"score_spread":0.24165119053826006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387326085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027629238,0.9762182,0.000039425384,0.00010713273,0.00024503758,0.02319443,0.00010514978,0.000029579418,0.000033414406],"genre_scores_gemma":[0.000014177433,0.9963069,0.00040980187,0.000018991055,0.00014696456,0.002427084,0.00012712553,0.00006910372,0.0004798727],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9914186,0.002674443,0.00476443,0.0005313349,0.00039637487,0.0002147937],"domain_scores_gemma":[0.9707966,0.025289936,0.0025746182,0.0011216698,0.000101149235,0.000116049225],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00804504,0.0004325887,0.010037712,0.00022802044,0.00003984409,0.000006549096,0.00019655062,0.00035419152,0.000019059413],"category_scores_gemma":[0.0088742925,0.00019278882,0.0017366019,0.00041421846,0.00010816081,0.00002216064,0.000064756874,0.00017963497,0.000010522033],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011936424,0.00038534132,0.000008256543,0.54875207,0.000660621,0.000005748283,0.000045607634,2.6963448e-8,2.8481426e-7,0.000006309657,0.000077132514,0.44993922],"study_design_scores_gemma":[0.0044133235,0.0008143931,0.00008830565,0.9021461,0.026863609,0.000024890083,0.000024084862,0.000006013365,0.0000049768164,0.000008575693,0.06547839,0.00012731372],"about_ca_topic_score_codex":0.000010777898,"about_ca_topic_score_gemma":0.0000013817311,"teacher_disagreement_score":0.4498119,"about_ca_system_score_codex":0.0001545855,"about_ca_system_score_gemma":0.00028301266,"threshold_uncertainty_score":0.9994744},"labels":[],"label_agreement":null},{"id":"W4388725740","doi":"10.1007/s40263-023-01048-x","title":"Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; George & Fay Yee Centre for Healthcare Innovation; University of Manitoba","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Zonisamide; Internal medicine; Adverse effect; Psychiatry; Topiramate; Epilepsy","score_opus":0.07539284631828222,"score_gpt":0.366625635527805,"score_spread":0.2912327892095228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388725740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016854939,0.97618175,0.0000080275595,0.00013217502,0.00003734611,0.022546466,0.00085961365,0.000027191916,0.000038898335],"genre_scores_gemma":[0.0015288696,0.99377185,0.000060478797,0.00006583765,0.000016946848,0.0036993907,0.0002537421,0.00006460197,0.00053827575],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9879303,0.004625262,0.0057708803,0.0007903323,0.00059049,0.00029273218],"domain_scores_gemma":[0.9858332,0.008986676,0.0038987529,0.0007532898,0.0001297616,0.00039830527],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01090033,0.0008414993,0.06991334,0.0012686907,0.00004739144,0.000029549446,0.00012114562,0.00021200613,0.000075138036],"category_scores_gemma":[0.009200611,0.00044679156,0.0073611406,0.0010995914,0.00022280012,0.00004815415,0.000124566,0.0001960331,0.000003322203],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008204968,0.00017540867,0.0000047087765,0.65469706,0.3354818,0.000056528774,0.00006076361,2.9086766e-7,1.1554649e-7,0.00012071354,0.000016195243,0.0011814602],"study_design_scores_gemma":[0.0900521,0.000034515644,0.000028652823,0.11624927,0.7910807,0.000005660422,0.00001892174,0.000023231747,2.196812e-7,0.000039596634,0.0022440946,0.00022303146],"about_ca_topic_score_codex":0.00005440842,"about_ca_topic_score_gemma":0.000009754305,"teacher_disagreement_score":0.5384478,"about_ca_system_score_codex":0.00008881222,"about_ca_system_score_gemma":0.00028371133,"threshold_uncertainty_score":0.99979836},"labels":[],"label_agreement":null},{"id":"W4388970634","doi":"10.1007/s40263-023-01044-1","title":"The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Research Domain Criteria; Psychology; Lysergic acid diethylamide; Mood; Happiness; Clinical psychology; Mental health; Psychiatry; Medicine; Psychotherapist","score_opus":0.13164598224215734,"score_gpt":0.48225955610918525,"score_spread":0.3506135738670279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388970634","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012259867,0.9668609,0.0000029040807,0.0005925827,0.0028156848,0.011812814,0.00016562265,0.00008710372,0.017650113],"genre_scores_gemma":[0.00009980192,0.98155165,0.000002483423,0.00018766953,0.00025577875,0.0112671675,0.00003357644,0.00012666856,0.0064751985],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98775125,0.0069208276,0.0021722033,0.00081177475,0.0012484809,0.0010954747],"domain_scores_gemma":[0.9663075,0.029058766,0.001286356,0.0027129387,0.0005036563,0.00013076255],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009755436,0.00079429155,0.004061041,0.000307947,0.0008587039,0.00016103238,0.002205857,0.0003628757,0.000023077528],"category_scores_gemma":[0.004784545,0.00037043463,0.0010787789,0.0017663179,0.0006709567,0.00004741019,0.00053497654,0.0012272076,0.0021187686],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014887389,0.00005781858,7.3807826e-8,0.9124153,0.0016547514,0.00004453168,0.003075694,1.6603927e-8,6.414561e-7,0.025644159,0.053377755,0.003714352],"study_design_scores_gemma":[0.00017104245,0.00021272028,0.0000023483567,0.830583,0.0013691377,0.000028722336,0.0031741962,7.893916e-7,0.000001024731,0.00051911164,0.16358386,0.0003540518],"about_ca_topic_score_codex":0.000090487614,"about_ca_topic_score_gemma":0.000013173324,"teacher_disagreement_score":0.11020611,"about_ca_system_score_codex":0.00033586117,"about_ca_system_score_gemma":0.00030464548,"threshold_uncertainty_score":0.9998748},"labels":[],"label_agreement":null},{"id":"W4388970721","doi":"10.1007/s40263-023-01053-0","title":"Context is a Critical for Psychoactive Drug Effects","year":2023,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Psychopharmacology; Context (archaeology); Drug; Psychoactive drug; Medicine; Pharmacology; Psychology; Psychiatry; Biology","score_opus":0.044034003831641515,"score_gpt":0.3884740242489851,"score_spread":0.34444002041734356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388970721","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030154787,0.0021278672,0.00033129574,0.9041551,0.013811336,0.0013603377,0.00075654965,0.00035316302,0.076802835],"genre_scores_gemma":[0.004809262,0.000047133326,0.00008955367,0.8565502,0.00987167,0.0024735492,0.00019165006,0.0002828535,0.12568411],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665964,0.0001624291,0.00046089786,0.0012334861,0.00036623792,0.0011173057],"domain_scores_gemma":[0.99398726,0.004566561,0.00015568837,0.0009192961,0.00025515762,0.000116017734],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029488385,0.0006394946,0.000945141,0.00026668396,0.0002766506,0.00008533871,0.00053312385,0.0009592847,0.00036752576],"category_scores_gemma":[0.00026394718,0.00060203223,0.00063208217,0.00025326057,0.0003360898,0.000049308717,0.00011608415,0.001530453,0.004124076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006776585,0.000085540174,0.000013162217,0.00041402344,0.0007242091,0.00013345288,0.013583852,1.3834278e-8,0.0000024634353,0.0038920734,0.97558063,0.00550281],"study_design_scores_gemma":[0.0012610838,0.0001166315,0.00016581992,0.0002143321,0.00024222468,0.000007521744,0.001964567,0.0000043915898,0.00002769929,0.008042251,0.98729986,0.00065360154],"about_ca_topic_score_codex":0.0001069367,"about_ca_topic_score_gemma":0.000011893603,"teacher_disagreement_score":0.048881277,"about_ca_system_score_codex":0.00009118782,"about_ca_system_score_gemma":0.000054861932,"threshold_uncertainty_score":0.9996431},"labels":[],"label_agreement":null},{"id":"W4391810680","doi":"10.1007/s40263-024-01061-8","title":"Targeting Pannexin-1 Channels: Addressing the ‘Gap’ in Chronic Pain","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Pannexin; Chronic pain; Neuroscience; Medicine; Adenosine; Purinergic receptor; Ion channel; Mechanism (biology); Bioinformatics; Pharmacology; Biology; Cell biology; Gap junction; Internal medicine; Connexin; Intracellular; Receptor","score_opus":0.0690528701644024,"score_gpt":0.34761524076179967,"score_spread":0.2785623705973973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391810680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007474077,0.99750036,0.000051065625,0.00015464556,0.00073767506,0.00051367946,0.000042347256,0.00002696354,0.0008985394],"genre_scores_gemma":[0.0014572751,0.99323994,0.00001841543,0.00021685641,0.0023913102,0.0002073418,0.00059416884,0.00009111167,0.0017835569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973953,0.00067103666,0.0005456652,0.00074271736,0.00009752276,0.00054779573],"domain_scores_gemma":[0.9990505,0.0001045506,0.00018085672,0.0005717249,0.000031323092,0.00006101991],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014270957,0.00047725343,0.00078149774,0.00012924969,0.000112909445,0.00008405816,0.0005540696,0.00060549827,0.000051108753],"category_scores_gemma":[0.00019414692,0.00029807174,0.00046378694,0.00027215562,0.00014400382,0.0000021164217,0.00041286935,0.00064523116,0.0001122602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000043295427,0.000016408907,8.900319e-7,0.0044420664,0.00014245785,0.000023307774,0.00013715737,0.000009548106,0.0002409488,0.000108471555,0.011353817,0.98352057],"study_design_scores_gemma":[0.00008925292,0.00008334999,1.8620298e-7,0.0037212146,0.00016510047,0.000018798395,0.000119866614,0.00010612107,0.00002073321,0.000044102882,0.99525595,0.00037530682],"about_ca_topic_score_codex":0.0000329322,"about_ca_topic_score_gemma":0.00003910209,"teacher_disagreement_score":0.98390216,"about_ca_system_score_codex":0.00013036448,"about_ca_system_score_gemma":0.0005713306,"threshold_uncertainty_score":0.99994713},"labels":[],"label_agreement":null},{"id":"W4392283745","doi":"10.1007/s40263-024-01069-0","title":"The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study","year":2024,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medizinische Universität Graz","keywords":"Opioid; Medicine; Morphine; Agonist; Hyperalgesia; Buprenorphine; Anesthesia; Neuropathic pain; Sensitization; Chronic pain; Methadone; Pharmacology; Nociception; Internal medicine; Physical therapy; Receptor","score_opus":0.04020969767706196,"score_gpt":0.30014388552686616,"score_spread":0.2599341878498042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392283745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997962,0.00021601302,0.000096512245,0.00022648006,0.00008038835,0.0012893133,0.000051703963,0.000043864464,0.00003370784],"genre_scores_gemma":[0.99905974,0.000023341196,0.000121840305,0.00006236014,0.000037955597,0.00024249397,0.00010618369,0.00002502471,0.00032105745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855596,0.00039051293,0.00027885195,0.0003125662,0.00025863812,0.0002034843],"domain_scores_gemma":[0.9980023,0.0016309287,0.00003505332,0.0002263134,0.000036532925,0.00006885835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011886513,0.00015716386,0.00015268606,0.00017304058,0.00029868804,0.00027309332,0.00005678967,0.00006229831,0.000007856057],"category_scores_gemma":[0.00024332713,0.00009997411,0.00003522313,0.00033963338,0.00007605921,0.00019443234,0.000023647397,0.00024386322,0.0000081390635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087126024,0.0005012726,0.99077994,0.000010639516,0.00004848804,0.00001323486,0.004398995,0.0000071272116,0.000006245137,0.0003611215,0.0000123419095,0.0029893355],"study_design_scores_gemma":[0.003954204,0.00088389346,0.9926578,0.00006694644,0.000016105485,6.6163676e-7,0.00048972055,0.000171684,0.0000050809113,0.0012238973,0.00042910964,0.00010089487],"about_ca_topic_score_codex":0.00022083757,"about_ca_topic_score_gemma":0.0003232004,"teacher_disagreement_score":0.0039092745,"about_ca_system_score_codex":0.00013309458,"about_ca_system_score_gemma":0.00014297247,"threshold_uncertainty_score":0.4076826},"labels":[],"label_agreement":null},{"id":"W4392954175","doi":"10.1007/s40263-024-01078-z","title":"An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brain and Cognition Discovery Foundation; University of Toronto","funders":"Neurocrine Biosciences; University of Kentucky","keywords":"Akathisia; Anticholinergic; Tardive dyskinesia; Medicine; Adverse effect; Movement disorders; Dyskinesia; Anticholinergic agents; Dystonia; Parkinsonism; Neurology; Intensive care medicine; Extrapyramidal symptoms; Psychiatry; Anesthesia; Pharmacology; Internal medicine; Schizophrenia (object-oriented programming); Antipsychotic; Disease; Parkinson's disease","score_opus":0.09967599939751602,"score_gpt":0.41015990142707126,"score_spread":0.3104839020295552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392954175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00087853055,0.99076515,0.000036187193,0.0026910582,0.0005958456,0.0045990287,0.00008706026,0.00025184956,0.000095280055],"genre_scores_gemma":[0.0007052371,0.9909767,0.00021086451,0.0038276715,0.0005982223,0.0013989764,0.00040810817,0.0002517741,0.0016224664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969947,0.00017216813,0.0007231009,0.0010088396,0.00045414193,0.00064707414],"domain_scores_gemma":[0.9976805,0.0006279592,0.00027458154,0.0010305749,0.00017361522,0.00021281328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048065264,0.00084124267,0.0021334854,0.0005023371,0.00014060044,0.000099693614,0.00033477947,0.00021706853,0.000028730676],"category_scores_gemma":[0.00019553473,0.00059354084,0.00093656563,0.0005302871,0.00008691706,0.00014853993,0.000051088275,0.0006567346,0.00018058452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023065608,0.0004747695,0.000009798111,0.032722283,0.0014353315,0.000029987827,0.0002978367,0.0000030889594,0.000102573,0.0006779285,0.017924156,0.9460916],"study_design_scores_gemma":[0.0009471504,0.0010646922,0.0000055532682,0.04196646,0.0046264827,0.0000017882609,0.000048380472,0.00006235936,0.00014736588,0.00024229969,0.9502659,0.0006215771],"about_ca_topic_score_codex":0.000027074444,"about_ca_topic_score_gemma":0.000025548059,"teacher_disagreement_score":0.94547004,"about_ca_system_score_codex":0.00045569945,"about_ca_system_score_gemma":0.00060030626,"threshold_uncertainty_score":0.9996516},"labels":[],"label_agreement":null},{"id":"W4396705661","doi":"10.1007/s40263-024-01089-w","title":"Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia","year":2024,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Mental Health; Monash University","keywords":"Psychopharmacology; Schizophrenia (object-oriented programming); Adverse effect; Antipsychotic; Psychiatry; Medicine; Psychology; Internal medicine; Neurology; Clozapine","score_opus":0.026063628324950388,"score_gpt":0.314193143153479,"score_spread":0.2881295148285286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396705661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923343,0.005813191,0.0000013072929,0.0005834856,0.000033643984,0.00091626873,0.000019699051,0.000016555447,0.00028156088],"genre_scores_gemma":[0.99838424,0.001024482,0.00022781428,0.00001355048,0.00006136276,0.00007487439,0.000016752761,0.0000113710485,0.00018558124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989108,0.00012478883,0.00019619575,0.00029572932,0.00023279006,0.00023973013],"domain_scores_gemma":[0.99880844,0.0008502458,0.000022469023,0.00020472398,0.000008144098,0.00010597298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020603063,0.00016279312,0.0003730776,0.00027922384,0.000033255877,0.000030286119,0.00006301421,0.000060365233,0.000025054207],"category_scores_gemma":[0.000032031352,0.0000947428,0.000045095567,0.0003180706,0.00014126443,0.00004885985,0.000021461507,0.00013077268,0.000012038893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064124324,0.00054818025,0.8892252,0.00028490365,0.00016105107,0.00031832576,0.006683467,2.6995426e-7,0.0000986007,0.00028189825,0.000022294254,0.10173461],"study_design_scores_gemma":[0.007936742,0.0013137776,0.98829925,0.00044779162,0.00012880345,0.000029341989,0.0005504047,0.00004675824,0.00065225246,0.00044415196,0.0000717708,0.0000789419],"about_ca_topic_score_codex":0.00010037127,"about_ca_topic_score_gemma":0.000064357155,"teacher_disagreement_score":0.10165567,"about_ca_system_score_codex":0.00004577755,"about_ca_system_score_gemma":0.00007434149,"threshold_uncertainty_score":0.38634995},"labels":[],"label_agreement":null},{"id":"W4396766573","doi":"10.1007/s40263-024-01090-3","title":"FcRn Inhibitor Therapies in Neurologic Diseases","year":2024,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Immunology; Neonatal Fc receptor; Adverse effect; Myelin oligodendrocyte glycoprotein; Intravenous Immunoglobulin Therapy; Antibody; Myasthenia gravis; Clinical trial; Multiple sclerosis; Neuromyelitis optica; Immunoglobulin G; Pharmacology; Internal medicine; Experimental autoimmune encephalomyelitis","score_opus":0.019468459335931974,"score_gpt":0.3168302589198834,"score_spread":0.2973617995839514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396766573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650854,0.012887993,0.0000023147052,0.0124325575,0.0002202388,0.0001689052,0.000023171435,0.000103688566,0.009075727],"genre_scores_gemma":[0.9879643,0.0005244034,0.00002866478,0.0010095009,0.0004354131,0.000023398467,0.000021181248,0.000015274847,0.009977897],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991328,0.00003815266,0.00013128833,0.00022200582,0.00022898609,0.0002467623],"domain_scores_gemma":[0.9995916,0.0001412222,0.000007378381,0.00012744058,0.000020452308,0.000111891335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084369836,0.0001029228,0.00015908551,0.00014939989,0.000034856123,0.000036444282,0.00007221816,0.000044154847,0.00050093513],"category_scores_gemma":[0.0000358042,0.00006829878,0.00009097924,0.00024690919,0.00010790856,0.000054090502,0.00005682336,0.00024632513,0.00042069444],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027059491,0.0014534747,0.46173126,0.0033882975,0.00036354177,0.009233907,0.010123808,0.000018044819,0.03848023,0.029280655,0.09776917,0.34545165],"study_design_scores_gemma":[0.0009723912,0.00067752314,0.3719376,0.00035099866,0.000059785012,0.00011474263,0.0005095064,0.0016843744,0.0018798651,0.006165375,0.6153319,0.00031595002],"about_ca_topic_score_codex":0.0000515489,"about_ca_topic_score_gemma":0.0000054877482,"teacher_disagreement_score":0.51756275,"about_ca_system_score_codex":0.000022869084,"about_ca_system_score_gemma":0.000082538245,"threshold_uncertainty_score":0.54848886},"labels":[],"label_agreement":null},{"id":"W4400179162","doi":"10.1007/s40263-024-01098-9","title":"The State of Synthetic Cannabinoid Medications for the Treatment of Pain","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; St. Michael's Hospital; Sinai Health System; McGill University; Arthritis Research Centre of Canada; Women's College Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Psychopharmacology; Medicine; Cannabinoid; Synthetic cannabinoids; Neurology; Psychiatry; Neuroscience; Psychology; Internal medicine","score_opus":0.03449198301650314,"score_gpt":0.37169122874033544,"score_spread":0.3371992457238323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400179162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009414414,0.9848606,0.000040566232,0.010899296,0.0002637498,0.0031615484,0.0004155237,0.000017011898,0.00033226627],"genre_scores_gemma":[0.000030121575,0.9244204,0.0000092606115,0.000022157363,0.00017179774,0.0025312777,0.00006366305,0.00005834697,0.07269296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805117,0.00018539288,0.000696822,0.0002853095,0.00045502017,0.00032628328],"domain_scores_gemma":[0.99787945,0.00053675927,0.0002517908,0.0009648408,0.0002444953,0.0001226755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013114647,0.00027334972,0.0010692057,0.0001485019,0.00014594603,0.000022899336,0.00033576565,0.000099790195,0.0000392479],"category_scores_gemma":[0.0001975269,0.00010885998,0.0010065022,0.00042642307,0.00052071194,0.000008337147,0.000043066262,0.00020884469,0.000015822794],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014383442,0.00012491863,1.6797381e-7,0.011903966,0.00084672665,0.0000021458195,0.00066488766,3.4374463e-7,8.2986423e-7,0.00028262145,0.06585679,0.9203022],"study_design_scores_gemma":[0.00020158822,0.00048124604,0.0000019986214,0.003521225,0.00421941,0.000011766811,0.00025616362,0.00007360701,0.000019570785,0.00016283896,0.990962,0.00008853249],"about_ca_topic_score_codex":0.00016526543,"about_ca_topic_score_gemma":0.000050332506,"teacher_disagreement_score":0.9251053,"about_ca_system_score_codex":0.0002627798,"about_ca_system_score_gemma":0.0018697181,"threshold_uncertainty_score":0.44391814},"labels":[],"label_agreement":null},{"id":"W4401654837","doi":"10.1007/s40263-024-01114-y","title":"Glutamatergic Modulators for Major Depression from Theory to Clinical Use","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glutamatergic; Psychopharmacology; Depression (economics); Neuroscience; Medicine; Psychology; Psychiatry; Glutamate receptor; Receptor; Internal medicine","score_opus":0.10415533249601573,"score_gpt":0.4413690056931374,"score_spread":0.3372136731971217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401654837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027094048,0.9891709,0.00031840813,0.00009695967,0.0028243652,0.003579633,0.000740318,0.0003842387,0.00017575729],"genre_scores_gemma":[0.000242246,0.9796713,0.0045570126,0.0002588472,0.0017614827,0.00078596344,0.0011960574,0.0003261749,0.011200917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637985,0.00028826896,0.0011596427,0.0013074166,0.000417188,0.00044762305],"domain_scores_gemma":[0.99638665,0.0013780768,0.00026399316,0.0013752899,0.00006503124,0.0005309335],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054612476,0.0007371512,0.0026040026,0.00032464444,0.00008203839,0.00010854997,0.00033134472,0.00084688066,0.00018838355],"category_scores_gemma":[0.00048484444,0.00045153298,0.0015630496,0.00024054963,0.000063786785,0.0000991612,0.00037483062,0.00059559615,0.0017732605],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020559785,0.0002254714,0.00017686191,0.0070154252,0.000806519,0.000105348125,0.000093013674,2.1027473e-7,0.0000019576735,0.00006686658,0.021666717,0.969636],"study_design_scores_gemma":[0.0011226049,0.00016550293,0.00021098804,0.046330135,0.009824351,0.000024575997,0.000013440139,0.00000983743,0.000015541655,0.0005843692,0.94129765,0.00040099173],"about_ca_topic_score_codex":0.000022719089,"about_ca_topic_score_gemma":0.0000016131055,"teacher_disagreement_score":0.969235,"about_ca_system_score_codex":0.00023067772,"about_ca_system_score_gemma":0.0002658417,"threshold_uncertainty_score":0.99979365},"labels":[],"label_agreement":null},{"id":"W4406514589","doi":"10.1007/s40263-024-01139-3","title":"Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Teva Pharmaceutical Industries","keywords":"Chorea; Huntington's disease; Dose; Medicine; Disease; Psychopharmacology; Pediatrics; Neurology; Psychiatry; Internal medicine; Psychology","score_opus":0.017318823487690458,"score_gpt":0.285920947540357,"score_spread":0.26860212405266654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406514589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99665225,0.00007667311,0.000003996039,0.0010384978,0.00023763145,0.00092801725,0.000058352292,0.00001798637,0.0009866141],"genre_scores_gemma":[0.99898875,0.000047851387,0.000009716707,0.00043885413,0.000021670066,0.000043514196,0.000004089109,0.0000133591775,0.00043221394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981517,0.0003902713,0.00030296948,0.00058976223,0.00029482556,0.00027046655],"domain_scores_gemma":[0.9983643,0.00093099143,0.00005189573,0.00052635313,0.000023860914,0.00010258656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001960072,0.00019374082,0.00024015334,0.00021082381,0.00010059458,0.000039547867,0.00037206407,0.000019302113,0.000025135058],"category_scores_gemma":[0.0010539221,0.00014782514,0.00004724598,0.00079822406,0.00012876901,0.00006448094,0.00026259525,0.000110150155,0.000012042268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022872163,0.015294953,0.58859783,0.00029648925,0.000047075016,0.00036501113,0.024256231,0.006919518,0.31347242,0.0029878474,0.0019458688,0.022944588],"study_design_scores_gemma":[0.0042394903,0.0002485518,0.91795677,0.000040201317,0.000045977624,1.2051154e-7,0.00050975423,0.000034194145,0.076453894,0.000040530373,0.0002883219,0.00014219746],"about_ca_topic_score_codex":0.000092079696,"about_ca_topic_score_gemma":0.00018809595,"teacher_disagreement_score":0.3293589,"about_ca_system_score_codex":0.000058701284,"about_ca_system_score_gemma":0.000056796758,"threshold_uncertainty_score":0.60281336},"labels":[],"label_agreement":null},{"id":"W4407574412","doi":"10.1007/s40263-025-01164-w","title":"Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome; Université de Montréal; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; EMD Serono; Schweizerische Multiple Sklerose Gesellschaft; Università di Catania; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Multiple Sclerosis Australia; Medical Research Council; Biogen; Celgene; Sanofi Genzyme; University of Melbourne; F. Hoffmann-La Roche; Monash University; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Bayer HealthCare; Sanofi; Atara Biotherapeutics; Universität Basel; Bristol-Myers Squibb; Multiple Sclerosis Society; European Committee for Treatment and Research in Multiple Sclerosis; National Science Foundation","keywords":"Relapsing remitting; Multiple sclerosis; Observational study; Medicine; Psychopharmacology; Neurology; Psychology; Internal medicine; Psychiatry","score_opus":0.23960495344703944,"score_gpt":0.3990076854640167,"score_spread":0.15940273201697727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407574412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950013,0.00017523738,0.00010993204,0.0014747292,0.00009425976,0.0011376239,0.00000616734,0.000087659864,0.0019130869],"genre_scores_gemma":[0.9968225,0.00009819214,0.0014944848,0.00015086039,0.00009608033,0.00029928758,0.000040964813,0.000016193306,0.0009814755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998428,0.00016441247,0.0003629023,0.00037243977,0.00032944625,0.000342798],"domain_scores_gemma":[0.9989944,0.00037098146,0.00005387036,0.0003339719,0.0001444086,0.00010235902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005221803,0.00016187821,0.00029819383,0.00025968297,0.00019145852,0.000036861904,0.000090991896,0.00006754038,0.000026107877],"category_scores_gemma":[0.0009588444,0.0001411246,0.00006534885,0.0005093855,0.000057673467,0.00015245074,0.00007023612,0.00017766247,0.0000129529835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001661817,0.0015367395,0.94466597,0.000028233537,0.00008782129,0.0000047066596,0.0057425597,0.00016979167,0.0066424264,0.00004794467,0.00017916497,0.040728454],"study_design_scores_gemma":[0.0053753285,0.0003209239,0.9719432,0.00027377167,0.000043670112,5.8768455e-7,0.0054756925,0.015308782,0.00081026123,0.000036194455,0.00031742273,0.00009417971],"about_ca_topic_score_codex":0.00073493156,"about_ca_topic_score_gemma":0.00049657864,"teacher_disagreement_score":0.04063427,"about_ca_system_score_codex":0.00083146204,"about_ca_system_score_gemma":0.00023774401,"threshold_uncertainty_score":0.5754894},"labels":[],"label_agreement":null},{"id":"W4408224561","doi":"10.1007/s40263-025-01171-x","title":"The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pharmacological Receptor Mechanisms and Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Huntington's disease; Psychopharmacology; Agonist; Pharmacology; Medicine; Neurology; Sigma-1 receptor; Disease; Sigma receptor; Psychiatry; Receptor; Internal medicine","score_opus":0.010175184945426548,"score_gpt":0.2802867210696093,"score_spread":0.2701115361241827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408224561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97052014,0.0045077843,0.013369856,0.0035199765,0.001451818,0.003417134,0.00069416943,0.000023619903,0.0024954933],"genre_scores_gemma":[0.9935782,0.0013970006,0.00047566224,0.00015280682,0.0001510434,0.00038972762,0.00007961581,0.000010813754,0.0037651153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933857,0.000030857253,0.0001938144,0.00018852274,0.00007191171,0.00017633954],"domain_scores_gemma":[0.9992757,0.00022564427,0.00010185654,0.00026517897,0.00008432959,0.000047320587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018904617,0.00011400522,0.0001387501,0.000011218229,0.00019042911,0.000010506869,0.00020622108,0.000055037144,0.000022007389],"category_scores_gemma":[0.0001645224,0.000058775622,0.0001878071,0.00007415093,0.00011916856,0.000001386261,0.00005539705,0.000028700406,0.0000011555353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088168157,0.00039620342,0.000088413995,0.000059889855,0.0001610977,3.363347e-8,0.00006155529,0.00003840471,0.96077293,0.0025829356,0.0044418955,0.03051496],"study_design_scores_gemma":[0.00071508274,0.00030996616,0.00039523683,0.0000126105015,0.000061677674,2.5242468e-8,0.000060405382,0.00017755206,0.66614103,0.00006656648,0.3320083,0.000051530256],"about_ca_topic_score_codex":0.000008978205,"about_ca_topic_score_gemma":0.0000031717252,"teacher_disagreement_score":0.3275664,"about_ca_system_score_codex":0.000023003593,"about_ca_system_score_gemma":0.00011706689,"threshold_uncertainty_score":0.23968002},"labels":[],"label_agreement":null},{"id":"W4409119267","doi":"10.1007/s40263-025-01172-w","title":"Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy Grail","year":2025,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Neuropeptides and Animal Physiology","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Sherbrooke","funders":"Canadian Institutes of Health Research; Université de Caen Normandie","keywords":"Holy Grail; Medicine; Opioid; Addiction; Chronic pain; Analgesic; Intensive care medicine; Methadone; Heroin; Buprenorphine; Morphine; Pharmacology; Neuropathic pain; Anesthesia; Drug; Psychiatry; Receptor; Internal medicine","score_opus":0.049801843465127726,"score_gpt":0.32548156395580086,"score_spread":0.27567972049067313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409119267","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010562331,0.9879049,0.0000019550744,0.00021129895,0.000097399694,0.00087199936,0.00010681251,0.0000104054325,0.00023287667],"genre_scores_gemma":[0.018827954,0.9804931,0.000011619046,0.00021202603,0.00027067238,0.000069394926,0.0000020733364,0.000017627115,0.000095507654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872833,0.00025411177,0.0002652574,0.0004702055,0.0000962788,0.00018579746],"domain_scores_gemma":[0.9973395,0.0021756773,0.00018026416,0.00024959238,0.000028212957,0.000026788139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024699245,0.00023788903,0.0006224226,0.00009569364,0.0001650251,0.000068839836,0.00038851114,0.00008710478,0.0000014776278],"category_scores_gemma":[0.00020442168,0.00012091005,0.00016521857,0.0003094941,0.00031036095,0.000047716745,0.00010560483,0.0003123871,6.871676e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008845691,0.00018341193,0.000010968109,0.016772395,0.000059410646,0.000027276557,0.008665152,0.0000021214037,0.011701572,0.024832137,0.0009517308,0.93670535],"study_design_scores_gemma":[0.00038493646,0.0002449386,0.00015944435,0.0032072098,0.0003295391,0.000017323118,0.0028386847,0.000014694212,0.0003407302,0.0010566842,0.991109,0.00029682697],"about_ca_topic_score_codex":0.000024878556,"about_ca_topic_score_gemma":0.000005453166,"teacher_disagreement_score":0.99015725,"about_ca_system_score_codex":0.000009334584,"about_ca_system_score_gemma":0.00008504043,"threshold_uncertainty_score":0.4930569},"labels":[],"label_agreement":null},{"id":"W4410719351","doi":"10.1007/s40263-025-01193-5","title":"Motor and Non-motor Complications Following Different Early Therapies in Parkinson’s Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"Ministère des Solidarités et de la Santé; Direction Générale de l’offre de Soins; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Parkinson's disease; Medicine; Neurology; Disease; Psychopharmacology; Cohort; Longitudinal study; Physical medicine and rehabilitation; Cohort study; Pediatrics; Psychiatry; Internal medicine; Pathology","score_opus":0.04695297528197971,"score_gpt":0.3447406105113509,"score_spread":0.2977876352293712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410719351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909201,0.0061029135,0.00033888753,0.0009195221,0.00009366728,0.00069585006,0.0008059464,0.00002201279,0.00010109841],"genre_scores_gemma":[0.9972821,0.0016649871,0.00011954174,0.0002903309,0.00003781313,0.00011750752,0.000375895,0.000013723163,0.00009813203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832237,0.00014444785,0.00045808192,0.0006257966,0.0002531808,0.00019614791],"domain_scores_gemma":[0.99794203,0.00057624903,0.00011590832,0.00109604,0.000041123658,0.00022866417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002918667,0.00021184087,0.0006574934,0.00017242828,0.00013400907,0.00004584661,0.00025686878,0.000072269344,0.000028091608],"category_scores_gemma":[0.000077646335,0.00014031028,0.00019154794,0.00037342054,0.00017728808,0.00005957148,0.00019437108,0.00014817994,0.000001971011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017421151,0.00041395306,0.99155194,0.000020331308,0.0047197607,0.000010205886,0.000251402,5.0033697e-7,0.00009124736,0.000099582874,0.00006690142,0.0025999383],"study_design_scores_gemma":[0.001672091,0.000055867804,0.9860921,0.00013876958,0.00625867,1.3183805e-7,0.00015274703,0.004521045,0.0000047083363,0.0003389043,0.00065821456,0.00010677343],"about_ca_topic_score_codex":0.0017577627,"about_ca_topic_score_gemma":0.00036409113,"teacher_disagreement_score":0.006361968,"about_ca_system_score_codex":0.000043688502,"about_ca_system_score_gemma":0.00013890762,"threshold_uncertainty_score":0.5721687},"labels":[],"label_agreement":null},{"id":"W4412492484","doi":"10.1007/s40263-025-01205-4","title":"Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying Therapy","year":2025,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tobacco Research Unit","funders":"","keywords":"Ethnic group; Medicine; Multiple sclerosis; Psychological intervention; Gerontology; Disease; Affect (linguistics); Health equity; Clinical trial; Race (biology); Public health; Psychology; Psychiatry; Gender studies; Pathology","score_opus":0.15206892879635742,"score_gpt":0.4136482932983195,"score_spread":0.26157936450196206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01485082,0.98175734,0.000023341145,0.00023943435,0.00009156485,0.0024876003,0.00039297246,0.000032861837,0.00012406187],"genre_scores_gemma":[0.03363673,0.964884,0.00011582733,0.0000339403,0.00009341079,0.00060268893,0.00021541372,0.00003838349,0.0003796401],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997945,0.00020865076,0.000491076,0.00058345817,0.00044559586,0.00032619582],"domain_scores_gemma":[0.9975268,0.0012445272,0.00022550067,0.0004238218,0.00020598034,0.00037332473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022472037,0.0003884838,0.0013218452,0.00044327613,0.00016874107,0.000046440524,0.00013296276,0.00008124216,0.00004457819],"category_scores_gemma":[0.0005760285,0.0002913212,0.00019460423,0.0006998109,0.0003708469,0.00020149835,0.00024735194,0.00043426032,0.0000031081597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008789335,0.0006241188,0.048611753,0.032654855,0.00065155764,0.00001776492,0.003076343,0.0000039127167,0.0000053740846,0.000017919901,0.00060398853,0.9128535],"study_design_scores_gemma":[0.007621661,0.00014966904,0.8376979,0.07117512,0.0023566615,0.0000035666735,0.0035446857,0.00033490334,0.0000019554263,0.000014005159,0.07646309,0.0006367469],"about_ca_topic_score_codex":0.0003033819,"about_ca_topic_score_gemma":0.0006502779,"teacher_disagreement_score":0.9122167,"about_ca_system_score_codex":0.00014282858,"about_ca_system_score_gemma":0.00069236243,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4413867879","doi":"10.1007/s40263-025-01215-2","title":"International Trends in Opioid Prescribing by Age and Sex from 2001 to 2019: An Observational Study Using Population-Based Databases from 18 Countries and One Special Administrative Region","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Drug Abuse; Health and Medical Research Fund; LEO Pharma; National Science and Technology Council; DAK-Gesundheit; Servier; Astellas Pharma; National Health Research Institutes; Innovation and Technology Commission; University of New South Wales; Novo Nordisk; National Institute for Health and Care Research; Teva Pharmaceutical Industries; World Health Organization; Sanofi; European Commission; Pfizer; Amgen","keywords":"Observational study; Medicine; Psychopharmacology; Population; Opioid; Database; Family medicine; Psychiatry; Demography; Internal medicine; Environmental health; Computer science","score_opus":0.14927235239509537,"score_gpt":0.38727656495572643,"score_spread":0.23800421256063106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413867879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964023,0.00018131839,0.00019773032,0.0010773938,0.00017126698,0.00047047413,0.0011671279,0.000023491852,0.00030887424],"genre_scores_gemma":[0.9875097,0.000024061876,0.0033747652,0.00050380145,0.00027716928,0.00003261926,0.0077615776,0.000013864974,0.00050243235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988272,0.00005946558,0.00028025304,0.0004343027,0.00026056851,0.00013818333],"domain_scores_gemma":[0.9994379,0.00015050329,0.000067396955,0.00020803318,0.000045443918,0.00009070378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000073435265,0.00016348282,0.00025892956,0.00021359773,0.00008519212,0.000071913106,0.00006565298,0.000041143856,0.00024514584],"category_scores_gemma":[0.000050385264,0.0001708197,0.000017785818,0.00017098719,0.000038626244,0.00022244468,0.000055619515,0.00008768773,8.9817155e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004014862,0.00095805735,0.98689973,0.000009089904,0.00011943719,0.00003187962,0.0045307744,0.000026240856,0.00032544357,0.00008806144,0.0039665527,0.0026432336],"study_design_scores_gemma":[0.0032301259,0.00015375196,0.9886611,0.000215212,0.00013010076,4.0911513e-7,0.003390163,0.0014015062,0.00024760253,0.00013953153,0.0022852705,0.00014523085],"about_ca_topic_score_codex":0.015183114,"about_ca_topic_score_gemma":0.0022680685,"teacher_disagreement_score":0.012915046,"about_ca_system_score_codex":0.00019301775,"about_ca_system_score_gemma":0.0001665643,"threshold_uncertainty_score":0.99137485},"labels":[],"label_agreement":null},{"id":"W4416168683","doi":"10.1007/s40263-025-01247-8","title":"The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bipolar disorder; PsycINFO; Methadone; Psychopharmacology; (+)-Naloxone; Randomized controlled trial; Mood stabilizer; Treatment-resistant depression; Narrative review; Depression (economics)","score_opus":0.016627223066847947,"score_gpt":0.3125415261979551,"score_spread":0.29591430313110717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416168683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98211145,0.013661421,0.00021304171,0.001991325,0.0005521051,0.0004910741,0.000014660636,0.000039663308,0.0009252831],"genre_scores_gemma":[0.9955925,0.0015633429,0.0004937419,0.0001469629,0.000068628295,0.000023062028,0.000030637646,0.000018043558,0.0020631023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855256,0.00012570688,0.00056824356,0.0002696381,0.00021321204,0.00027061373],"domain_scores_gemma":[0.9989775,0.00034322214,0.00009352556,0.0004429883,0.00007353895,0.000069247355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038580623,0.00015276081,0.00033542505,0.00010772516,0.00012816566,0.000026379119,0.00012112632,0.00012757826,0.000046758578],"category_scores_gemma":[0.00019909265,0.00010464319,0.00021208316,0.00033822117,0.00018330908,0.00007021953,0.00010647928,0.00029736734,0.000026535641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013327894,0.00054395886,0.7252929,0.000053359523,0.00016100288,0.0000012318285,0.00060275383,0.000015111282,0.0001739706,0.00096453424,0.00052528636,0.2715326],"study_design_scores_gemma":[0.0032280644,0.00012255972,0.8415837,0.0001791557,0.0001678067,0.000001582713,0.0009479435,0.0012249352,0.00031930357,0.00042215874,0.15167321,0.00012954332],"about_ca_topic_score_codex":0.00062176824,"about_ca_topic_score_gemma":0.00018468402,"teacher_disagreement_score":0.27140304,"about_ca_system_score_codex":0.000047451453,"about_ca_system_score_gemma":0.00016069623,"threshold_uncertainty_score":0.42672256},"labels":[],"label_agreement":null},{"id":"W4416841651","doi":"10.1007/s40263-025-01251-y","title":"Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Atrophy; Surrogate endpoint; Magnetic resonance imaging; Observational study; Cognitive decline; Neurology; Neurodegeneration; Clinical trial; Dementia","score_opus":0.14805935427086206,"score_gpt":0.42566074582562824,"score_spread":0.27760139155476615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416841651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98658156,0.009269715,0.00010188537,0.002955347,0.00009765314,0.00085472676,0.00008395264,0.0000093067365,0.000045865687],"genre_scores_gemma":[0.9980651,0.00050990225,0.00051420723,0.00028115546,0.000059634276,0.00023754007,0.00003885941,0.000009319826,0.00028427146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982396,0.00032623167,0.0006384395,0.00034644132,0.00029956974,0.00014972113],"domain_scores_gemma":[0.9958014,0.0036842015,0.00011268802,0.00014138734,0.00016734366,0.00009301992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015097249,0.00011555624,0.00036442882,0.00015231864,0.000048874834,0.000043246364,0.00006205505,0.000034067532,0.00008828242],"category_scores_gemma":[0.0033476534,0.000095404095,0.00013049049,0.00013494906,0.00012515666,0.00012799332,0.000058957903,0.000093964714,0.0000029414432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020964104,0.00018767148,0.8678659,0.00011090531,0.000047057198,0.0000056837594,0.000038510134,7.4006806e-7,0.00021736167,0.0003727843,0.00014209366,0.12891486],"study_design_scores_gemma":[0.0020037012,0.00030082883,0.9880695,0.002097687,0.0003484308,5.974137e-7,0.00002912966,0.0040977523,0.000382604,0.0024993059,0.00009966714,0.000070826456],"about_ca_topic_score_codex":0.00006264173,"about_ca_topic_score_gemma":0.000011090305,"teacher_disagreement_score":0.12884404,"about_ca_system_score_codex":0.000017974102,"about_ca_system_score_gemma":0.0001345377,"threshold_uncertainty_score":0.40076956},"labels":[],"label_agreement":null},{"id":"W4417331117","doi":"10.1007/s40263-025-01252-x","title":"Assessing Cognitive Function over Time in Patients with Refractory Chronic Migraine Who Received Ketamine Infusions: A Prospective, Observational Study","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Johns Hopkins University","keywords":"Ketamine; Observational study; Cognition; Chronic Migraine; Refractory (planetary science); Migraine; Neurology; Neuropsychology","score_opus":0.025562890167183706,"score_gpt":0.3166538224132983,"score_spread":0.2910909322461146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417331117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902718,0.00040965478,0.000025556963,0.00043656313,0.000028509472,0.0015852754,0.000010097135,0.00005584968,0.0071767047],"genre_scores_gemma":[0.9828554,0.000020866451,0.000052243366,0.00049616327,0.00009773726,0.00016494728,0.0001633297,0.000018748178,0.016130565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986439,0.00007738211,0.00031844564,0.00038133748,0.00034564867,0.0002332979],"domain_scores_gemma":[0.9989908,0.00021248669,0.000108552995,0.00018320585,0.00045663834,0.000048365517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022624046,0.00020574676,0.00040974002,0.00027775293,0.00016421868,0.000027144757,0.000044544642,0.000068694506,0.00021701431],"category_scores_gemma":[0.000374253,0.00016157182,0.000055363507,0.00070825644,0.00008563667,0.00027541711,0.00006713576,0.00031901346,0.000019408095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000834566,0.0015762841,0.987052,0.00007752422,0.0003258907,0.000005381617,0.0022537452,0.0000015523955,0.00016590847,0.000020671534,0.005595859,0.0020906043],"study_design_scores_gemma":[0.009463842,0.001347385,0.98380625,0.0009662737,0.00030316727,2.6531055e-7,0.001988796,0.00010947662,0.00001502223,0.000044993227,0.0018034298,0.00015111789],"about_ca_topic_score_codex":0.00008625214,"about_ca_topic_score_gemma":0.00030226714,"teacher_disagreement_score":0.00895386,"about_ca_system_score_codex":0.00034261396,"about_ca_system_score_gemma":0.00036643576,"threshold_uncertainty_score":0.65887076},"labels":[],"label_agreement":null},{"id":"W52030589","doi":"10.2165/00023210-200620010-00005","title":"Prescription Privileges for Psychologists","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Healthcare Decision-Making and Restraints","field":"Psychology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medical prescription; Mental health; Context (archaeology); Psychology; Health care; Scope (computer science); Public relations; Medicine; Psychiatry; Political science; Law; Nursing","score_opus":0.1496865604322397,"score_gpt":0.4961522133049184,"score_spread":0.34646565287267866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W52030589","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020826748,0.95924294,0.0007116747,0.000125348,0.006059681,0.0020022844,0.0003478208,0.00021413834,0.031275257],"genre_scores_gemma":[0.000066014116,0.97871757,0.0005290051,0.00013146823,0.0017157773,0.0010679448,0.00050159486,0.00013425715,0.01713637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967969,0.0004000258,0.00094707945,0.00094114704,0.00024012063,0.00067473686],"domain_scores_gemma":[0.99751514,0.00068911794,0.0004896546,0.0010596866,0.00009725364,0.00014916653],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007282669,0.0004896238,0.0013775667,0.0003181093,0.00014792975,0.00005862077,0.00059882493,0.0011513865,0.00027009717],"category_scores_gemma":[0.00016645006,0.00037547952,0.00075057545,0.00027190743,0.000117537995,0.000036060024,0.000047677193,0.00059312937,0.0013061339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008050386,0.00011474949,4.8576754e-7,0.0033463223,0.00007379413,0.0000889705,0.0001520739,1.1162744e-7,2.4768285e-8,0.0007999227,0.053819362,0.94159615],"study_design_scores_gemma":[0.00024531828,0.00008709884,0.00004784925,0.0045737266,0.00019371264,0.0002554737,0.000054077158,5.709001e-7,2.6032689e-8,0.0010511138,0.993122,0.00036904207],"about_ca_topic_score_codex":0.00007460167,"about_ca_topic_score_gemma":0.000008364728,"teacher_disagreement_score":0.9412271,"about_ca_system_score_codex":0.00013440999,"about_ca_system_score_gemma":0.00018394132,"threshold_uncertainty_score":0.9998697},"labels":[],"label_agreement":null},{"id":"W52111744","doi":"10.2165/00023210-200317140-00004","title":"The Cost-Benefit of Cholinesterase Inhibitors in Mild to Moderate Dementia","year":2003,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Dementia; Willingness to pay; Adverse effect; Population; Medicine; Health economics; Economic evaluation; Psychology; Gerontology; Disease; Public health; Environmental health; Internal medicine; Economics; Nursing","score_opus":0.21388832466335742,"score_gpt":0.39824230767505586,"score_spread":0.18435398301169845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W52111744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97086924,0.0026433791,0.0007866398,0.014823533,0.0008007766,0.0010681684,0.00009894057,0.000019490397,0.0088898195],"genre_scores_gemma":[0.99278265,0.00010692771,0.0007677454,0.0051741847,0.00009846621,0.00017419865,0.0000072240523,0.000024924931,0.000863696],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630755,0.00015583757,0.002741647,0.00035305187,0.00007028833,0.00037164116],"domain_scores_gemma":[0.99803984,0.00049188576,0.0007870012,0.00047910895,0.00005732474,0.00014485842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008706076,0.00014181362,0.0005202801,0.00024319858,0.000148273,0.00006517156,0.0002287323,0.00008003117,0.00010662966],"category_scores_gemma":[0.0012795737,0.00015255735,0.00007864956,0.00028257063,0.00004294323,0.0002082693,0.00003607788,0.00012013436,0.0007445572],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008664641,0.00040434505,0.22190674,0.00037614183,0.00018793531,0.0000019093525,0.016603637,0.014984218,0.00003364971,0.6867103,0.0560631,0.0026413645],"study_design_scores_gemma":[0.0046995664,0.00014277347,0.0729786,0.00037427907,0.000021942136,0.0000048446896,0.005899066,0.011322435,0.0013284859,0.06186993,0.8400685,0.0012895407],"about_ca_topic_score_codex":0.0004614369,"about_ca_topic_score_gemma":0.00042228814,"teacher_disagreement_score":0.78400546,"about_ca_system_score_codex":0.00022935508,"about_ca_system_score_gemma":0.00008750528,"threshold_uncertainty_score":0.95700246},"labels":[],"label_agreement":null},{"id":"W74776018","doi":"10.2165/11538990-000000000-00000","title":"Sleep Problems in the Child with Attention-Deficit Hyperactivity Disorder","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"Purdue University; Eli Lilly and Company","keywords":"Irritability; Attention deficit hyperactivity disorder; Restless legs syndrome; Psychiatry; Sleep (system call); Insomnia; Bedtime; Sleep disorder; Psychology; Psychopharmacology; Neurology; Medicine; Cognition","score_opus":0.03032443102086022,"score_gpt":0.31768415016061613,"score_spread":0.2873597191397559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W74776018","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02203929,0.9581762,0.00012207976,0.0013132609,0.00027611287,0.00415077,0.00004438312,0.00012965582,0.013748233],"genre_scores_gemma":[0.017922293,0.9781893,0.000095697,0.00017008811,0.00031072015,0.0010312137,0.0005071455,0.00022206832,0.0015514576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966367,0.00036259345,0.00071598793,0.00088212884,0.0008065035,0.00059608143],"domain_scores_gemma":[0.9974106,0.00043359923,0.00052040233,0.0013819969,0.00012979566,0.0001236122],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006627605,0.000775297,0.0020075983,0.00041202476,0.0002540636,0.000111845264,0.00044852664,0.0006002682,0.00030656968],"category_scores_gemma":[0.00016340471,0.00045146974,0.00067679933,0.0011086464,0.00020747862,0.00026913424,0.00009805083,0.0033577867,0.00061933266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019391988,0.001972655,0.011575913,0.00890096,0.00028721182,0.00007621157,0.00024577172,0.000008143782,0.0000013583812,0.00020749132,0.000055859018,0.97664905],"study_design_scores_gemma":[0.0012164952,0.000117168405,0.005122304,0.006798311,0.00168113,0.0012968405,0.0009427915,0.000020444586,1.5900081e-8,0.000007698954,0.9821878,0.00060900557],"about_ca_topic_score_codex":0.00011854195,"about_ca_topic_score_gemma":0.00029229926,"teacher_disagreement_score":0.98213196,"about_ca_system_score_codex":0.000118845,"about_ca_system_score_gemma":0.00024354401,"threshold_uncertainty_score":0.9997937},"labels":[],"label_agreement":null},{"id":"W90711603","doi":"10.2165/00023210-200013010-00005","title":"Pharmacoeconomics of Clozapine, Risperidone and Olanzapine","year":2000,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Riverview Hospital; University of British Columbia","funders":"","keywords":"Pharmacoeconomics; Olanzapine; Risperidone; Clozapine; Medicine; Psychiatry; Schizophrenia (object-oriented programming); Intensive care medicine; Ziprasidone; Health care; Quality of life (healthcare); Cost effectiveness; Nursing; Political science","score_opus":0.012169393553419741,"score_gpt":0.3037392562900297,"score_spread":0.29156986273660995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W90711603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984444,0.00228669,0.0000024866447,0.0014092065,0.0000262384,0.0001856019,0.000019585586,0.00002290761,0.0062028235],"genre_scores_gemma":[0.99146485,0.0042288736,0.0011474101,0.00022187538,0.00011472229,0.000012032801,0.000021790842,0.000012508056,0.0027759077],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99945813,0.00001231571,0.0001395989,0.00014441258,0.00009169691,0.00015387058],"domain_scores_gemma":[0.99959123,0.0000272994,0.000020893905,0.00016198016,0.000024677387,0.0001739023],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000069066984,0.00008342857,0.00019613115,0.000054918728,0.00002697567,0.00000625724,0.000037879116,0.000028535695,0.0026110096],"category_scores_gemma":[0.0000086089685,0.00006755943,0.000045646062,0.00006458327,0.00008002378,0.000037391037,0.00001564957,0.00008091456,0.00015303392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010918152,0.0004927535,0.008613449,0.0001433741,0.0003521266,0.00008073247,0.0005569855,0.000005797925,0.004793335,0.00075087254,0.006150912,0.9671415],"study_design_scores_gemma":[0.10226823,0.0027907463,0.37894514,0.00034063752,0.000743907,0.00065138505,0.00049204077,0.0048676883,0.16952005,0.0019030031,0.3366152,0.0008619632],"about_ca_topic_score_codex":0.00006664787,"about_ca_topic_score_gemma":0.0000062132813,"teacher_disagreement_score":0.96627957,"about_ca_system_score_codex":0.000027527982,"about_ca_system_score_gemma":0.00006578259,"threshold_uncertainty_score":0.99830073},"labels":[],"label_agreement":null},{"id":"W91356277","doi":"10.2165/00023210-200115090-00001","title":"Choosing the Right Dose of Antipsychotics in Schizophrenia","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Medicine; Adverse effect; Antipsychotic; Schizophrenia (object-oriented programming); Positron emission tomography; Haloperidol; Population; Pharmacology; Neuroimaging; Psychosis; Psychiatry; Internal medicine; Dopamine; Nuclear medicine","score_opus":0.04690341841344119,"score_gpt":0.3661368305843829,"score_spread":0.3192334121709417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W91356277","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010618328,0.9940932,0.0000028665831,0.00024489732,0.0001879703,0.001358736,0.000030129924,0.000027219947,0.0029931946],"genre_scores_gemma":[0.0010170869,0.9970897,0.0006087634,0.000028143502,0.00028733962,0.000077044315,0.0001005341,0.000059273243,0.0007321371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978164,0.0001851975,0.0006727666,0.00039021595,0.0004881114,0.0004473468],"domain_scores_gemma":[0.99827915,0.00031533928,0.00023536701,0.00091314316,0.000069643786,0.0001873689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038457394,0.0003867104,0.0016042262,0.0004181051,0.00006834549,0.000027416856,0.00032514936,0.0002376961,0.00020179244],"category_scores_gemma":[0.0001043596,0.00020684475,0.00054019195,0.0010677846,0.00017878045,0.000037869064,0.00007989019,0.0008018829,0.00019263651],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079852314,0.0003069849,0.00003378491,0.0038044506,0.0002560832,0.00025773086,0.000065184366,1.3908604e-7,3.9205503e-7,0.0005969504,0.0006193578,0.99326044],"study_design_scores_gemma":[0.0043049306,0.00015031976,0.0006589009,0.022569358,0.0010293127,0.00028417606,0.000030320976,0.000008863834,0.000010096829,0.00043493908,0.97026783,0.00025092755],"about_ca_topic_score_codex":0.000033684857,"about_ca_topic_score_gemma":0.000035756995,"teacher_disagreement_score":0.9930095,"about_ca_system_score_codex":0.000206217,"about_ca_system_score_gemma":0.0008350397,"threshold_uncertainty_score":0.8434884},"labels":[],"label_agreement":null}]}